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1.0 Introduction to osmotic Drug Delivery system: 
In recent years, considerable attention has been focused on the development of novel 
drug delivery systems (NDDS). The reason for this paradigm shift is relatively low development 
cost and time required for introducing a NDDS as compared to developing a new chemical 
entity. In the form of NDDS, an existing drug molecule can get a new life thereby, increasing its 
market value, competitiveness, and patent life.  
Among the various NDDS available in market, per oral controlled release (CR) systems 
hold the major market share because of their obvious advantages of ease of administration and 
better patient compliance 
[1]
. CR delivery systems provide desired concentration of drug at the 
absorption site allowing maintenance of plasma concentrations within the therapeutic range and 
reducing the dosing frequency. These products typically provide signiﬁcant beneﬁts over 
immediate-release formulations, including greater effectiveness in the treatment of chronic 
conditions, reduced side effects, and greater patient convenience due to a simpliﬁed dosing 
schedule.A number of design options are available to control or modulate the drug release from a 
dosage form. Majority of per oral CR dosage forms fall in the category of matrix, reservoir, or 
osmotic systems. In matrix systems, the drug is embedded in a polymer matrix and the release 
takes place by partitioning of drug into the polymer matrix and the release medium. In contrast, 
reservoir systems have a drug core surrounded / coated by a rate controlling membrane. 
However, factors like pH, presence of food, and other physiological factors may affect drug 
release from conventional CR systems (matrix and reservoir). Osmotic systems utilize the 
principles of osmotic pressure for the delivery of drugs. Drug release from these systems is 
independent of pH and other physiological parameters to a large extent and it is possible to 
modulate the release characteristics by optimizing the properties of drug and system 
[2]
. Alza 
Corporation of the USA (now merged with Johnson & Johnson, USA) was ﬁrst to develop an 
oral osmotic pump and today also, they are the leaders in this ﬁeld with a technology named 
OROS. The oral osmotic pumps have certainly come a long way and the available products 
based on this technology 
[1]
 and number of patents granted in the last few years 
[3]
 makes its 
presence felt in the market. They are also known as GITS (gastro-intestinal therapeutic system) 
and today, different types of osmotic pumps are available to meet variety of drug delivery 
demands (Table 1). Osmotic pumps can be used as experimental tools to determine important 
pharmacokinetic parameters of new or existing drugs. At the same time, they can also be utilized 
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to deliver drugs at a controlled and predetermined rate. 
1.1. Osmotically controlled oral drug delivery 
Osmotic systems utilize osmotic pressure as driving force for controlled delivery of 
drugs. Fig. 1a shows schematic diagram of elementary osmotic pump (EOP), which in its 
simplest design, consists of an osmotic core (containing drug with or without an osmagent) 
coated with a semipermeable membrane (SPM). The dosage form, after coming in contact with 
the aqueous ﬂuids, imbibes water at a rate determined by the ﬂuid permeability of the membrane 
and osmotic pressure of core formulation 
[5]
. This osmotic imbibition of water results in 
formation of a saturated solution of drug within the core, which is dispensed at a controlled rate 
from the delivery oriﬁce in the membrane. Though 60–80% of drug is released at a constant rate 
from EOP, a lag time of 30–60 min is observed in most of the cases as the system hydrates 
before zero-order delivery from the system begins 
[6]
. These systems are suitable for delivery of 
drugs having moderate water solubility. Push–pull osmotic pump (PPOP) can be used for 
delivery of drugs having extremes of water solubility. As shown in Fig. 1b, it is a bilayer tablet 
coated with a SPM. Drug along with osmagents is present in the upper compartment whereas 
lower compartment consists of polymeric osmotic agents 
[7,8]
. The drug compartment is 
connected to the outside environment via a delivery oriﬁce. After coming in contact with the 
aqueous environment, polymeric osmotic layer swells and pushes the drug layer, thereby 
delivering the drug in the form of a ﬁne dispersion via the oriﬁce [9]. A number of modiﬁcations 
are available for this type of system such as delayed push–pull system (as used in Covera HS, 
extended release formulation for verapamil), multi-layer push–pull system (for pulsatile or 
delayed drug delivery), and push–stick system (for delivery of insoluble drugs requiring high 
loading, with an optional delayed, patterned, or pulsatile release proﬁle). OROS-CT is used as a 
once- or twice-a-day formulation for targeted delivery of drugs to the colon 
[10]
. The OROS-CT 
can be a single osmotic unit or it can comprise of as many as ﬁve to six push–pull osmotic units 
ﬁlled in a hard gelatin capsule (Fig. 2). After coming in contact with the gastrointestinal ﬂuids, 
gelatin capsule dissolves and the enteric coating prevents entry of ﬂuids from stomach to the 
system. As the system enters into the small intestine, the enteric coating dissolves and water is 
imbibed into the core thereby causing the push compartment to swell. At the same time, ﬂowable 
gel is formed in the drug compartment which is pushed out of the oriﬁce at a rate which is 
precisely controlled by the rate of water transport across the SPM. 
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Table 1: Commercially available osmotic systems:  
 
Systems and introducers Features of the system 
(i) Osmotic pumps for experimental 
research 
ALZET 
 
 
 
 
 
OSMET 
 
Miniature implantable osmotic pumps 
for laboratory animals. 
Different models having delivery rates 
from 0.25 to 10 µl/h and duration from 
1 day to 4 weeks available. Delivery 
profile independent of drug 
formulation. 
Used as experimental tools for human 
pharmacological studies and can be 
used for oral, rectal or vaginal 
administration. Available with release 
rate ranging from 8 to 120 µl/h. 
II) Osmotic pumps for humans oral 
Elementary osmotic pump (Alza) 
 
 
 
 
Push-pull osmotic pump (Alza) 
 
 
 
 
 
 
 
L- OROS (Alza) 
 
Single layer tablet for delivery of drugs 
having moderate water solubility.  
Can be utilized for zero order delivery 
as well as pulsed release. 
Bilayer tablet, used to deliver drugs 
having too low water solubility. 
Products such as Ditropan XL 
(Oxybutinin chloride), procardial XL 
and Glucotrol XL are based on this 
technology. Number of modifications 
available such as delayed push-pull, 
multi layer push pull and push stick 
system. 
Designed to deliver lipophilic liquid 
formulations and is suitable for delivery 
of insoluble drugs 
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OROS-CT 
 
 
 
Portab System (Andrx Pharma, USA) 
 
 
 
SCOT (Single Composition Osmotic 
Tablet) (Andrx Pharma, USA) 
 
 
 
ENSOTROL drug delivery system (Shire 
Labs) 
 
 
 
 
Zero Os (ADD drug delivery technologies) 
 
 
 
 
Implantable 
DUROS (Durect Corp.) 
 
 
 
For targeted drug delivery to colon and 
can be used for local or systemic 
delivery 
 
Tablet core consists of soluble agent, 
which expands and creates microporous 
channels for drug release. 
 
Utilizes various osmotic modulating 
agents and polymer coating to provide 
zero order release. 
 
Utilizes various solubilizing and 
wicking agents for delivery of poorly 
soluble drugs. 
 
 
Specially for delivery of lipophilic 
compounds. Consists of gel forming 
agents in the core that form gel after 
coming in contact with water. Drug is 
released as a fine dispersion. 
 
Miniature, implantable osmotic pumps 
for long term, parenteral, zero order 
delivery of patent therapeutic agents. 
Deliver drugs at a precisely controlled 
and constant rate within therapeutic 
range for long periods. 
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Figure 1:  Schematic diagram of an elementary osmotic pump (a) and a push–pull osmotic 
 
 
 
 
 
 
 
 
 
pump (b). 
 
 
  
 
 
 
III) Osmotic pumps for veterinary use  
 
VITS  (Veternary Implantable Therapeutic 
System) (Alza) 
 
 
 
 
RUTS  (Ruminal therapeutic system) 
(Alza) 
 
 
Designed to deliver drugs at a 
controlled rate in animals for a period 
of 1 day to 1 year and can be implanted 
subcutaneously or intraperitoneally. 
 
For controlled delivery of drugs up to 1 
year in the rumen of cattle and sheep. 
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Figure 2. Cross-sectional diagram of OROS CT delivery system.  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cross-sectional diagram of L-OROS delivery system before and during operation  
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    Liquid OROS controlled release systems are designed to deliver drugs as liquid formulations and 
combine the beneﬁts of extended-release with high bioavailability [11]. Fig. 3 shows the cross-sectional diagram 
for L-OROS SOFTCAP delivery system before and during operation. These systems are suitable for controlled 
delivery of liquid drug formulations including lipophilic self-emulsifying formulations (SEF). The liquid drug 
formulation is present in a soft gelatin capsule, which is surrounded with the barrier layer, the osmotic layer, and 
the release rate-controlling membrane. A delivery oriﬁce is formed through these three layers. When the system 
is in contact with the aqueous environment, water permeates across the rate controlling membrane and activates 
the osmotic layer. The expansion of the osmotic layer results in the development of hydro- static pressure inside 
the system, thereby forcing the liquid formulation to break through the hydrated gelatin capsule shell at the 
delivery oriﬁce. The liquid drug formulation is pumped through the delivery oriﬁce. L-OROS HARDCAP is 
similar to L-OROS SOFTCAP and consists of a liquid drug layer, a barrier layer, and an osmotic engine, all 
encased in a hard gelatin capsule and coated with a SPM 
[12]. A delivery oriﬁce, drilled in the membrane at the 
end of the drug layer, provides an outlet for the drug suspension. After coming in contact with the aqueous 
environment, water is imbibed across the SPM, expanding the osmotic engine. The osmotic engine pushes 
against the barrier, releasing drug through the delivery oriﬁce. 
   In majority of cases, osmotic systems have a pre-formed passageway in the membrane from where the 
drug release takes place. Controlled porosity osmotic pumps (CPOP), contain water-soluble additives in the 
coating membrane, which after coming in contact with water, dissolve resulting in an in situ formation of a 
microporous membrane (Fig. 4). The resulting membrane is substantially permeable to both water and dissolved 
solutes and the mechanism of drug release from these systems was found to be primarily osmotic, with simple 
diffusion playing a minor role 
[13–15]
. 
   Multi-particulate delayed release systems consist of pellets of drug (with or without osmagents) coated 
with a SPM. These pellets, after coming in contact with the aqueous environment, imbibe water osmoticcally, 
which results in a rapid expansion of the membrane leading to the formation of pores and drug release 
[16,17]
. 
    Use of asymmetric membranes in osmotic drug delivery that consist of very thin, dense skin structure 
supported by a thicker, porous substructural layer is also described in the literature 
[18–22]
. These membranes have 
high ﬂux characteristics and thus, higher release rates for poorly water-soluble drugs can be obtained.  
    In sandwiched osmotic tablet (SOTS), a tablet core consisting of a middle push layer and two attached 
drug layers is coated with a SPM 
[23]
. As seen in Fig. 5, both the drug layers are connected to the outside 
environment via two delivery oriﬁces (one on each side). After coming in contact with the aqueous environment, 
the middle push layer containing swelling agents swells and the drug is released from the delivery oriﬁces. The 
advantage with this type of system is that the drug is released from the two oriﬁces situated on two opposite 
sides of the tablet and thus can be advantageous in case of drugs which are prone to cause local 
irritation of gastric mucosa 
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Figure 4. Schematic diagram of controlled porosity osmotic pump before and during 
operation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic diagram of sandwiched osmotic tablet before and during operation.  
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1.2 Formulation aspects: 
 Before discussing the formulation variables that affect the release of drugs from oral 
osmotic systems, it will be prudent to deal with some of the theoretical aspects.  The delivery of 
agent from oral osmotic systems is controlled by the influx of solvent across the SPM, which in 
turn carries the agent to the outside environment.  Water influx into EOP can be described by the 
following equation 
[5]
: 
---------------------------------------------------(1) 
Where dv/dt is water influx, A and h are the membrane area and membrane thickness, 
respectively; Lp is mechanical permeability; σ is the reflection coefficient; and ΔΠ and Δp are 
the osmotic and hydrostatic pressure differences, respectively, between the inside and outside of 
the system.  The general expression for the solute delivery rate, dM/dt, obtained by pumping 
through the orifice is given by: 
---------------------------------------------------------------(2) 
 Where C is the concentration of compound in the dispensed fluid. 
 Reflection coefficient takes into account the leakage of solute through the membrane.  A 
perfectly semi permeable membrane is selectively permeable to water only and doesnot allow 
solute to pass through it.  Thus, in case of a perfectly semipermeable membrane, σ is close to 
unity.  As size of the delivery orifice increases, hydrostatic pressure inside the system is 
minimized and ΔΠ >> Δp.  Since, osmotic pressure of the gastro intestinal fluid is negligible as 
compared to that of core, Π can be safely substituted for ΔΠ.  By replacing the product Lp σ, in 
equation (1), by a constant K and substituting equation (1) in equation (2), the following 
equation is obtained: 
----------------------------------------------------------------(3) 
The best possible way to achieve a constant release from osmotic systems is through proper 
selection and optimization of the SPM (To maintain the first three terms on the right hand side of 
the quation constant) and maintaining a saturated solution of drug within the core.  As long as 
excess solid agent is present inside the system, both Π and C in equation (3) can be maintained at 
constant levels.  Therefore, it is possible to obtain zero-order release rates from osmotic system 
by maintaining the terms in equation (3) constant.   
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1.3. Factors that affect the drug release from osmotic pumps: 
 
1.3.1  Solubility: 
The kinetics of osmotic drug release is directly proportional to the solubility of the drug 
within the core. Assuming a tablet core of pure drug, the fraction of core released with zero order 
kinetics is given by the following equation 
[24, 25]
 
F(z} = 1-S/p-------------------------------------------------------equation (4) 
Where, F(z) is the fraction released by zero order kinetics, S is the solubility of drug, and 
p is the density of the core tablets. Drugs with the solubility of less than 0.05 gm/cc would be 
released with more than 95 % zero order kinetics according to equation (4).  However, the zero-
order relase rate would be slow according to equation (3), due to the small osmotic pressure 
gradient.  Conversely, highly water soluble drugs would demonstrate a high release rate that 
would be zero-order for a small percentage of the initial drug load.  Thus, the intrinsic water 
solubility of many drugs might preclude them from incorporation into an osmotic pump. 
However, it is possible to modulate the solubility of the drugs within the core, and thus, extend 
this technology for delivery of drugs that might otherwise have been poor candidates for osmotic 
delivery. Some of the approaches that have been used to deliver drugs having extremes of 
solubility are: 
1.3.1.1 Co compression of drugs with excipients: 
Incorporation of excipients that modulate the solubility of drug within the core can be one 
approach to control the release of drugs from the osmotic systems. McClelland and coworkers 
[24, 
25]
 reported CPOP of a highly water-soluble drug, diltiazem hydrochloride (solubility more than 
590 mg / ml at 37 C). Because of very high water-solubility, the majority of the drug fraction 
was released predominantly at a ﬁrst-order rather than the desired zero-order rate. The solubility 
of diltiazem hydrochloride was reduced to 155 mg / ml by incorporation of sodium chloride (at 
1M concentration) into the core tablet formulation. The modiﬁcation resulted in more than 75% 
of the drug to be released by zero-order kinetics over a 14-16 h period. 
Controller porosity solubility modulated osmotic pumps for delivery of drugs having low water 
solubility are described in US patent nos. 4946686 and 4994273 
[26, 27].
The composition 
described consists of controlled release solubility modulating agents, which are either surfactants 
or complexing agents.  In order to prolong the availability of these excipients within the device, 
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they were either surrounded by a rate controlling membrane or dispersed in a matrix.  In the 
examples, tablet cores of two different drugs, namely, simvastatin and lovastatin, along with the 
solubility modulating agents were prepared and coated with a microporous membrane.  The 
release of drug from the systems was controlled for an extended period of 4-24 h. 
Herbig et al. 
[20]
 reported osmotic delivery of doxazosin, which has pH-dependent solubility.  
Tablets cores containing drug, along with organic acids (succinin and adipic acid) to increase the 
solubility of doxazosin within the core, were prepared and coated with asymmetric membranes.  
The solubility of doxazosin was improved in the presence of organic acids and pH-independent 
release patterns were obtained. 
Use of polymer coated buffer components to modulate the drug solubility within the core is 
described in US patent no. 4755180 
[28].
  Solubility of a weakly acidic drug, acetyl salicylic acid, 
was modified by a basic excipient, which maintains alkaline pH within the device.  The drug and 
the solubility modifying agent (sodium acetate) were coated separately by a rate controlling film 
of HPMC, mixed, and compressed in the form of a tablet.  The tablet cores were coated and a 
hole drilled in the membrane wall.  Coating of sodium acetate ensures its availability within the 
device for prolonged period and thus solubility of the drug is controlled throughout the operation 
life span of the device.  The drug was released in predominantly zero-order fashion for the 
desired period of time.  
Use of buffers, which react with the drug to produce a new compound having thermodynamic 
properties different from the parent drug, is described in US patent no. 4,326,525 
[29]
. 
Theophylline, along with L-tartaric acid and polyvinyl pyrrolidone (PVP), was formulated in the 
form of EOP. Theophylline, in presence of tartaric acid, is converted to theophylline tartarate. 
Theophylline free-base had a solubility of 10 mg/ml and theophylline tartarate had a solubility of 
220 mg/ml in water at 37 C. Drug release from the systems was found to be constant over a 
period of 7 h.   
In another study 
[30]
, solubility of a weakly acidic drug, nimesulide, was improved by using 
alkalinizing agents like disodium hydrogen phosphate and sodium bicarbonate. Nimesulide, 
along with different alkalinizing agents, was formulated in the form of EOP and release proﬁle 
compared with immediate release tablets. It was found that release of nimesulide from the 
osmotic pumps was relatively slow and prolonged for 12 h. 
Co-compression of drugs along with solubility modulating agents can also be utilized for 
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pulsatile delivery of drugs. This was demonstrated in the case of salbutamol 
[31–33]
, a highly 
water-soluble drug (270 mg/ml in pure water). Solubility of salbutamol was reduced by the 
addition of sodium chloride in the tablet core (11 mg/ml in a saturated salt solution). Salbutamol, 
along with sodium chloride was formulated in the form of osmotic pumps, which after coming in 
contact with the aqueous environment, initially imbibes water at a rate controlled by the osmotic 
pressure of the core formulation. Due to the presence of excess of salbutamol within the tablets, 
sodium chloride is depleted ﬁrst from the device. This results in decrease of osmotic pressure of 
the solution inside the tablets and thus the rate of water ﬂow into the tablet decreases. However, 
the solubility of salbutamol is increased due to a fall in sodium chloride concentration and its 
delivery to the body actually increases. The net result is a tablet formulation that initially delivers 
salbutamol at a relatively constant rate, until sodium chloride gets exhausted. After this, the 
remaining drug is delivered as a large pulse. Using this approach, zero-order release was 
achieved for about 7 h, followed by a pulsatile release of 7–9 h. 
 
1.3.1.2 Use of encapsulated excipients: 
Thombre and coworkers 
[34, 35]
 described a capsule device coated with asymmetric 
membranes to deliver drugs having poor water-solubility (Fig. 6). In the examples, solubility of a 
poorly water-soluble drug, glipizide, was improved by incorporation of encapsulated excipients 
(pH-controlling excipients)  within the capsule device. The solubility modiﬁer (meglumine), in 
the form of mini-tablets, was coated  with a rate controlling membrane to prolong its availability 
within the core. Thus, the solubility of glipizide was improved leading to its prolonged release 
from the device. 
Fig 6: Schematic view of delivery system having encapsulated excipients: 
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1.3.3.3 Use of swellable polymers: 
Swellable polymers can be utilized for osmotic delivery of drugs having poor aqueous 
solubility. Examples using this approach are reported in US  patent no. 4,992,278 
[36] 
for 
carbamazepine, theo-  phylline, acetylsalicylic acid, and nifedipine. The formulation mainly 
consists of a compartment, containing the drug, swelling agents, and osmagents, coated with a 
rate controlling membrane. Vinylpyrrolidone /vinyl acetate copolymer (Kollidon VA 64, BASF) 
and polyethylene oxide (MW: 5 x 10
6
, Polyox -coagulant, Union Carbide) were used as swelling 
agents. Uniform rate of swelling of these polymers ensures that the drug is released at a 
relatively constant rate. Also, the pressure produced during swelling does not lead to rupture of 
the system.   
In addition, PPOP can also be utilized for delivery of drugs having either high, e.g. oxybutynin 
chloride
 [37]
, or low water solubility, e.g. glipizide 
[38–41]
. Drug is released from the delivery 
oriﬁce in the form of very ﬁne dispersion ready for dissolution and absorption. 
Sandwiched osmotic tablets (SOTS) have also been utilized for osmotic delivery of water 
insoluble drugs, such as nifedipine 
[23]
. The release proﬁle from the tablets was found to be 
comparable with the 
commercially available push–pull osmotic system of the drug. 
 
1.3.3.4 Use of effervescent mixtures:  
Use of effervescent mixtures can be another approach to deliver poorly water soluble 
drugs from osmotic dosage forms. After administration, the effervescent mixture containing the 
drug is delivered under pressure through the delivery orifice in the membrane. This method of 
enhancing release of poorly water-soluble drug is reported in US patent no. 4,036,228 
[42]
. In one 
of the examples, citric acid and sodium bicarbonate were used as the effervescent couple for the 
delivery of acetyl salicylic acid. The formulation imbibes aqueous ﬂuids across the membrane 
causing the couple to generate an effervescent solution that dispenses the drug in a suspension 
form. 
 
1.3.3.5 Use of cyclodextrin derivatives: 
Incorporation of the cyclodextrin–drug complex has also been used as an approach for 
delivery of poorly water-soluble drugs from the osmotic systems. A CPOP has been described 
Chapter 1                                                                                                                    Introduction 
 
Osmotic Drug Delivery System                                                                                                         Page 14 
 
for testosterone (having a solubility of 0.039 mg/ml at 37 C), solubility of which was improved 
to 76.5 mg/ml through complexation with sulfobutyl ether-b-cyclodextrin sodium salt
[43]
. In a 
comparative study with hydroxypropyl-b-cyclodextrin (HP-b-CD) and a sugar mixture, it was 
found that testosterone release from the device in the presence of (SBE)- -b-CD was mainly due 
to osmotic pumping while for HP-b -CD, the major contribution was due to diffusion. In case of 
the sugar mixture, the drug was poorly released due to the absence of solubilizer. Similar results 
were obtained with prednisolone 
[44]
 and chlorpromazine 
[45]
.  
 
1.3.3.6 Resin modulation approach: 
Release of a highly water-soluble drug, diltiazem hydrochloride from a CPOP was 
modulated effec- tively using positively charged anion-exchange resin, poly (4-vinyl pyridine) 
[25]
. Pentaerythritol was used as osmotic agent and citric and adipic acids were added to maintain 
a low core pH to assure that both the drug and resin carry a positive charge. The solubility of 
diltiazem hydrochloride was reduced for an extended period and pH-independent zero-order 
release was obtained. 
 
1.3.3.7 Use of alternative salt form: 
For an ionic drug, an alternative salt form can also be used as reported for metoprolol and 
oxprenolol
[2].
 Hydrochloride salt used in commercial formulations of oxprenolol was found to 
have high water solubility (70% w/v) making it difﬁcult to achieve extended zero-order delivery 
from osmotic systems. It was replaced by the less soluble succinate salt. In case of metoprolol, 
they used fumarate salt form as drug and osmotic driving agent, instead of tartrate salt. These salt 
forms were found to have optimum solubility and provided extended release up to 24 h. 
 
1.3.3.8 Use of crystal habit modifier: 
If the drug exists in more than one crystal form, each having different aqueous solubility, 
it is beneﬁ-  cial to include a crystal modifying agents. One such example is reported in US 
patent no. 5,284,662 
[46]
, wherein a slightly soluble drug, carbamazepine,  along with crystal 
modifying agents (combination of hydroxymethyl cellulose and hydroxyethyl cellulose) and 
other excipients was formulated in the form of osmotic pumps that were able to provide 
approximately zero-order release for the desired period of time. 
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1.3.3.9 Use of Lyotropic crystals: 
Use of lyotropic liquid crystals, to assist osmotic delivery of poorly water soluble drugs, 
is also reported in the literature 
[47, 48]
. The lyotropic liquid crystals are non-polymeric 
compounds, generally in the molecular weight range of 200–1500. Also known as amphipathic 
compounds, these form mesophases and swell in presence of water. Compounds that can be used 
as lyotropic liquid crystals include natural phosphatides such as phosphatidylcholine (lecithin), 
phosphatidylethanolamine, phosphatidylserine, phosphatidylglycerol, and the like. Few examples 
using this approach are mentioned in US patent no. 5,108,756 and 5,030,452. In these examples, 
Alcolec lecithin (American Lecithin Co.,Atlanta, GA) and mixture of soybean phospholipids was 
utilized for osmotic delivery of two insoluble drugs, namely, glipizide and prazosin. The 
inventors claimed that the extended drug release up to 24 h was achieved. 
 
1.3.3.10 Use of wicking agents: 
Inclusion of wicking agents in the osmotic formulations has also been reported as an 
approach for poorly water-soluble drugs 
[49]
. A wicking agent is dispersed throughout the 
composition that enhances the contact surface area of drug with the incoming aqueous ﬂuids. 
Thus, the drug is released predominantly in a soluble form through the delivery oriﬁce in the 
membrane. The authors delivered nifedipine using this approach and some of the reported 
wicking agents are colloidal silicon dioxide, PVP, sodium lauryl sulfate, etc. 
 
1.3.2 Osmotic pressure 
Osmotic pressure, like vapor pressure and boiling point, is a colligative property of a 
solution in which a nonvolatile solute is dissolved in a volatile solvent. Osmotic pressure of a 
solution is dependent on the number of discrete entities of solute present in the solution. From 
Eq. (3), it is evident that the release rate of a drug from an osmotic system is directly 
proportional to the osmotic pressure of the core formulation. For controlling the drug release 
from these systems, it is important to optimize the osmotic pressure gradient between inside 
compartment and the external environment. It is possible to achieve and maintain a constant 
osmotic pressure by maintaining a saturated solution of osmotic agent in the compartment 
[6]
. If a 
drug does not possess sufﬁcient osmotic pressure, an osmagent can be added in the formulation. 
Some of the compounds that can be used as osmagents are listed in Table 2. 
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Polymeric osmagents are mainly used in the fabrication of PPOPs and other modiﬁed devices for 
controlled release of drugs with poor water solubility. These are swellable, hydrophilic polymers 
that interact with the aqueous ﬂuids and swell or expand to an equilibrium state. These polymers 
have a capacity to retain a signiﬁcant portion of the imbibed water within the polymer structure 
[8]
. 
   It is possible to conﬁrm the contribution of osmotic pressure in drug release from osmotic 
systems by conducting the release studies in media of different osmotic pressure. The release 
rates obtained can be plotted against the osmotic pressure difference across the device wall. 
Using this approach, release of potassium chloride from CPOP was studied in aqueous media of 
different osmotic pressure. An inverse relationship was found between the two 
[13,14]
. A linear 
relationship was obtained conﬁrming osmotic release from the system. 
Table 2: List of Compounds that can be used as osmagents 
Category Examples 
Water-soluble salts of inorganic acids Magnesium chloride or sulfate; lithium, sodium, or 
potassium chloride; lithium, sodium, or potassium 
sulfate; sodium or potassium hydrogen phosphate, 
etc. 
Water-soluble salts of organic acids Sodium and potassium acetate, magnesium 
succinate, sodium benzoate, sodium citrate, 
sodium ascorbate, etc. 
Water-soluble amino acids Glycine, leucine, alanine, methionine, etc. 
Carbohydrates Arabinose, ribose, xylose, glucose, fructose, 
galactose, mannose, sucrose, maltose, lactose, 
rafﬁnose, mannitol. 
Organic polymeric osmagents Sodium carboxy methylcellulose, HPMC, 
hydroxyethyl methylcellulose, cross-linked PVP, 
polyethylene oxide, carbopols, polyacrylamides, 
etc. 
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1.3.3 Delivery orifice: 
 
 
 
Osmotic delivery systems contain at least one delivery oriﬁce in the membrane for drug 
release. The size of delivery oriﬁce must be optimized in order to control the drug release from 
osmotic systems. If the size of delivery oriﬁce is too small, zero-order delivery will be affected 
because of development of hydrostatic pressure within the core. This hydrostatic pressure may not be 
relieved because of the small oriﬁce size and may lead to deformation of delivery system, thereby 
resulting in unpredictable drug delivery. On the other hand, size of delivery oriﬁce should not also be 
too large otherwise; solute diffusion from the oriﬁce may take place. There are mathematical 
calculations that can be used to calculate the optimum size of the delivery oriﬁce [5]. Drug release from 
osmotic systems is not affected by the size of the delivery oriﬁce withincertain limits as reported in the 
following examples   Drug release from osmotic pumps of nifedipine was studied as a function of 
oriﬁce diameter and no signiﬁcant differences were found in the release proﬁles for oriﬁce diameter 
ranging from 0.25 to 1.41 mm 
[50]
. Drug release was somewhat rapid with an oriﬁce diameter of 2.0 
mm possibly because of signiﬁcant diffusion. On the other hand, a longer lag time and unpredictable 
and slower release rates were obtained from the systems without any oriﬁce. 
    In a study by Theeuwes 
[5]
, a complete membrane controlled delivery of potassium chloride 
was obtained with oriﬁce diameter in the range of 0.075– 0.274 mm. At oriﬁce size of 0.368 mm and 
above, control over the delivery rate was lost because of signiﬁcant contribution from diffusion and 
possibly convection. However, no systematic trends were observed within the oriﬁce diameter 
between 0.075 and 0.274 mm. 
    Delivery oriﬁces in the osmotic systems can be created with the help of a mechanical drill [30, 
51–56], but for commercial production scale, tablets need to be produced using a continuous process. 
Some of the reported processes to create delivery oriﬁces in the osmotic systems are  
1) Laser drilling 
2) Systems with passage way formed in situ 
3) Use of modified punches 
4) Use of pore formers 
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1.3.4 Membrane types and characteristics 
The choice of a rate-controlling membrane is an important aspect in the formulation 
development of oral osmotic systems. From Eq. (3), the importance of rate-controlling 
membrane in the drug release can be easily recognized. Drug release from osmotic systems is 
independent of the pH and agitational intensity of the GI tract to a large extent. This is because 
of selectively water permeable membrane and effective isolation of dissolution process from the 
gut environment 
[2,5]
. To ensure that the coating is able to resist the pressure within the device, 
thickness of membrane is usually kept between 200 and 300 mm 
[3]
. However, this may be 
problematic in cases where the drug is having low osmotic pressure because of which incomplete 
/ slow drug release may take place. Selecting membranes that are having high water 
permeabilities can be a solution to this problem. One approach that can be utilized is by using 
composite walls 
[64] 
.The tablet cores are coated with a membrane that has a passageway through 
the wall for releasing the agent. The wall is formed of a multiplicity of materials comprising a 
material permeable to an external ﬂuid and substantially impermeable to agent (like CA) and at 
least one additional material selected from a group of materials that imparts stability to the wall 
and enhances the permeability of the wall to ﬂuids (like HPMC or hydroxyl butyl 
methylcellulose). Another approach that can be explored is to use a multilayer composite coating 
around the tablet 
[65]. The ﬁrst layer is a thick microporous ﬁlm that provides the strength 
required to withstand the internal pressure, while the second layer is a relatively thin SPM that 
produces the osmotic ﬂux. Hence, high delivery rates can be obtained even for drugs with poor 
water solubility. 
Some of the membrane variables that are important in the design of oral osmotic systems 
are; 
 
1.3.4.1. Type and nature of polymer 
    Since the membrane in osmotic systems is semipermeable in nature, any polymer that is 
permeable to water but impermeable to solute can be selected. Some of the polymers that can be 
used for above purpose include cellulose esters such as cellulose acetate, cellulose diacetate, 
cellulose triacetate, cellulose propionate, cellulose acetate butyrate,etc. 
[66]
; cellulose ethers like 
ethyl cellulose 
[67]
;and eudragits 
[68]
. 
    Cellulose acetate (CA) has been widely used to form rate-controlling membranes for 
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osmotic systems. CA ﬁlms are insoluble, yet semipermeable to allow water to pass through the 
tablet coating. The water permeability of CA membrane is relatively high and can be easily 
adjusted by varying the degree of acetylation. As the acetyl content in the CA increases, the CA 
ﬁlm permeability decreases, and solvent resistance increases. The permeabilities of these ﬁlms 
can be further increased by the addition of hydrophilic ﬂux enhancers. Incorporation of 
plasticizer in CA coating formulation generally lowers the glass transition temperature, increases 
the polymer-chain mobility, enhances the ﬂexibility, and affects the permeability of the ﬁlm [69]. 
   Ethyl cellulose is also widely used in the formation of membranes for oral osmotic 
systems. However, the water permeability of pure ethyl cellulose membrane is very low that may 
result in slow release of drugs 
[70]
. Nevertheless, drug release from osmotic systems coated with 
ethyl cellulose membrane can be enhanced by incorporation of water-soluble additives. Addition 
of HPMC in the coating composition improves the permeability of ethyl cellulose membranes. 
Tablet cores of potassium chloride coated with a mixture of ethyl cellulose and up to 24% of 
HPMC, were shown to release the contents mainly through osmotic mechanism 
[70,71]
. In another 
study 
[62]
, urea was added to commercially available ethyl cellulose aqueous dispersion 
(Aquacoat) in an attempt to increase the release rates of potassium chloride and diltiazem 
chloride from osmotic tablets. It was found that the drug release from these systems is affected 
by coating thickness, plasticizer type and concentration, and pore-former level. 
The use of eudragit acrylic latexes as membrane formers for osmotic systems has also 
been reported in the literature 
[68]
. Potassium chloride tablets were coated with mixtures of 
eudragit RS30D and RL30D containing triethyl citrate or acetyl tributyl citrate as plasticizers and 
urea as a pore-forming agent. The release rate was most affected by the ratio of RS30D to 
RL30D and the level of urea was found to have effect on lag time and burst strength. The type of 
plasticizer and amount of pore former were alsofound to be critical for the desired release rates. 
The mechanism of release from the formulations containing acetyl tributyl citrate as plasticizer 
and 100% urea level (of total polymer solids) was found to be primarily osmotic and these 
formulations exhibited similar release rates in water and phosphate buffer saline pH 7.4. 
 
1.3.4.2. Membrane thickness 
   Thickness of the membrane has a profound effect on the drug release from osmotic 
systems. It can be seen from Eq. (3) that release rate from osmotic systems is inversely 
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proportional to membrane thickness. Pellets of phenylpropanolamine coated with an aqueous 
ethyl cellulose based ﬁlms were found to release the drug mainly through the mechanisms of 
osmotic pumping and diffusion 
[72]
. On studying the release as a function of coating thickness, it 
was found that as the coating thickness increased from 9 to 50 mm, the drug release decreased in 
an inversely proportional manner. In case of monolithic osmotic tablets of nifedipine, release 
rates were found to decrease with increase in membrane thickness from 85 to 340 mm 
[50]
. An 
increased resistance of the membrane to water diffusion resulted in this effect. 
  On the other hand, thickness of the membrane in case of asymmetric coating was found 
to have insigniﬁcant effect on drug release. In a study by Herbig et al. [20], release rates were 
found to be virtually unaffected by the overall membrane thickness in the range of 95–150 mm. 
The possible reason for this may be the unique structure of the asymmetric membrane coatings in 
which the porous substrate consists of open pores (void volume between 60 and 90%). Since 
most of resistance to the transport is the skin structure rather than the porous substrate of the 
asymmetric membranes, the thickness of the porous substrate had only a slight effect on the 
release kinetics. 
 
1.3.4.3. Type and amount of plasticizer 
   In pharmaceutical coatings, plasticizers or low molecular weight diluents are added to 
modify the physical properties and improve ﬁlm-forming characteristics of polymers. Plasticizers 
can change visco-elastic behavior of polymers signiﬁcantly. In particular, plasticizers can turn a 
hard and brittle polymer into a softer, more pliable material, and possibly make it more resistant 
to mechanical stress. These changes also affect the permeability of polymer ﬁlms. 
    The effect of different types of plasticizers (TA and polyethylene glycols) on the water 
permeation and mechanical properties of CA was reported by Guo 
[73].
 The water permeability of 
CA ﬁlms was found to decrease with increasing plasticizer concentration to a minimum and then 
increases with higher concentration of plasticizer. Low plasticizer concentrations were found to 
decrease water permeability by their antiplasticization effect. This antiplasticization effect could 
be because of interaction between the polymer and the plasticizer molecules that decreased the 
molecular mobility of the polymer. In a similar study 
[74]
, Guo investigated the effect of PEG-600 
on the sucrose permeability, void volume, and morphology of CA ﬁlms. The sucrose 
permeability was found to decrease with increasing PEG-600 concentration and increase 
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dramatically when they were plasticized by over 30% (w / w). The decrease in sucrose 
permeability at lower plasticizer concentration was attributed to the antiplasticization effect. The 
increase in sucrose permeability at higher plasticizer concentration was because of formation of 
plasticizer channels, results of which were conﬁrmed by the void volume and scanning electron 
microscopic studies. 
    Liu et al. 
[75]
 studied the inﬂuence of nature and amount of plasticizers on the properties 
of CA membrane including drug release proﬁle, thermal properties, microporosity, and 
mechanical properties. Hydrophilic plasticizer (PEG-200) was found to increase the drug release, 
whereas hydrophobic plasticizer (TA) was found to decrease the drug release from osmotic 
pumps of nifedipine. Films plasticized with PEG developed completely porous structure after 24 
h leaching, whereas ﬁlms plasticized with TA retained their dense structure and porosity was 
observed only on the surface. At low plasticizer levels (0–5% w / w), it was found that both the 
ultimate tensile strength (σu) and elastic modulus (E) of dry membranes increased as the 
plasticizer level increased and there was no signiﬁcant difference because of the nature of 
plasticizer. However, at higher plasticizer levels (5–40% w / w), both σu and E of membranes 
decreased as plasticizer levels increased.  
    Drug release from potassium chloride tablets coated with microporous membrane was 
found to decrease with increasing plasticizer concentrations from 24 to 48% w / w 
[62]
. Higher 
release rates were observed with TEC as compared to dibutyl sebacate (DBS) at equal 
concentrations. These results can be attributed to differences in aqueous solubilities of 
plasticizers. Since DBS is more hydrophobic than TEC, it decreases the water permeability of the 
membrane and hence the drug release. 
    In another study by Okimoto et al. 
[76]
, chlorpromazine (CLP) release from controlled 
porosity osmotic tablets was found to increase with decreasing amounts of TEC. Drug release 
was also found to be much faster in formulations containing PEG-400 as a plasticizer than with 
TEC and was similar to that PEG-400 is not a very effective plasticizer. 
    Bindshaedler et al. 
[77]
 have described mechanically strong ﬁlms produced from CA 
latexes. By proper choice of type of plasticizer and its content in the coating composition, 
membranes comparable with those obtained from organic solutions can be produced from CA 
latexes. Water-soluble plasticizers possessing some degree of volatility resulted in ﬁlms that had 
high ultimate tensile strength and elasticity modulus. In the series of ﬁlms prepared with 
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cellulose latexes containing different types and amount of plasticizers, it was found that the ﬁlms 
plasticized with volatile additives (ethylene glycol monoacetate and ethylene glycol diacetate) 
were nearly as strong as those resulting from evaporation of solution in acetone. The majority of 
volatile plasticizer evaporates during the processing of the ﬁlm at 60 C. On the other hand, more 
permanent plasticizers (triethyl phosphate and diethyl tartarate) are retained in the ﬁlm and yield 
membranes that are weak and less resistant. Thus, by proper selection of these volatile 
plasticizers, it is possible to balance two contradictory requirements, i.e. high mechanical 
strength of ﬁlms and initial high amounts of plasticizer. In a similar study by the same group of 
workers 
[78]
, very volatile plasticizers, such as ethylene glycol monoacetate and ethylene glycol 
diacetate, were used to produce ﬁlms with low permeability. More permanent plasticizers, such 
as diethyl tartrate or diacetin, resulted in ﬁlms that were much more permeable. 
 
1.4 Advantages of ODDS: 
1. Drug release from these systems is independent of pH and other physiological parameters to a 
large extent  
2. Release Rates are Independent of Agent Properties 
3. Can Deliver Macromolecules and Ionic Species 
4. Relatively High Fluxes 
5. Release Rates are not dependent on Environmental Conditions 
6. Osmotic pumps can be used as experimental tools to determine important pharmacokinetic 
parameters of new or existing drugs. 
 
1.5 Disadvantages of ODDS: 
1. Subject to dose dumping if membrane breaks [e.g. someone chews it] 
2. Slightly more expensive to formulate than coating tablets 
3. Possible hole plugging. 
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2.0 Review of literature: 
Theeuwes et al, 1983 
85
 Designed a system based on the principle of an elementary osmotic 
pump to deliver Indomethacin in solution at a constant rate. Total amount of drug released & 
80% of drug released at time t80 was studied. To allow selection of the optimal delivery rate into 
the body, three different prototypes were prepared with respective values for release rate, amt 
and t80: 7mg\hr, 85 mg, 11 hr, 9mg\hr, 85mg, 8 hr, and 12mg \hr, 85mg, 6hr.  Systems were 
found to deliver 70% of their content at zero – order rates. Delivery rates were independent of 
pH, method of estimation & stirring rate. In GI tract of dogs system delivered at the same rate as 
the vitro, which qualifies the in vitro test as bioanalogaus method predictive of the in vivo 
performance of the dosage forms. 
 
Theeuwes et al, 1985 
86
 Described oral osmotic system development aspects and evaluation for 
Metoprolol fumarate and Oxprenolol succinate  Release was unaffected by pH, dissolution 
media, long term storage at different temperatures and test procedures. 
. 
Theeuwes et al, 1985 
87
 Developed an elementary osmotic pump, a new delivery system for 
drugs or other active agents that delivers the agents by an osmotic process at a controlled rate. 
Control resides in :(a) water permeation characteristics of a semipermeable membrane 
surrounding the formulated agent, and (b) osmotic properties of the formulation. In its simplest 
embodiment, the system is constructed by coating an osmotically active solid agent with the rate 
controlling, semipermeable membrane. This membrane contains an orifice of critical size 
through which solubilized agent is dispensed. The system contains the agent in solid form at 
loading higher than 90% of the total volume, and the agent can be delivered at rates several order 
of magnitude higher than can be achieved by solution diffusion through polymeric membranes. 
The delivery rate, the fraction of total content delivered at zero order, and the system’s delivery 
portal size have been calculated for delivery of a single compound. The release rate from the 
system was found to be independent of outside agitation when the system was not deformed by 
shaking action, the pH of the environment, and delivery portal size for sizes within a specified 
Chapter 2                                                                                                                      Review of Literature 
 
Osmotic Drug Delivery System                                                                                                                         Page 24 
 
range. The delivery rate from this system in vitro and in the GI tract of dogs was found to be 
equal. 
 
Zentner et al, 1985 
88
 Investigated the zero-order release of water soluble osmotically active 
agents from tablets coated with controlled porosity walls containing Cellulose acetate.  Release 
rate was a function of the wall thickness, level of leachable additives incorporated, and 
permeability of the polymer component of the walls, total solubility of the core tablet, drug 
loading and the osmotic pressure difference across the wall. Rate of release was insensitive to the 
pH and degree of the agitation in the receptor media. 
 
Bindschaedler et al, 1987 
89
 Proposed the use of aqueous colloidal dispersion of cellulose 
acetate instead of organic solutions as an alternative to obtain osmotic tablets.  They observed 
that the release rate of model drug potassium chloride from coated tablets produced from 
aqueous dispersions was higher because semipermeable membranes produced from latexes were 
more permeable to water and swollen to a greater extent than those prepared from organic 
solutions. They also observed that the physico–chemical properties, concentration of plasticizer 
and coating conditions determine the permeability and solute release rates of the membranes. 
 
Haslam, 1989 
90
 Prepared an osmotic pump for the controlled release of Diltiazem. The core 
consisted of Sodium bitartarate, Dilitizem and Povidone potassium, coated with a membrane that 
is impermeable to solute but permeable to water, with a pH insensitive pore forming additive. A 
solution containing Cellulose acetate, Sorbitol and Polyethylene glycol was used as a coating 
agent. Controlled released was achieved at pH 1.2 and pH 7.5. 
 
Edgren, 1990 
91
 Prepared a compressed drug core containing hydralazine HCl, coated with a 
semi-permeable enteric composition consisting of Cellulose acetate, Hydroxypropyl 
methylcellulose phthalate and triacetin. A 1.0 mm hole was laser drilled through the wall.  
Hydralazine HCl release rate was found to be 0.5 mg/h in gastric fluid and 3 mg/h in intestinal 
fluid. 
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Sutinen, 1990 
92
 Studied the release of lipophilic (Propranolol) and hydrophilic (Sotalol) weak 
bases from silicone reservoir devices. Solid HCl salts of the drugs were entrapped between two 
silicon membranes along with their buffering or osmotic additives. Drug release was achieved by 
water influx into the core. Mannitol in the silicone membrane increased the water influx but did 
not increase the release of model drug. Sodium chloride in the core increased water influx but the 
pH of the core and the model drug release were unaffected. When Tris and/or Na2HPO4 added to 
the core, the pH increased and the drug release rate also increased by several hundred folds. 
Sotalol was too hydrophilic even in its unionized state to be released through the silicone walls. 
 
Deters, 1994 
93
 Formulated an osmotic device for Doxazosin in which the first composition 
contained Doxazosin, Polyethylene oxide and HPMC and a second composition contained 
Polyethylene oxide, Sodium chloride and HPMC. The components were compressed to give a 
bilayer tablet containing a drug layer and an osmotic push layer and coated with coating 
composition consisting of 90% cellulose acetate and 10% polyethylene glycol. A 20mm orifice 
was drilled. They obtained controlled release of 0.48 mg/h. 
 
Lindstedt, 1994 
94
 studied the permeability of ethyl cellulose film was increased by addition of 
HPMC in the film composition. They found that core of Potassium chloride coated with ethyl 
cellulose and up to 24% HPMC, released their contents mainly through osmotic pumping.  It was 
reported that water permeability of a semipermeable membrane was the primary release rate-
regulating parameter in osmotic devices. 
 
Brain et al, 1994 
95
 Outlined the mechanism governing the release of osmotically active agents 
from hydrophobic polymeric monoliths. The release kinetic was loading dependent. Below 
required loading, excipients released with zero order kinetics while above the percolation 
diffusion & osmotic release mechanism occurs simultaneously resulting in a release profile that 
appears to be diffusionally controlled but whose slope increases with excipient osmotic activity.  
A model was developed to correlate concentration and density of the incorporated agents. The 
tensile strength of elastic model system and hydraulic permeability of the polymer and the 
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fraction of particles released by dissolution and diffusion were correlated. The model was 
correlated against data form experiments and the literature. 
 
Brain et al, 1994 
96
 prepared Ethylenecovinylacetate monolith containing osmotic excipient of 
varying particles size and at various volume fractions. The excipients chosen were Potassium 
chloride, Sodium chloride, Sodium salicylate, Sodium phosphate, Monobasic sodium carbonate. 
The total fraction released was found to be increased as the volumetric loading and the excipient 
osmotic activity increased and was weakly inversely dependent on particle size. The total 
fraction release was enhanced by osmotic pressure inducing polymer. A model was developed 
based on the concept of distribution of particles wall thickness around encapsulated particles in 
the monolith and the existence of a critical wall thickness. The model effectively explains the 
contribution of osmotic rupturing to the overall fraction releasable. 
 
Shah, 1995 
97
 Prepared an oral osmotic system for the controlled release of metoprolol, which 
consisted of an osmotically active amount of a Metoprolol salt, a separate inner layer of a water 
soluble coating material, a separate outer semipermeable layer and a passageway between the 
two layers.  System has improved adhesion to the core and avoided the disadvantages of usual 
osmotic system, such as flaking of the outer layer breaking up due to the action of the body 
fluids. 
 
Wong, 1995 
98
 The osmotic device comprises of a drug compartment surrounded by a wall. KCI 
98.7%, SIO2  1.2% & Stearic acid 0.1% w/w were compressed in to core of 500 mg and were 
coated with an aqueous emulsion containing Ethyl acrylate – Methyl acrylate copolymer 36%, 
ethyl cellulose 24% and PVA 4% w/w. The coated product was cured in a forced air oven for 30 
hours at 50 C and a 0.37 mm exit pore was laser drilled.  Zero order release of KCl was observed 
from the coated tablets. The film characteristics were affected by curing time and temperature. 
. 
Vyas et al, 1995 
99
 Designed an elementary osmotic pump bearing Ciprofloxacin HCl, which 
delivers drug by osmotic process. The system was coated with 2% cellulose solution. The 
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coating thickness was optimized. The exit pore was drilled on the system. The effect of variables, 
which could influence release pattern, was elucidated. The system was subjected to stability 
study at accelerated temperature conditions. The release profile of the developed system was 
compared with conventional capsular form. The system was found to release drug at controlled 
rate and showed appreciable stability. 
 
Schultz, 1997 
100
 Investigated the effect of varying amount of TEC as plasticizer and micronized 
talc. The mechanical properties of dry & swollen film samples & plasticizer elution from free 
films during swelling were determined and compared to dissolution results.  Increased 
lipophilicity of Plasticizer led to an increase in swelling time of the pellets. The dissolution rate 
was decreased by the use of more lipophilic plasticizer. The type of plasticizer employed had no 
effect on the mechanical properties of dry and wet films containing various amounts of 
plasticizer and talc. In addition, the dissolution rate was influenced mainly by the plasticizer 
fraction. An increasing amount of talc had no effect on the mechanical properties of swollen film 
but increased lag time of drug dissolution from the coated formulation. 
 
Johnson, 1997 
101
 Prepared a once an year implantable osmotic delivery system (DUROS 
leuprolide implant) for the treatment of advanced prostate cancer Leuprolide acetate was 
formulated as a 37% solution in an aqueous and non-aqueous solution for use in the DUROS 
application.  The formulation was stable during the operational life of the implant (1 year). The 
feasibility of the DUROS implants was demonstrated 
 
Cardinal et al, 1997 
102
 Described delivery systems, which provide controlled release of drug 
through different membranes by diffusion and/or osmotic pumping. Tablets containing Glipizide, 
N – Methyl glucomine and Magnesium stearate were prepared and then coated with glycerol and 
cellulose acetate solution. The tablet coating consisted of a largely porous layer.  In simulated 
intestinal fluid, the drug was released at a controlled rate (50% in 3.5 hours and 90% in 10-12 
hours.). 
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Lee  and co workers (1998) 
103
 prepared osmotic drug delivery system of metoprolol using 
povidone and magnesium stearate. The cores were coated with cellulose acetate and 
subsequently a bore with 0.5 mm diameter was drilled. Amount of the drug released during 0-2, 
4-6 and 10-12 hours was 18.7, 61.2 and 92.5% respectively. 
 
Magruder et al, 1999  
104
 A mixture of Salbutamol sulfate, Sodium chloride, 
Carboxymethylcellulose and Polyvinyl pyrrolidone sulfate was compressed using 14.7-19.6 N 
pressure. The cores were coated with a mixture of Cellulose acetate (39.8% acetyl content) 
Cellulose acetate (32% acetyl content), Hydroxypropyl methyl cellulose in dichloromethane-
methanol (4:1), dried and a 0.25 mm hole was bored in the coating with a laser.  Zero-order 
release of Salbutamol sulfate was Obtained. The drug chamber contained a modulating agent, 
which prompted the drug release. 
 
Herbig et al, 1999 
105
 Developed a new type of membrane coating for osmotic drug delivery that 
offers significant advantages over the membrane coating used in conventional osmotic tablets. 
These new coatings have an asymmetric structure, similar to asymmetric membranes made for 
reverse osmosis or ultra filtration, in that the coating consists of a porous substrate with a thin 
outer skin.  These asymmetric membrane coatings can be used to make osmotic drug delivery 
formulations with several unique characteristics. High water fluxes can be achieved, facilitating 
osmotic delivery of drugs with low solubility and making higher released. The permeability of 
the coating to water can be adjusted by controlling the membrane structure, thereby allowing 
control of the release kinetics without altering the coating material or significantly varying the 
coating thickness. In addition, porosity of the skin can be controlled, minimizing the time lag 
before drug delivery begins and allowing the drug to be released from a large number of delivery 
ports. The coatings have also been applied to capsules and multiparticulate formulations. 
 
Longxiao Liu, et al. 2000 
106
, studied Sandwiched Osmotic Tablet System (SOTS) which is 
composed of a sandwiched osmotic tablet core surrounded by a cellulose acetate membrane with 
two oriﬁces on both side surfaces prepared with the purpose of delivering nifedipine. The 
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sandwiched osmotic tablet core consists of a middle push layer and two attached drug layers.  
Inﬂuences of tablet formulation variables, oriﬁce size and membrane variables on nifedipine 
release of SOTS have been studied.  It wad observed that the SOTS gives fairly comparable in 
vitro release features as that of commercialized push–pull osmotic tablet system, such as an 
approximately constant rate up to 24 h and independence of release media and agitation rate. 
Exempting side identiﬁcation before drilling, it is easier to prepare the SOTS than the push–pull 
osmotic tablet system. 
 
En-Xian Lu, 2003 
107
, studied a monolithic osmotic tablet system (MOTS) with two orifices in 
both side surfaces.  Water-insoluble naproxen was selected as the model drug. Gum arabic was 
used as an osmotic, suspending and expanding agent and cellulose acetate (CA) was used as 
semipermeable membrane. Polyethylene glycol 400 (PEG-400) was employed as plasticizer for 
controlling membrane porosity. The influences of gum arabic, PEG-400, membrane thickness 
and orifice size on the naproxen release profiles were investigated, and the optimal MOTS was 
evaluated in different environment media and stirring rates. The optimal MOTS was found to be 
able to deliver naproxen at a rate of approximately zero order up to 12 h in pH 6.8, cumulative 
release at 12 h is 81%, independent on environment media and stirring rate. Therefore, this 
MOTS can be used in oral drug-controlled delivery field, especially for water-insoluble drug 
 
D. Prabakaran, 2003 
108
 Sustained release asymmetric membrane capsular systems were 
developed for simultaneous oral delivery of rifampicin and isoniazid sodium in order to reduce 
the problems associated with the multi drug therapy of tuberculosis. Dense semipermeable 
membrane coating capsules were also prepared for the delivery of these drugs by adopting two 
different filling approaches.  Asymmetric membrane capsules provided sustained release of 
rifampicin associated with initial burst release, where isoniazid release rates were comparatively 
high due to higher aqueous solubility. Dense semipermeable membrane systems provided 
controlled release of both drugs but were devoid of initial burst release of isoniazid.  The system 
provided satisfactory sustained release of rifampicin and isoniazid with initial burst release may 
be sufficient to achieve minimum effective concentration in blood. In vitro dissolution kinetics of 
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the systems followed first order kinetics and statistical analysis of release rate data proved that 
modified asymmetric system was better amongst the developed systems. 
 
MEENA RANI, 2003 
109
 designed Osmotic Pump (OP) tablets and evaluated with the aim to 
deliver diclofenac sodium (DS) in a controlled manner. In vitro evaluation was done in various 
release me dia and kinetics was evaluated using the regression coefficient analysis. Effects of 
orifice size, coating membrane type, coating thickness, static and stirred conditions and pH 
variation were studied. In vivo evaluation was performed on six healthy human volunteers and 
various pharmacokinetic parameters (cmax, tmax, AUC0–24, MRT) and relative bioavailability 
were calculated.  The drug release from OP tablets was dependent on the type and thickness of 
the coating membrane, but was independent of the orifice size and static and stirred conditions of 
the release medium. The OP tablets provided a prolonged and controlled DS release compared to 
commercial sustained-release and conventional tablets of DS. 
 
D. Prabakaran, 2003,
110
 studied the effect of appropriate hydrophilic polymers (HP) on the 
release pattern of  Plain Diltiazem elementary osmotic pump.  Ingredients of the system were 
optimized for parameters like drug:polymer ratio and amount of osmogent, for the desired 
release pattern.  From the results obtained, it was inferred that the release of freely water-soluble 
drug Diltiazem from elementary osmotic pump can be controlled efﬁciently by the addition of 
HPs in to the core formulations.  The pumps gave better controlled release and time duration for 
the release can be extended up to 24 h. This can lead to the development of these formulations as 
potential candidate for once a day dosage form. The kinetics of drug release from formulations 
follow Hixson–Crowell cube root model and mechanism of  release would follow non-Fickian 
diffusion process. It can be concluded from the study that HPs can play a considerable role in 
controlling the release of Diltiazem (or other highly water-soluble drugs) from elementary 
osmotic pumps. 
 
Longxiao Liu, 2006,
111
  studied a method for the preparation of monolithic osmotic pump tablet 
by coating the indented core tablet compressed by the punch with a needle. Atenolol was used as 
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the model drug, sodium chloride as osmotic agent and polyethylene oxide as suspending agent. 
Ethyl cellulose was employed as semipermeable membrane containing polyethylene glycol 400 
as plasticizer for controlling membrane permeability.  It was observed that indentation size of 
core tablet hardly aﬀected drug release in the range of (1.00–1.14) mm. The optimal osmotic 
tablet was found to be able to deliver atenolol at an approximately constant rate up to 24 h, 
independent of both release media and agitation rate. The method that is simpliﬁed by coating 
the indented core tablet with the elimination of laser drilling may be promising in the ﬁeld of the 
preparation of osmotic pump tablet. 
 
M. W. E. Teunissen (1985) 
112 
investigated the utility of an osmotic rectal drug delivery system 
as a tool in steady-state pharmacokinetic interaction studies using the cimetidine-antipyrine 
interaction.  It is  concluded  that  the  osmotic rectal  drug  delivery system is  a  useful  tool  in 
pharmacokinetic interaction studies, because  it provides very  constant  steady-state  
concentrations, thus  permitting investigation of  the time course of drug interactions. 
 
G. van den Berg, et al. (1990) 
113
 studied the influence of food on the bioavailability of 
metoprolol from an OROS system; a study in healthy volunteers.  The influence of food intake 
on the bioavailability of metoprolol from an OROS system was investigated. No significant 
difference was found between OROS  administration to fasting subjects or after breakfast in any 
of the kinetic parameters (AUC, Cmax, tmax, C24 and lag time). Therefore, metoprolol OROS 
can be administered with breakfast.  
 
Sapna N. Makhija, studied,
114
 a controlled porosity osmotic pump-based drug delivery system.   
Pseudoephedrine was chosen as a model drug with an aim to develop a controlled release system 
for a period of 12 h. Sodium bicarbonate was used as the osmogent. The effect of different ratios 
of drug:osmogent on the in-vitro release was studied. Cellulose acetate (CA) was used as the 
semipermeable membrane. Different channeling agents tried were diethylphthalate (DEP), 
dibutylphthalate (DBP), dibutylsebacate (DBS) and polyethyleneglycol 400 (PEG 400). The 
effect of polymer loading on in-vitro drug release was studied. It was found that drug release rate 
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increased with the amount of osmogent due to the increased water uptake, and hence increased 
driving force for drug release. This could be retarded by the proper choice of channeling agent in 
order to achieve the desired zero order release profile. Also the lag time seen with tablets coated 
using diethylphthalate as channeling agent was reduced by using a hydrophilic plasticizer like 
polyethyleneglycol 400 in combination with diethylphthalate. This system was found to deliver 
pseudoephedrine at a zero order rate for 12 h. The effect of pH on drug release was also studied. 
The optimized formulations were subjected to stability studies as per ICH guidelines at different 
temperature and humidity conditions. 
 
Xing Liu et al,
115
 evaluated  the monolithic osmotic tablet system (MOTS) containing a solid 
dispersion with the practically water-insoluble drug nifedipine in vitro and in vivo. In the drug 
release study in vitro, the release profiles of this system had almost zero-order kinetics. The 
influences of tablet formulation variables, sizes of the delivery orifice, membrane variables, and 
values of pH in the dissolution medium on nifedipine release from MOTS have been 
investigated. The results provided evidence that the tablet core played an important role in 
MOTS. While orifice sizes and membrane variables affected the nifedipine release rate, MOTS 
was independent of the dissolution medium. The appropriate orifice size was found to be in the 
range of 0.5–1.0 mm. The coating membrane incorporating hydrophilic polyethylene glycol 
(PEG) formed a porous structure. The human pharmacokinetics and relative bioavailability of 
MOTS containing nifedipine were compared with a commercial Adalat_ osmotic tablet system 
containing an equivalent dose of nifedipine following an oral single dose of 30 mg given to each 
of 11 healthy volunteers in an open, randomized crossover study in vivo. The relative 
bioavailability for MOTS was 112%. There was no statistically significant difference in the 
pharmacokinetic parameters between two dosage forms. It is concluded that the monolithic 
osmotic tablet controlled release system is feasible for a long-acting preparation as a once-daily 
treatment.  
 
Nurten Ozdemir et al 
116
 studied the effect of the delivery orifices and the concentration of 
osmotic agents on the rate of release of the active material was investigated. For this purpose, 
ibuprofen tablets were prepared and sodium chloride and polyethylene glycol 6000 were used as 
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osmotic agents. The tablets were coated with a mixture of cellulose acetate and polyethylene 
glycol 400 by the use of a modified fluidized bed apparatus. Delivery orifices on the coated 
tablets are produced using a microdrill. The tablets were tested for dissolution rate using the USP 
paddle method. Finally, it was observed that the release rate of ibuprofen was influenced by the 
concentration of osmotic agents sodium chloride and polyethylene glycol 6000. 
 
N. Ramakrishna et al. 
117
 compared the performance of cellulose acetate (CA) and 
ethylcellulose (EC)–HPMC combination coatings as semipermeable membranes (SPMs) for 
osmotic pump tablets(OPTs) of naproxen sodium (NPS) so as to deliver a constant, 
predetermined amount of drugin solution form over a fixed span of time, independent of external 
environmental conditions. Osmotic pump tablets were designed with different coating variables 
and optimized in terms of nature of plasticizer, membrane thickness, and orifice diameter. The 
effect of insertion of an inner microporous film around the NPS core to minimize deformation of 
the SPM due to peristaltic movement of the gut was also studied. Osmotic pump tablets 
composed of membranes with water-soluble plasticizer, propyleneglycol (PG), released drug 
mainly through diffusion, whereas those designed with CA and EC–HPMC (4:1) coats 
containing water-insoluble plasticizer, castor oil, released their contents by perfect zero-order 
kinetics over a prolonged period of time, though the average release rate that could be achieved 
with the EC–HPMC (4:1) membrane was only about half the rate achieved with the CA 
membrane for the same membrane thickness. Release rates for both the membranes decreased 
with increasingmem brane thickness and were found to be independent of orifice diameter, 
agitation intensity, and pH of the dissolution medium. 
 
S. Mohammadi-Samani et al 
118
 produced a propranolol osmotic pump by coating the core 
tablets with cellulose acetate. The effects of membrane thickness, pore size, and stirring rate on 
the release rate of propranolol hydrochloride were studied. It was found that the thickness of 
cellulose acetate membrane had a profound effect on the release rate of propranolol 
hydrochloride from the membrane-coated tablets. The results showed that, when the membrane 
thickness increased, the release rate of propranolol decreased. The drug release follows a zero-
order release when the delivery orifice is between 200 and 800 mm, but when the delivery orifice 
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size is increased to 1000 mm, the release kinetic is abnormal. Fluid dynamics have an important 
effect on the delivery rate of propranolol from this device; the delivery rate increases as a 
function of the fluid flow. The drug release is higher under a turbulent condition  
 
Yong Gan et al. 
119
 prepared a Cyclodextrin Complex Osmotic Tablet for Glipizide Delivery.  
Poorly soluble glipizide was selected as the model drug to prepare osmotic pump tablets (OPT) 
with proper accessorial material after it was made an inclusion complex by kneading method in 
order to increase solubility. Polyethylene glycol 4000 (PEG4000) and cellulose acetate (CA) 
were selected as the coating materials, and acetone–water (95:5) co-solvent was employed as the 
coating medium. The effects of the osmotic promoting agent, diameter of the drug-releasing 
orifice, coating composition, and coat weight on the drug release profile were investigated. The 
drug release profile of the optimal formulation was compared with a commercialized push–pull 
osmotic tablet. The results indicated that glipizide–cyclodextrin inclusion complex OPT had 
excellent zero-order release characteristics in vitro. 
 
Amir M. Razaghi et al. 
120
 studied  Release of Cyclobenzaprine Hydrochloride from 
Osmotically Rupturable Tablets.  Osmotically rupturable systems were developed and the release 
of cyclobenzaprine hydrochloride (model drug) from the systems was investigated. Systems were 
designed using mannitol (osmotic agent) and increasing amounts of polyethylene oxide (PEO,a 
water-swellable polymer) surrounded by a semipermeable membrane. When placed in an 
aqueous environment,osmo tic water imbibition into the systems distended and swelled the 
systems until the membrane ruptured and released the active compound to the outside 
environment. Tablets with increasing amount of PEO exhibited longer rupture times. This may 
be due to osmotic pressure-modulating properties of the polymer,changi ng the rate of water 
imbibition into the systems. The integrity of the membranes was investigated using high-pressure 
mercury intrusion porosimetry. Minimal mercury intrusion into the membrane structure and core 
tablet indicated membrane integrity and lack of defective areas or pinholes. The results were in 
agreement with the release profiles where no drug release was detected prior to membrane 
rupture. Mercury intrusion porosimetry appears to be a promising technique for evaluation of 
membrane integrity. Once the systems ruptured,drug was released by osmotic pumping and 
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diffusion mechanisms through the ruptured area. There was a decrease in drug release rate with 
inclusion of PEO in the core.  The effects of film thickness on rupture and release times were 
also investigated. Devices with thicker films produced longer rupture times. This is in agreement 
with the theoretical prediction. 
 
Amir M. Razaghi 
121
 carried out an Investigation of Cyclobenzaprine Hydrochloride Release 
from Oral Osmotic Delivery Systems Containing a Water-Swellable Polymer.  Oral osmotic 
delivery systems containing polyethylene oxide (PEO, a waterswellable polymer) were designed 
and the release of cyclobenzaprine hydrochloride (model drug) from the devices was 
investigated. The systems consisted of model drug, mannitol (osmotic agent), and increasing 
amounts of PEO surrounded by a semipermeable membrane drilled with a delivery orifice. There 
was a decrease in drug release rate with PEO in the core. This may be due to solubility-
modulating properties of the polymer. Visual inspection of the devices with PEO showed 
significant swelling during dissolution testing. Swelling (internal pressure) may influence water 
imbibition rate into the core and subsequently drug release rate. The release rates were a function 
of membrane thickness. The release rates were independent of orifice size (range of 150–510 m 
diameter) and hydrodynamic conditions for the devices. This would be advantageous in the 
delivery of drugs in man. 
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3.0 Aim of the present work:  
Various physical and chemical approaches have been applied to produce a well-
characterized dosage form that controls drug input into the body within the specifications of the 
desired release profile. This is generally accomplished by attempting to obtain “zero-order” 
release from the dosage form, i.e., the rate of drug release is independent of the drug 
concentration. Extended-release systems generally do not attain this type of release and usually 
try to mimic zero-order release. Also factors like pH, presence of food, and other physiological 
factors may affect drug release from conventional CR systems (matrix and reservoir). Osmotic 
systems utilize the principles of osmotic pressure for the delivery of drugs. Drug release from 
these systems is independent of pH and other physiological parameters to a large extent and it is 
possible to modulate the release characteristics by optimizing the properties of drug and system.  
At the same time, they can also be utilized to deliver drugs at a controlled and predetermined 
rate. 
Trimetazidine dihydrochloride is a clinically effective antianginal agent that has been 
used in the prophylaxis and management of angina pectoris and in ischemia of neurosensorial 
tissues also in Meniere’s disease 126. It is freely soluble in water, is rapidly absorbed, and its half-
life is relatively short (t1/2 = 6.0 ± 1.4 h). Therefore, it is a potential candidate for extended-
release formulations; however, controlling its release is a challenging task due to its high water 
solubility.  
Most cardiovascular events are prone to occur in the early mornings hours with the 
renewal of daily activities, and this is accompanied by various neurohumoral stimuli  Precise 
knowledge of the circadian variations paves the way to designing antianginal agents with an 
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appropriate pharmacokinetic profile that ensures effective plasma concentration on trough and 
continuous anti-ischemic and cardio protective effect. 
Treatment of angina pectoris involves long term therapy. Conventional dosage regimen is 
20 mg thrice daily. Hence the objective of our work was to formulate once daily tablets 
containing 60 mg of drug to maintain steady drug blood levels, prolong therapeutic action and 
improved patient compliance. 
The purpose of this work was to formulate a solid dosage form system (tablets) for 
Trimetazidine dihydrochloride using the principles of osmosis which will bring down its dosing 
frequency to once a day and at the same time produce a zero-order release system. It was planned 
to formulate the 3 types of osmotic drug delivery system viz. Monolayer osmotic Tablets 
(Elementary osmotic pump), Bilayer osmotic tablets (Push-pull osmotic pump) and trilayer 
osmotic tablets (Sandwitched osmotic tablet system).  The amount of polymers and osmogens to 
be incorporated in each formulation were decided by optimization technique. Evaluation of the 
prepared tablets was performed by determination of the hardness, friability, content uniformity, 
weight variation. The in vitro release studies for the determination of trimetazidine released from 
the tablet formulations were performed and analyzed. The optimized formulations were then 
compared with the theoretically calculated target release profile to select the best formulation.   
 The optimized formulations were subjected to various comparative tests to study the 
effect of variables on release profiles of the optimized formulations.  The effect of osmotically 
active dissolution medium, effect of agitation rate and the effect of orifice diameter were studied. 
The effect of the storage at high temperatures, namely, 40°C, 50°C, and 60°C for a period of 3 
months on the chemical stability of the selected tablets and prediction of the shelf life was also 
assessed. 
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4.0 Calculation of total dose and theoretical dissolution profile (target profile): 
The pharmacokinetic parameters of Trimetazidine dihydrochloride were utilized for the 
calculation total dose and the theoretical drug release profile for 24 h, once a day, osmotic drug 
delivery of Trimetazidine dihydrochloride.  . 
 
4.1 Calculation of the amount of trimetazidine dihydrochloride to be incorporated in a 
single tablet: 
131
 
The amount of trimetazidine dihydrchloride to be incorporated in a single tablet was 
determined using the following formula: 
Dt = Di (1 + 0.693 x t/t1/2) 
 Where, Dt is the total dose to be incorporated, 
  Di is the dose of the immediate-release formulation (20mg) 
  t is the dosing interval (24hr) 
  t1/2
 
is the biological half life of the drug (7 hours) 
Putting the values in the above equation, the amount of trimetazidine dihydrochloride needed to 
be incorporated into a unit dosage form in order to achieve a 24-hour sustained release was found 
out to be 62.268 mg.  Hence it was decided to formulate a tablet having 60 mg of trimetazidine 
dihydrochloride. 
 
4.2 Calculation of theoretical dissolution profile (target profile) with zero order release 
kinetics: 
The pharmacokinetics parameters of Trimetazidine dihydrochloride which were utilized 
for the calculation of theoretical dissolution profile (target profile) are as below: 
Table 3: Pharmacokinetic parameters of Trimetazidine dihydrochloride 
Bioavailability 
(F) 
 
Therapeutic 
Concentration 
mg/1itre 
Volume of 
Distribution 
(Vd) 
1itre/kg 
Half life 
(h) 
Steady state 
plasma 
concentration 
(Css) 
µg/ml 
82% 0.59 – 1.30 5.1 7 96 
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The immediate release part of sustained release tablet of Trimetazidine dihydrochloride tablet 
can be calculated using the following formula: 
Immediate release part = (Css x Vd) / F 
Where, Css is Steady state plasma concentration, 
 Vd is volume of distribution and 
 F is Fraction bioavailable. 
Putting the values for the parameters in the above equation, the immediate release part in 
a 60 mg sustained release tablet of Trimetazidine dihydrochloride came out to be 5.97 mg  
(≈ 6mg).   
 As we intended to formulate an osmotic drug delivery system, it was decided to have a 
lag phase of 2 hrs, which would permit the flow of fluids through the semipermeable membrane, 
in order to develop a suitable osmotic pressure to release the drug from the tablet.    This meant 
that there should be almost no drug release in the initial two hours.  For calculating the drug 
release from 3
rd
 hour onwards, the portion of immediate release (6mg) and the maintenance dose 
(remaining 54 mg) were each divided by the remaining 22 hours and the fractions were added to 
give the drug release per hour.   The theoretical release profile (target profile) calculated is as 
shown below in Table 4:   
Table 4: Theoretically calculated % cumulative drug release of trimetazidine dihydrochloride: 
 
Time 
(hr) 
Total Amt of Drug 
release (mg) 
% cumulative 
drug  release 
1 0 0 
2 0 0 
3 2.73 4.5 
4 5.45 9.1 
5 8.18 13.6 
6 10.91 18.2 
7 13.64 22.7 
8 16.36 27.3 
9 19.09 31.8 
10 21.82 36.4 
11 24.55 40.9 
12 27.27 45.5 
13 30.00 50.0 
14 32.73 54.5 
15 35.45 59.1 
16 38.18 63.6 
17 40.91 68.2 
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18 43.64 72.7 
19 46.36 77.3 
20 49.09 81.8 
21 51.82 86.4 
22 54.55 90.9 
23 57.27 95.5 
24 60.00 100.0 
 
The graph of Time (hr) v/s % cumulative drug release was plotted to get the r
2
 value for the 
target profile as shown in Figure 7. 
Figure 7: Time (hr) v/s % cumulative drug release of the theoretical target release profile 
 
 
All the trial batches were compared with the target release profile using similarity factor (F2) and 
difference factor (F1) to select the best trial formulation.   
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5.0 Profile of Drug and excipients: 
5.1 List of Drug and excipients used: 
Sr. no. Material Manufacturer/Supplier 
1 
Trimetazidine 
dihydrchloride 
USV Limited, Mumbai. 
2 HPMC K4M  Dow Chemicals Ltd.  
3 Carbopol 71G Noveon 
4 Lactose monohydrate DMV Fontera 
5 Isopropyl alccohol Samir tech. chem. Pvt. 
Ltd. 6 Povidone K/30 ISP Technologies 
7 Sodium chloride Merck Limited 
8 Talc Lar Chem Industries 
9 Magnesium stearate Vasundhara Rasayans Ltd 
10 Cellulose acetate Qualigens Fine Chemicals 
11 Dibutyl cebecate Qualigens Fine Chemicals 
12 Ethanol Qualigens Fine Chemicals 
13 Acetone Qualigens Fine Chemicals 
14 Ferric Oxide Red Dow Chemicals Ltd. 
15 Ferric Oxide Yellow Dow Chemicals Ltd. 
16 Magnesium sulphate Merck Limited 
17 Mannitol  DMV Fontera 
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5.2 Drug and excipients profile 
127
: 
5.2.1 Profile of Trimetazidine dihydrochloride: 
Trimetazidine dihydrochloride: 
It protects the ischaemic cell from the metabolic consequences of ischaemia. It 
specifically opposes intracellular acidification, reduction in energy production and free 
radical over production. Trimetazidine prevents the electro physiological manifestations of 
ischaemia. 
5.2.1.1 Chemistry: 
Trimetazidine dihydrochloride 
IUPAC name: 1-[(2,3,4-trimethoxyphenyl)methyl] piperazine 
Molecular formula: Cl4H22N203.2HCI 
5.2.1.2 Structural formula: 
        OMe 
 
5.2.1.3 Molecular weight: 339.3 
5.2.1.4 Action and use: Vasodilator 
5.2.1.5 Definition: 
1-[(2,3,4-trimethoxyphenyl)methyl] piperazine having a percentage content of 98.5 °A to 
101.5% (dried substance). 
.2HCI 
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5.2.1.6 Characters: 
Appearance 
White or almost white, crystalline powder, slightly hygroscopic. 
Solubility  
Freely soluble in water, sparingly soluble in alcohol 
5.2.1.7 Identification: 
A. Infrared absorption spectrophotometry 
The spectrum obtained is compared with the Reference spectrum of Trimetazidine 
dihydrochloride in Pharmacopoeia of Europe. 
B. Dissolve 25 mg in 5 ml of water R. 2 ml of the solu tion gives reaction of 
chlorides. 
5.2.1.8 Melting point: 220-225°C 
5.2.1.9 Mechanism of Action: 
Trimetazidine dihydrochloride (TMZ) is an anti-ischemic compound whose 
precise mode of action is unknown, although several studies have suggested a metabolic 
effect, and there have been reports of protection of mitochondria against oxidative stress 
damage. Using a Langendorff rat  heart  model,  scientists  examined the effects of  
TMZ on the mitochondrial damage following 30 minutes of ischemia and 5 minutes of 
reperfusion. Mitochondrial respiration with succinate, glutamate-malate and ascorbate-
N,N,N',N'- tetramethylphenylenediamine (TMPD) as substrates was significantly 
decreased following ischemia-reperfusion. Preperfusion with 10
(-5) 
M TMZ had no effect 
on these rates in normoxic or ischemic hearts. However, 10
3)
 M TMZ significantly decreased the 
glutamate-malate rate in mitochondria from normoxic hearts, and this rate was not 
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further decreased following ischemia-reperfusion, and 10°
)
 M TMZ also partially 
protected ascorbate-TMPD activity. The effect on glutamate-malate was probably due to an 
inhibition of complex I by TMZ, which specifically inhibited reduced nicotinamideadenine-
dinucleotide-cytochrome c reductase and complex I in lysed mitochondria They also 
studied the effects of TMZ on the activity of pyruvate dehydrogenase (PDH) in 
normoxic and ischemic hearts perfused with 0.5 mM palmitate, which caused the enzyme to 
be almost completely inactivated. After short periods of ischemia (10-20 minutes) the PDH 
inactivation by palm itate was progressively lost. Preperfusion with 10°
)
 M TMZ had a 
tendency to decrease lactate dehydrogenase release, accompanied by maintenance of the 
inhibition of PDH by palmitate. This may allow the heart to oxidize fatty acids 
preferentially during reperfusion, hence removing possible toxic acyl esters. 
5.2.1.10 Pharmacokinetics: 
Trimetazidine is absorbed through the intestinal mucosa with a Tmax (time to reach maximum 
concentration) of 5.4 hours. The Cmax is 89 microg/L. the t75 (time during which the plasma 
concentration remains above 75% of Cmax) is 11 hours. The bioavailability is 87%, slightly 
inferior with trimetazidine modified release than with the immediate-release formulation, 
explaining the increase in the dose of trimetazidine (35 mg compared with 20 mg for the 
immediate-release tablet). The bioavailability is not influenced by food. The steady state is 
reached 2 to 3 days after starting the treatment. The volume of distribution, unaffected by the 
modified-release formulation, is 4.8 L/kg which means good tissue diffusion. Protein binding 
affinity is low (16%), with equal binding to albumin and alpha-glycoprotein. No uptake of 
trimetazidine in red blood cells was observed. The major drug related component observed in 
plasma and urine was unchanged trimetazidine. In addition to the parent drug, 10 metabolites 
were detected in urine. Seven routes of metabolism have been identified in man: 2 phase I 
oxidation and 5 phase II conjugation routes. Trimetazidine and its metabolites are predominantly 
eliminated in urine. A small proportion of trimetazidine is excreted in the faeces (about 6% of 
the administered dose). The renal trimetazidine clearance is 350 ml/min and is independent of 
the urine and plasma concentration of the drug, whereas it is correlated with renal creatinine 
clearance. That is why the elimination half-life is shorter in the healthy patient compared with 
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the elderly patient (7 and 12 hours, respectively). Trimetazidine can be safely prescribed without 
adapting the dose in elderly patients and in case of renal insufficiency (if creatinine clearance 
remains above 15 ml/min). 
5.2.1.11 Pharmacokinetic features of the immediate release formulation (20 mg) : 
 Cmin = 28.4 µg/L 
Cmax= 94.7 µg/L  
Elimination half  life = 7 hrs 
5.2.1.12 Indications 
Ischaemic heart disease (angina pectoris, sequelae of infarction) 
5.2.1.13 Dosage: 
Adults: 20 mg thrice daily after meals.  
Children: Not recommended. 
5.2.1.14 Contraindications: Hypersensitivity  
5.2.1.15 Special Precautions: 
 Paediatric: Not recommended 
 Pregnancy: Should not be used 
 Lactation: Should not be used 
 Elderly: Caution should be taken  
5.2.1.16 Side effects: G.I.disturbances, nausea, vomiting. 
5.2.1.17 Drug interactions: None reported 
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5.2.2 HYDROXYPROPYL METHYLCELLULOSE (HPMC) 
5.2.2.1 Synonyms 
HPMC, Hydroxypropyl methyl cellulose, Benecel MHPC,Methocel, Methyl cellulose propylene 
glycol ether, Methyl hydroxylpropyl cellulose, Metolose 
5.2.2.2 Chemical name  
Cellulose hydroxylpropyl methyl ether 
5.2.2.3 Functional category  
Coating agent, film former, rate controlling polymer for sustained release, suspending agent, 
tablet binder, Viscosity increasing agent. 
5.2.2.4 Application in Pharmaceutical Formulation:   
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical formulationIn oral 
products, hypromellose is primarily used as a tablet binder, in film coating and as a matrix for 
used in extended release tablet formulation. Depending upon the viscosity grad, concentration of 
2 – 20% w/w is used for film coating solutions to film coat tablets. 
Hypromellose is also used as a suspending agents and thickening agent in topical 
formulation. Hypromellose is also used as an emulsifier, and stabilizers in gels and ointment. 
In addition hypromellose is also used in the manufacturing off capsule, as adhesive 
inplastic bandages and as a wetting agent for hard contact lenses. 
5.2.2.5 Description:  
Hypromellose is an odor less and tasteless, White to creamy white powder. 
5.2.2.6 Typical properties: 
pH     : 5.5 -8.0 for 1 % w/w aqueous solution 
Density (Bulk)   : 0.341 gm/cm
3 
Density (Tapped)   : 0.557 gm/cm
3
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Density (True)   : 1.326 gm/cm
3
 
Glass transition temperature : 170 – 180  
Moisture content   : Hypromellose absorb moisture from the atmosphere 
Solubility    : Practically insoluble in hot water, in acetone, in ethanol,    
                                                              in ether and in toluene. It swells in water forming an   
                                                             opalescent, viscous colloidal solution 
Specific gravity   : 1.26 
5.2.2.7 Stability and Storage Conditions: 
HPMC is stable and should be stored in air tight container. 
5.2.2.8 Incompatibility: 
Hypromellose is incompatible with some oxidizing agents  
5.2.2.9 Safety: 
HPMC is generally regarded as nontoxic and nonirritant material however excessive oral 
consumption may have laxative effect. 
 
5.2.3 CARBOPOL 71 G(CP 974 P NF)
 
Carbomer are synthetic high molecular weight polymer of acrylic acid, that croslinked with 
eitherallyl sucrose or allyl ethers of pentaery thritol. 
5.2.3.1 Synonyms 
Acritamer, Acrilic acid polymer, Carbomer, Carboxyvinyl polymer, Poly acrylic acid. 
5.2.3.2 Chemical Name 
Carbomer 
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5.2.3.3 Molecular Weight 
3x10
6 
D 
5.2.3.4 Functional Category 
Bioadhesive, Emulsifying agent, suspending agent, tablet    binder, viscosity increasing agent, 
Release modifying agent. 
5.2.3.6 Application in Pharmaceutical Formulation or Technology: 
 Carbopol 934 is used mainly in liquid or semisolid pharmaceutical formulations as 
suspending or viscosity increasing agent and in formulation including Creams, gels and 
ointments for ophthalmic, rectal and topical preparations. 
In the tablet formulations carbomers are used as dry or wet binder and as a rate 
controlling excipients. 
Carbomer rasines have also been investigated in the preparation of sustained release 
matrix beads, as enzyme inhibitors of intestinal proteases in peptide containing dosage forms, as 
a bioadhesive patch for cervical patch and for intranasally administered microspears, in magnetic 
granules for site specific drug delivery to the esophagus and in oral mucoadhesive controlled 
drug delivery system 
                         Table 5 : Use of carbopol 
Use Concentration 
Emulsifying agent 0.1 - 0.5% 
Gelling agent 0.5 – 2.0 % 
Suspending agent 0.5 – 1 % 
Tablet binder 5.0 – 10 % 
5.2.3.7 Description: 
 Carbopol is white, fluffy powder, having slight characteristic odour. It is hygroscopic. 
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5.2.3.8 Typical properties 
pH     : 2.7 – 3.5 for a 0.5 %w/v aqueous dispersion 
       2.5 – 3.0 for 1 % w/v aqueous dispersion 
Density (Bulk)   :1.76 – 2.08 gm/cm3 
Density (Tapped)   :1.4 gm/cm
3 
Glass transition temperature : 100 – 105 c 
Particle size distribution  : primary particle average about 0.2 um in diameter 
Solubility    : Soluble in water and after neutralization in ethanol (95%)  
                                                               and glycerin. 
Specific gravity   : 1.41 
Viscosity    : 0.5% w/v 30500 – 39400 mpa 
5.2.3.9 Stability and Storage Conditions: 
 Carbopol is stable and should be stored in tight containers. 
5.2.3.10 Incompatibilities: 
Carbomer are discoloured by resorsinol and are incompatible with phenol,cationic 
polymers strong acids and high level of electrolite 
5.2.3.11 Safety: 
 It is regarded as essentially nontoxic and nonirritant materials. 
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5.2.4 Povidone 
5.2.4.1 Nonproprietary Names 
BP: Povidone 
JP: Povidone 
PhEur: Povidonum 
USP: Povidone 
5.2.4.2 Synonyms 
E1201; Kollidon; Plasdone; poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; polyvidone; 
polyvinylpyrrolidone; PVP; 1-vinyl-2-pyrrolidinone polymer 
5.2.4.3 Chemical Name and CAS Registry Number 
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
5.2.4.4 Structural Formula  
 
5.2.4.5 Functional Category 
Disintegrant; dissolution aid; suspending agent; tablet binder. 
5.2.4.6 Applications in Pharmaceutical Formulation or Technology 
Although povidone is used in a variety of pharmaceutical formulations, it is primarily used in 
solid-dosage forms. In tableting, povidone solutions are used as binders in wet-granulation 
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processes.  Povidone is also added to powder blends in the dry form and granulated in situ by the 
addition of water, alcohol, or hydroalcoholic solutions. Povidone is used as a solubilizer in oral 
and parenteral formulations and has been shown to enhance dissolution of poorly soluble drugs 
from solid-dosage forms. Povidone solutions may also be used as coating agents. Povidone is 
additionally used as a suspending, stabilizing, or viscosity-increasing agent in a number of 
topical and oral suspensions and solutions. The solubility of a number of poorly soluble active 
drugs may be increased by mixing with povidone. Special grades of pyrogen-free povidone are 
available and have been used in parenteral formulations. 
Table 6:  Uses of povidone. 
Use 
Concentration 
(%) 
Carrier for drugs 10–25 
Dispersing agent Up to 5 
Eye drops 2–10 
Suspending agent Up to 5 
Tablet binder, tablet diluent, or coating 
agent 
0.5–5 
 
5.2.4.7 Description 
Povidone occurs as a fine, white to creamy-white colored, odorless or almost odorless, 
hygroscopic powder. Povidones with K-values equal to or lower than 30 are manufactured by 
spray-drying and occur as spheres. Povidone K-90 and higher K-value povidones are 
manufactured by drum drying and occur as plates. 
5.2.4.8 Typical Properties 
Acidity/alkalinity: pH = 3.0–7.0 (5% w/v aqueous solution). 
Density (bulk): 0.29–0.39 g/cm3 
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Density (tapped): 0.39–0.54 g/cm3 
Density (true): 1.180 g/cm 
Melting point: softens at 1508C 
5.2.4.9 Solubility:  
freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and water; practically 
insoluble in ether, hydrocarbons, and mineral oil. In water, the concentration of a solution is 
limited only by the viscosity of the resulting solution, which is a function of the K-value. 
5.2.4.10 Stability and Storage Conditions 
Povidone darkens to some extent on heating at 150 C, with a reduction in aqueous solubility. It is 
stable to a short cycle of heat exposure around 110–130 C; steam sterilization of an aqueous 
solution does not alter its properties. Aqueous solutions are susceptible to mold growth and 
consequently require the addition of suitable preservatives. Povidone may be stored under 
ordinary conditions without undergoing decomposition or degradation. However, since the 
powder is hygroscopic, it should be stored in an airtight container in a cool, dry place 
5.2.4.11 Incompatibilities 
Povidone is compatible in solution with a wide range of inorganic salts, natural and synthetic 
resins, and other chemicals. It forms molecular adducts in solution with sulfathiazole, sodium 
salicylate, salicylic acid, phenobarbital, tannin, and other compounds. The efficacy of some 
preservatives, e.g. thimerosal, may be adversely affected by the formation of complexes with 
povidone. 
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5.2.5 Lactose, Monohydrate 
5.2.5.1 Nonproprietary Names 
BP: Lactose monohydrate 
PhEur: Lactosum monohydricum 
JP: Lactose 
USPNF: Lactose monohydrate 
5.2.5.2 Chemical Name and CAS Registry Number 
O-b-D-Galactopyranosyl-(1!4)-a-D-glucopyranose monohydrate [64044-51-5] 
5.2.5.3 Empirical Formula and Molecular Weight 
C12H22O11.H2O   360.31 
5.2.5.4 Structural Formula 
 
5.2.5.5 Functional Category 
Binding agent; diluent for dry-powder inhalers; tablet binder; tablet and capsule diluent. 
5.2.5.6 Applications in Pharmaceutical Formulation or Technology 
Lactose is widely used as a filler or diluent in tablets and capsules, and to a more limited 
extent in lyophilized products and infant formulas.  Lactose is also used as a diluent in dry-
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powder inhalation. Various lactose grades are commercially available that have different 
physical properties such as particle size distribution and flow characteristics. This permits the 
selection of the most suitable material for a particular application; for example, the particle size 
range selected for capsules is often dependent on the type of encapsulating machine used. 
Usually, fine grades of lactose are used in the preparation of tablets by the wet-granulation 
method or when milling during processing is carried out, since the fine size permits better mixing 
with other formulation ingredients and utilizes the binder more efficiently.  Other applications of 
lactose include use in lyophilized products, where lactose is added to freeze-dried solutions to 
increase plug size and aid cohesion. Lactose is also used in combination with sucrose 
(approximately 1:3) to prepare sugar-coating solutions. Direct-compression grades of lactose 
monohydrate are available as granulated/agglomerated a-lactose monohydrate, containing small 
amounts of anhydrous lactose. Direct-compression grades are often used to carry lower 
quantities of drug and this permits tablets to be made without granulation. Other directly 
compressible lactoses are spray-dried lactose and anhydrous lactose.  
5.2.5.7 Description 
In the solid state, lactose appears as various isomeric forms,depending on the crystallization and 
drying conditions, i.e. α -lactose monohydrate, β -lactose anhydrous, and α -lactose anhydrous. 
The stable crystalline forms of lactose are α -lactose monohydrate, β -lactose anhydrous, and 
stable α -lactose anhydrous. Lactose occurs as white to off-white crystalline particles or powder. 
Lactose is odorless and slightly sweet-tasting; α -lactose is approximately 20% as sweet as 
sucrose, while β -lactose is 40% as sweet. 
5.2.5.8 Typical Properties 
Density (true): 1.545 g/cm3 (a-lactose monohydrate) 
Density (bulk): 0.75 g/cm3 
Density (tapped): 0.88 g/cm3 
Melting point: 201–202 C (for dehydrated α -lactose monohydrate) 
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5.2.5.9 Solubility of lactose: 
Solvent Solubility at 20 C unless otherwise stated 
Chloroform Practically insoluble 
Ethanol Practically insoluble 
Ether Practically insoluble 
Water 
1 in 5.24 
1 in 3.05 at 40 C 
1 in 2.30 at 50 C 
1 in 1.71 at 60 C 
1 in 0.96 at 80 C 
5.2.5.10 Stability and Storage Conditions 
Mould growth may occur under humid conditions (80%relative humidity and above). Lactose 
may develop a brown coloration on storage, the reaction being accelerated by warm, damp 
conditions. The purities of different lactoses can vary and color evaluation may be important, 
particularly if white tablets are being formulated. The color stabilities of various lactoses also 
differ. Solutions show mutorotation. Lactose should be stored in a well-closed container in a 
cool, dry place. 
5.2.5.11 Incompatibilities 
A Maillard-type condensation reaction is likely to occur between lactose and compounds with a 
primary amine group to form brown, or yellow-brown-colored products.  Lactose is also 
incompatible with amino acids, aminophylline, amphetamines and lisinopril.  
 
5.2.6 Isopropyl alcohol 
5.2.6.1 Nonproprietary Names 
BP: Isopropyl alcohol 
JP: Isopropanol 
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PhEur: Alcohol isopropylicus 
USP: Isopropyl alcohol 
5.2.6.2 Synonyms 
Dimethyl carbinol; IPA; isopropanol; petrohol; 2-propanol; sec-propyl alcohol. 
5.2.6.3 Chemical Name and CAS Registry Number 
Propan-2-ol [67-63-0] 
5.2.6.4 Empirical Formula and Molecular Weight 
C3H8O   60.1 
5.2.6.5 Structural Formula 
 
5.2.6.6 Functional Category 
Disinfectant; solvent 
5.2.6.7 Applications in Pharmaceutical Formulation or Technology 
Isopropyl alcohol (propan-2-ol) is used in cosmetics and pharmaceutical formulations primarily 
as a solvent in topical formulations.  It is not recommended for oral use owing to its toxicity. 
Although it is used in lotions, the marked degreasing properties of isopropyl alcohol may limit its 
usefulness in preparations used repeatedly. Isopropyl alcohol is also used as a solvent both for 
tablet film-coating and for tablet granulation, where the isopropyl alcohol is subsequently 
removed by evaporation. It has also been shown to significantly increase the skin permeability of 
nimesulide from carbomer 934. Isopropyl alcohol has some antimicrobial activity and a 70% v/v 
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aqueous solution is used as a topical disinfectant. Therapeutically, isopropyl alcohol has been 
investigated for the treatment of postoperative nausea or vomiting. 
5.2.6.8 Description 
Isopropyl alcohol is a clear, colorless, mobile, volatile, flammable liquid with a characteristic, 
spirituous odor resembling that of a mixture of ethanol and acetone; it has a slightly bitter taste. 
5.2.6.9 Typical Properties 
Boiling point: 82.4 C 
Flammability: flammable. 
Freezing point: -89.5 C 
Melting point: -88.5 C 
5.2.6.10 Solubility:  
miscible with benzene, chloroform, ethanol (95%), ether, glycerin, and water. Soluble in acetone; 
insoluble in salt solutions. Forms an azeotrope with water, containing 87.4% w/w isopropyl 
alcohol (boiling point 80.37 C). 
5.2.6.11 Stability and Storage Conditions:  
Isopropyl alcohol should be stored in an airtight container in a cool, dry place. 
5.2.6.12 Incompatibilities 
Incompatible with oxidizing agents such as hydrogen peroxide and nitric acid, which cause 
decomposition. Isopropyl alcohol may be salted out from aqueous mixtures by the addition of 
sodium chloride, sodium sulfate, and other salts, or by the addition of sodium hydroxide. 
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5.2.7 Cellulose acetate: 
5.2.7.1 Nonproprietary Names 
BP: Cellulose acetate 
PhEur: Cellulosi acetas 
USPNF: Cellulose acetate 
5.2.7.2 Synonyms 
Acetyl cellulose; cellulose diacetate; cellulose triacetate. 
5.2.7.3 Chemical Name and CAS Registry Number 
Cellulose acetate [9004-35-7] 
Cellulose diacetate [9035-69-2] 
Cellulose triacetate [9012-09-3] 
5.2.7.4 Empirical Formula and Molecular Weight 
Cellulose acetate is cellulose in which a portion or all of the hydroxyl groups are acetylated. 
Cellulose acetate is available in a wide range of acetyl levels and chain lengths and thus 
molecular weights. 
5.2.7.5 Structural Formula 
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5.2.7.6 Functional Category 
Coating agent; extended release agent; tablet and capsule diluents 
5.2.7.7 Applications in Pharmaceutical Formulation or Technology 
Cellulose acetate is widely used in pharmaceutical formulations both in sustained-release 
applications and for taste masking. Cellulose acetate is used as a semipermeable coating on 
tablets, especially on osmotic pump-type tablets and implants. This allows for controlled, 
extended release of actives. Cellulose acetate films, in conjunction with other materials, also 
offer sustained release without the necessity of drilling a hole in the coating as is typical with 
osmotic pump systems. Cellulose acetate and other cellulose esters have also been used to form 
drug-loaded microparticles with controlled-release characteristics.  Cellulose acetate films are 
used in transdermal drug delivery systems and also as film coatings on tablets or granules for 
taste masking. For example, acetaminophen granules have been coated with a cellulose acetate-
based coating before being processed to provide chewable tablets. Extended-release tablets can 
also be formulated with cellulose acetate as a directly compressible matrix former.  The release 
profile can be modified by changing the ratio of active to cellulose acetate and by incorporation 
of plasticizer, but was shown to be insensitive to cellulose acetate molecular weight and particle 
size distribution. Therapeutically, cellulose acetate has been used to treat cerebral aneurysms, 
and also for spinal perimedullary arterio-venous fistulas. 
5.2.7.8 Description 
Cellulose acetate occurs as a white to off-white powder, free-flowing pellets, or flakes. It is 
tasteless and odorless, or may have a slight odor of acetic acid. 
5.2.7.9 Typical Properties 
Density (bulk): typically 0.4 g/cm3 for powders 
Glass transition temperature: 170–190 C 
Melting point: melting range 230–300 C 
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5.2.7.10 Solubility:  
The solubility of cellulose acetate is greatly influenced by the level of acetyl groups present. In 
general, cellulose acetates are soluble in acetone–water blends of varying ratios, 
dichloromethane–ethanol blends, dimethyl formamide, and dioxane. The cellulose acetates of 
higher acetyl level are generallymore limited in solvent choice than are the lower-acetyl 
materials. 
5.2.7.11 Stability and Storage Conditions 
Cellulose acetate is stable if stored in a well-closed container in a cool, dry place. Cellulose 
acetate hydrolyzes slowly under prolonged adverse conditions such as high temperature and 
humidity, with a resultant increase in free acid content and odor of acetic acid. 
5.2.7.12 Incompatibilities 
Cellulose acetate is incompatible with strongly acidic or alkaline substances. Cellulose acetate is 
compatible with the following plasticizers: diethyl phthalate, polyethylene glycol, triacetin, and 
triethyl citrate 
 
5.2.8 Dibutyl Cebecate 
5.2.8.1 Nonproprietary Names 
USPNF: Dibutyl sebacate 
5.2.8.2 Synonyms 
Butyl sebacate; decanedioic acid, dibutyl ester; dibutyl decanedioate; dibutyl 1,8-
octanedicarboxylate; Kodaflex DBS. 
5.2.8.3 Chemical Name and CAS Registry Number 
Decanedioic acid, di-n-butyl ester [109-43-3] 
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5.2.8.4 Empirical Formula and Molecular Weight 
C18H34O4    314.47 
5.2.8.5 Structural Formula 
 
5.2.8.6 Functional Category 
Plasticizer. 
5.2.8.7 Applications in Pharmaceutical Formulation or Technology 
Dibutyl sebacate is used in oral pharmaceutical formulations as a plasticizer for film coatings on 
tablets, beads, and granules, at concentrations of 10–30% by weight of polymer. It is also used as 
a plasticizer in controlled-release tablets and microcapsule preparations. Dibutyl sebacate is also 
used as a synthetic flavor and flavour adjuvant in food products; for example, up to 5 ppm is 
used in ice cream and nonalcoholic beverages. 
5.2.8.7 Description 
Dibutyl sebacate is a clear, colorless, oily liquid with a bland to slight butyl odor. 
5.2.8.8 Typical Properties 
Boiling point: 344–349 C 
Flash point: 193 C 
Melting point: -10 C 
5.2.8.9 Stability and Storage Conditions 
Dibutyl sebacate is stable. It is not reactive with water and hazardous polymerization does not 
occur. Dibutyl sebacate should be stored in a closed container in a cool, dry location. 
5.2.8.10 Incompatibilities 
Dibutyl sebacate is incompatible with strong oxidizing materials and strong alkalis. 
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5.2.9 Sodium chloride: 
5.2.9.1 Nonproprietary Names 
BP: Sodium chloride 
JP: Sodium chloride 
PhEur: Natrii chloridum 
USP: Sodium chloride 
5.2.9.2 Synonyms 
Alberger; chlorure de sodium; common salt; hopper salt; natural halite; rock salt; saline; salt; sea 
salt; table salt. 
5.2.9.3 Chemical Name and CAS Registry Number 
Sodium chloride [7647-14-5] 
5.2.9.4 Empirical Formula and Molecular Weight 
            NaCl                  58.44 
5.2.9.5 Structural Formula 
NaCl 
5.2.9.6 Functional Category 
Tablet and capsule diluent; tonicity agent 
5.2.9.7 Applications in Pharmaceutical Formulation or Technology 
Sodium chloride is widely used in a variety of parenteral and nonparenteral pharmaceutical 
formulations, where the primary use is to produce isotonic solutions. Sodium chloride has been 
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used as a lubricant and diluent in capsules and direct-compression tablet formulations in the past, 
although this practice is no longer common. Sodium chloride has also been used as a channeling 
agent and as an osmotic agent in the cores of controlled-release tablets. It has been used as a 
porosity modifier in tablet coatings, and to control drug release from microcapsules. 
5.2.9.8 Description 
Sodium chloride occurs as a white crystalline powder or colorless crystals; it has a saline taste. 
The crystal lattice is a face-centered cubic structure. Solid sodium chloride contains no water of  
crystallization although, below 08C, salt may crystallize as a dihydrate. 
 
5.2.9.9 Typical Properties 
Boiling point: 141.3 C 
Density: 
2.17 g/cm
3
; 
1.20 g/cm
3
 for saturated aqueous solution. 
Density (bulk): 0.93 g/cm3 
Density (tapped): 1.09 g/cm3 
5.2.9.10 Stability and Storage Conditions 
Aqueous sodium chloride solutions are stable but may cause the separation of glass particles 
from certain types of glass containers. Aqueous solutions may be sterilized by autoclaving or 
filtration. The solid material is stable and should be stored in a well-closed container, in a cool, 
dry place. It has been shown that the compaction characteristics and the mechanical  properties 
of tablets are influenced by the relative humidity of the storage conditions under which sodium 
chloride was stored 
 
5.2.9.11 Incompatibilities 
Aqueous sodium chloride solutions are corrosive to iron. They also react to form precipitates 
with silver, lead, and mercury salts. Strong oxidizing agents liberate chlorine from acidified 
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solutions of sodium chloride. The solubility of the antimicrobial preservative methylparaben is 
decreased in aqueous sodium chloride solutions and the viscosity of carbomer gels and solutions 
of hydroxyethyl cellulose or hydroxypropyl cellulose is reduced by the addition of sodium 
chloride. 
 
5.2.10 Mannitol 
5.2.10.1 Nonproprietary Names 
BP: Mannitol 
JP: D-Mannitol 
PhEur: Mannitolum 
USP: Mannito 
5.2.10.2 Synonyms 
Cordycepic acid; C*PharmMannidex; E421; manna sugar; D-mannite; mannite; Mannogem; 
Pearlitol. 
5.2.10.3 Chemical Name and CAS Registry Number 
D-Mannitol   [69-65-8] 
5.2.10.4 Empirical Formula and Molecular Weight 
C6H14O6     182.17 
5.2.10.5 Structural Formula 
 
Chapter 5                                                                                                                 Profile of Drug and excipients 
Osmotic Drug Delivery System                                                                                                                         Page 65 
 
5.2.10.6 Functional Category 
Diluent; diluent for lyphilized preparations; sweetening agent; tablet and capsule diluent; tonicity 
agent. 
5.2.10.7 Applications in Pharmaceutical Formulation or Technology 
Mannitol is widely used in pharmaceutical formulations and food products. In pharmaceutical 
preparations it is primarily used as a diluent (10–90% w/w) in tablet formulations, where it is of 
particular value since it is not hygroscopic and may thus be used with moisture-sensitive active 
ingredients. Mannitol may be used in direct-compression tablet applications, for which the 
granular and spray-dried forms are available, or in wet granulations. Granulations containing 
mannitol have the advantage of being dried easily. Specific tablet applications include antacid 
preparations, glyceryl trinitrate tablets, and vitamin preparations. Mannitol is commonly used as 
an excipient in the manufacture of chewable tablet formulations because of its negative heat of 
solution, sweetness, and ‘mouth feel’.Also úsed as an osmotic agent 
5.2.10.8 Description 
Mannitol is D-mannitol. It is a hexahydric alcohol related to mannose and is isomeric with 
sorbitol. 
Mannitol occurs as a white, odorless, crystalline powder, or free-flowing granules. It has a sweet 
taste, approximately as sweet as glucose and half as sweet as sucrose, and imparts a cooling 
sensation in the mouth. Microscopically, it appears as orthorhombic needles when crystallized 
from alcohol. Mannitol 
shows polymorphism 
 
5.2.10.9 Typical Properties 
Flash point: <150 C 
Density (bulk): 
0.430 g/cm3 for powder; 
0.7 g/cm3 for granules. 
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Density (tapped): 
0.734 g/cm3 for powder; 
0.8 g/cm3 for granules. 
Density (true): 1.514 g/cm3 
5.2.10.10 Stability and Storage Conditions 
Mannitol is stable in the dry state and in aqueous solutions. Solutions may be sterilized by 
filtration or by autoclaving and if necessary may be autoclaved repeatedly with no adverse 
physical or chemical effects. In solution, mannitol is not attacked by cold, dilute acids or alkalis, 
nor by atmospheric oxygen in the absence of catalysts. Mannitol does not undergo Maillard 
reactions. The bulk material should be stored in a well-closed container in a cool, dry place. 
5.2.10.11 Incompatibilities 
Mannitol solutions, 20% w/v or stronger, may be salted out by potassium chloride or sodium 
chloride. Precipitation has been reported to occur when a 25% w/v mannitol solution was 
allowed to contact plastic. Sodium cephapirin at 2 mg/mL and 30 mg/mL concentration is 
incompatible with 20% w/v aqueous mannitol solution. Mannitol is incompatible with xylitol 
infusion and may form complexes with some metals such as aluminum, copper, and iron. 
Reducing sugar impurities in mannitol have been implicated in the oxidative degradation of a 
peptide in a lyophilized formation. Mannitol was found to reduce the oral bioavailability of 
cimetidine compared to sucrose. 
  
 
 
CHAPTER 6 
ANALYTICAL METHODS 
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6.0 ANALYTICAL METHOD 
 
6.1 DEVELOPMENT OF ANALYTICAL METHOD 
 
6.1.1 Selection of solvent 
Distilled water was selected as a dissolution media because it proved to be most 
suitable for development of osmotic pressure by dissolving the osmogens and also had good 
permeability through the semi permeable membrane coating on the prepared tablets. 
  
Solubility of Trimetazidine dihydrochloride in distilled water. 
Solubility of drug in distilled water was determined by dissolving the known quantity 
of drug in cumulative manner with the aid of sonication till the drug remains insoluble.  
The solubility of Trimetazidine dihydrochloride in distilled water was found to be 9.7 
mg/ml 
 
6.1.2 Determination of λmax.  
The absorption maxima of Trimetazidine dihydrochloride was determined by running 
the spectrum of drug solution in double beam ultraviolet spectrophotometer  
Procedure 
UV spectrum of the drug was carried out in distilled water . Trimetazidine dihydrochloride 
(10 mg) was accurately weighed and dissolved in distilled water. The solution was then diluted 
using the same medium. An 80 ug/m1 solution was kept in a fused silica cell and UV spectrum 
was recorded in the wavelength range of 200-400 nm range in U.V. Spectrophotometer 
(SCHIMADHZU). 
 
The spectrum peak point graph of absorbance of Trimetazidine dihydrochloride 
versus wave length was shown in figure No.7.   
The Trimetazidine dihydrochloride shows the absorbance maxima at 270 nm.in 
distilled water. 
 
 
 
 
 
 
Chapter 6                                                                                                                    Analytical method 
Osmotic Drug Delivery System                                                                                                   Page 68 
 
Figure 8: UV spectrum of Trimetazidine dihydrochloride in distilled water 
 
 
     
6.2 VALIDATION OF ANALYTICAL METHOD
128, 129
. 
6.2.1 Linearity and Range. 
6.2.1.1 Linearity 
The linearity of an analytical procedure is its ability (within a given range) to obtain 
test results which are directly proportional to the concentration (amount) of analyte in the 
sample. 
A linear relationship should be evaluated across the range of the analytical procedure. 
It may be demonstrated directly on the active substance (by dilution of a standard stock 
solution) and/or on separate weighings of synthetic mixtures of the product components, 
using the proposed procedure. The latter aspect can be studied during investigation of the 
range
128, 129
. 
6.2.1.2 Range 
The range of an analytical procedure is the interval between the upper and lower 
concentration (amounts) of analyte in the sample (including these concentrations) for which it 
has been demonstrated that the analytical procedure has a suitable level of precision, accuracy 
and linearity.   
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The specified range is normally derived from linearity studies and depends on the 
intended application of the procedure. It is established by confirming that the analytical 
procedure provides an acceptable degree of linearity, accuracy and precision when applied to 
samples containing amounts of analyte within or at the extremes of the specified range of the 
analytical procedure
128, 129
. 
Procedure 
Trimetazidine dihydrochloride (10mg) was accurately weighed and dissolved in 100 
ml of medium [distilled water] to give a stock solution of concentration 100 ug/ml. From 
this stock aliquots of solutions were transferred into nine 10 ml volumetric flasks and the 
final volume was adjusted with the appropriate medium to give concentrations of 5, 10, 20, 
30, 40, 50, 60, 70 and 80 ug/ml.  The absorbances were measured at 270 nrn against a blank 
medium. 
This experiment was performed in replicate of three and the average of absorbance 
was calculated and curve of absorbance verses concentration was plotted. The results were 
shown in table no.6. 
Acceptance criteria: The absorbance of solution of drug in solution be linear with 
concentration of drug in solution with lower (5ug/ml) and higher level (80μg/ml) of target 
concentration i.e. 30 µg/ml. 
    
Table 7: Absorbance of Trimetazidine dihydrochloride at 270 nm. 
Conc. 
(µg/ml) 
Absorbance 
Average 
Series 1 Series 2 Series 3 
0 0 0 0 0.000 
5 0.013 0.012 0.012 0.012 
10 0.028 0.025 0.026 0.026 
20 0.056 0.06 0.06 0.059 
30 0.084 0.084 0.084 0.084 
40 0.114 0.112 0.111 0.112 
50 0.146 0.14 0.141 0.142 
60 0.167 0.168 0.168 0.168 
70 0.186 0.183 0.184 0.184 
80 0.199 0.199 0.199 0.199 
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Figure 9: Linearity curve of Trimetazidine dihydrochloride at 270 nm in distilled 
water 
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The results of Linearity test shows that the absorbance of the Trimetazidine 
dihydrochloride in distilled water at 270 nm is linear (r
2
=0.992) with concentration range of 
5ug/ml to 80ug/ml.  
 
6.2.2 Specificity 
Specificity is the ability to assess unequivocally the analyte in the presence of 
components, which may be expected to be present. Typically these might include impurities, 
degradants, matrix, etc
128, 129
. 
Specificity test is done by measuring the absorbance of placebo solution standard 
solution and mixing of placebo and standard solution. 
Procedure: 
  Standard solutions were prepared by dissolving 10 mg of accurately weighed drug in 
500 ml of distilled water with aid of sonication for 20 minute. From this stock solution, 30 ml 
of solution was withdrawn and diluted up to 100 ml with same media in 100 ml volumetric 
flask. 
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Placebo solution was prepared by the addition and mixing of excipients required for 
the formulation in 500 ml of distilled water. From this solution 30 ml of the solution was 
diluted up to 100 ml with the same media in 100 ml volumetric flask. 
Mixture of drug and placebo were prepared by dissolving accurately weighing 10 mg 
of drug and equivalent quantity of mixed excipients required in formulation in 500 ml of 
distilled water in volumetric flask with aid of sonication for 20 minutes. From this solution 30 
ml of solution was withdrawn and was diluted up to 100 ml with same media in 100 ml 
volumetric flask. All these three solutions were filtered through 0.45μm filter and scan in U.V 
in overlay mode was taken. 
Acceptance criteria:  There should not be any marked change in the absorbance of the 
standard after addition of placebo.  Also the placebo solution should not show significant 
absorbance.  
The results were shown in table no.8. 
Table 8: Results of Specificity test for analytical method development 
Test solution Absorbance at 270 nm 
Placebo 0.001 
Standard 0.084 
Standard + Placebo 0.083 
 
The results of the specificity test showed that there is no placebo interference at 270 
nm.  
6.2.3 Precision:  
The precision of an analytical procedure expresses the closeness of agreement (degree 
of scatter) between a series of measurements obtained from multiple sampling of the same 
homogeneous sample under the prescribed conditions. Precision may be considered at three 
levels: repeatability, intermediate precision and reproducibility. 
Precision should be investigated using homogeneous, authentic samples. However, if 
it is not possible to obtain a homogeneous sample it may be investigated using artificially 
prepared samples or a sample solution
128, 129
. 
The precision of an analytical procedure is usually expressed as the variance, standard 
deviation or coefficient of variation of a series of measurements. 
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A. Method precision:  
Method precision test was performed by measuring the absorbance of the target 
solution of target concentration at its λ max in six replicates128, 129. 
Procedure: 
Stock solution was prepared according to the earlier procedure and suitable dilution 
was made to prepare 30 μg/ml solutions. The absorbance of these solutions was measured at 
270 nm. This experiment was performed in six replicates. Standard deviation and %R.S.D 
between six absorbances were calculated as shown in table no.8. 
Acceptance criteria: The %R.S.D should not be more than 2%. 
 
               Table 9: Results of Method Precision. 
Sample I.D. Absorbance at 270 nm 
T1 0.087 
T2 0.086 
T3 0.084 
T4 0.086 
T5 0.087 
T6 0.084 
Avg. 0.08566 
S.D. 0.001366 
%RSD 1.604 
 
The results of the method precision show that the percentage RSD of the absorbance 
is less than 2%. 
B. System Precision: 
System precision test was done by measuring the absorbance of solution at small time 
interval in replicates of nine. This test is also known as repeatability
128, 129
. 
Procedure: 
The stock solution was prepared as described previously and suitable dilution was 
made to prepare 30 μg/ml solutions. The absorbance of this solution was read at 270 nm at 
small time interval in 9 replicates. The R.S.D and standard deviation was shown in table no.9 
Acceptance criteria:  The %R.S.D should not be more than 1 %. 
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                Table 10: Results of System Precision. 
Sr.no 
Absorbance at 
270 nm 
1 0.084 
2 0.084 
3 0.084 
4 0.083 
5 0.084 
6 0.085 
7 0.084 
8 0.084 
9 0.084 
Avg. 0.084 
S.D. 0.0005 
%RSD 0.5952 
 
The results of the system precision shows that the % RSD of the absorbance is less 
than 1% 
 
C. Interday and Intraday Precision: 
Interday precision was done by measuring the absorbance of 30 μg/ml solution of 
Trimetazidine dihydrochloride in distilled water at 270 nm at 2 hours interval within a day. 
Intraday precision test was done by measuring the measuring the absorbance of the 30 
μg/ml solution of Trimetazidine dihydrochloride distilled water at 270 nm in three day128, 129.   
  
The average, standard deviation and percentage RSD of the absorbance was 
calculated as show in Table 11 and12. 
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Table 11: Results of inter day precision   Table 12: Results of intraday precision 
. 
 
 
 
 
 
 
 
 
 
The results of the intraday and interday precisions shows that the %RSD of the 
absorbance is less than 1% 
 
 
6.2.4 Accuracy  
The accuracy of an analytical procedure expresses the closeness of agreement 
between the value which is accepted either as a conventional true value or an accepted 
reference value and the value found. This is sometimes termed trueness
128, 129
. 
Accuracy should be established across the specified range of the analytical procedure. 
 
Procedure:  
 Prepare the blend of placebo and the active by mixing the active drug in to the 
placebo powder at 25%, 50%, 75%, 100%, 125%, 150% level of the target concentration 
each in triplicate. Analyze the recovery of sample as per proposed test method and calculate 
the amount of drug recovered at each spike level and 5 recovery at each spike level. The 
results were shown in table no. 12. 
  
 
 
 
 
Time 
Absorbance 
at 270 nm 
09:00AM 0.084 
12:00AM 0.084 
05:00AM 0.083 
Avg. 0.084 
S.D 0.000707 
%RSD 0.8333 
Day 
Absorbance 
at 270 nm 
1st Day 0.084 
2nd Day 0.083 
3rd Day 0.083 
Avg. 0.08333 
S.D. 0.000577 
%RSD 0.6 
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Table 13: Results of Accuracy Test. 
Recovery 
Level 
Amount 
Of Drug 
Recovered(mg) 
Amount 
of Drug 
added(mg) 
%Recovery Average S.D. %RSD 
25% 
14.95 15 99.67 
100.04 
 
0.49 
 
0.49 
 
14.98 15 99.87 
15.09 15 100.60 
50% 
29.60 30 98.67 
99.69 
 
0.89 
 
0.89 
 
30.08 30 100.27 
30.04 30 100.13 
75% 
44.2 45 98.22 
99.48 
 
1.14 
 
1.15 
 
44.9 45 99.78 
45.2 45 100.44 
100% 
59.0 60 98.33 
98.94 
 
0.79 
 
0.80 
 
59.9 60 99.83 
59.2 60 98.67 
125% 
74.2 75 98.93 
100.13 
 
1.14 
 
1.14 
 
75.9 75 101.20 
75.2 75 100.27 
150% 
90.9 90 101.00 
100.07 0.94 0.94 89.2 90 99.11 
90.1 90 100.11 
 
 Acceptance criteria: the difference between the individual recovery and the average 
recovery at each spike level shall be ± 2% and the recovery shall be not less than 98% and not 
more than 102%. 
The percentage RSD for the triplicate at each spike level shall be not more than 2%. 
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6.2.5 Robustness test 
The robustness of an analytical method is a measure of capacity to maintained 
unaffected by small, deliberate variation in method parameters and provides an indication of 
its reliability during normal usage
128, 129
. 
Robustness test was done by measuring the solution stability for 8 hours. 
Procedure 
The main stock solution was prepared as described previously. From this stock 
aliquots of solutions were transferred into 10 ml volumetric flasks and the final volume was 
adjusted with the appropriate medium to give concentrations of 10, 20, 30, 40 ug/ml solution. 
The absorbances of these solutions were measured in interval of 1 hour for 8 hours. 
The results of Solution Stability were shown in table no.14. 
 
Table 14: Results of Solution Stability. 
Time (hr) Absorbance at 270 nm 
10 ug/ml 20 ug/ml 30 ug/ml 40 ug/ml 
Initial 0.028 0.054 0.083 0.116 
1 0.027 0.053 0.083 0.115 
2 0.028 0.053 0.084 0.116 
3 0.028 0.054 0.084 0.114 
4 0.028 0.054 0.084 0.115 
5 0.028 0.054 0.083 0.116 
6 0.028 0.052 0.082 0.114 
7 0.027 0.053 0.084 0.116 
8 0.0275 0.054 0.084 0.116 
Avg. 0.027722 0.053444 0.083444 0.115333 
S.D. 0.00044 0.00072 0.00072 0.00086 
%RSD 1.5906 1.3593 0.87 0.75 
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6.3 CONCLUSION OF ANALYTICAL METHOD 
Trimetazidine dihydrochloride shows the absorption maxima at 270 nm in distilled 
water. The absorption of the solution is linear with the concentration of Trimetazidine 
dihydrochloride in the range of 10 to 80 ug/ml. The correlation coefficient and slope was 
found to be 0.992 and 0.0026 with a Y-axis intercept of 0.0037.  
This analytical method for Trimetazidine dihydrochloride was validated for Accuracy, 
Precisions, and Specificity according to ICH guidelines [Note: Guidance for validation of 
analytical procedure text and methodology CPMP/ICH/138/95] 
The analytical method described above is specific for Trimetazidine dihydrochloride 
because there is no placebo interference. The method is also precise because the %R.S.D of 
method precision was found to be less than 2%.and %RSD of the system precision was less 
than 1%. 
The method is accurate as accuracy of the method was found to be 99.26%  
The Robustness test was done to know the solution stability and it was found that the 
solution was stable for 8 hrs in distilled water. 
Table 15: Results of Analytical method: 
PARAMETERS RESULTS 
ACCEPTANCE 
CRITERIA 
Beer’s law limit(ug/ml) 5 to 80 ug/ml - 
Regrassion equation 
Slope 
Intercept 
Correlation coefficient 
 
0.0026 
0.0037 
0.9922 
 
- 
- 
Should be closer to 1 
Specificity 
Specific; no placebo 
interference 
Should be Specific 
Precision 
Method precision 
System precision 
Intraday precision 
Interday precision 
 
%RSD = 1.604 
%RSD = 0.5952 
%RSD = 0.6 
%RSD = 0.8333 
 
%RSD should  NMT 2% 
%RSD Should NMT 1% 
%RSD Should NMT 1% 
%RSD Should NMT 1% 
Accuracy 99.26% 98 to102% 
Solution stability stable for 8 hrs solution should be stable 
 
  
 
 
CHAPTER 7 
PREFORMULATION STUDIES 
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List of equipments used: 
 
Sr. no Equipment /instrument Make 
1 Electronic Balance Shimadzu 
2 Halogen moisture balance Mettler Toledo 
3 Hot air oven Polar Industries 
4 pH meter Lab india 
5 Tray drier Cintex 
6 8 Station compression machine Cadmach 
7 Sieve shaker Cisa 
8 Water purifier Barnstead 
9 Fourier infra red spectrophotometer Shimadzu  
10 UV visible double beam 
spectrophotometer 
Shimadzu 
11 Friability tester Electrolab 
12 Vernier calipers (digital) Miyutoyo 
13 Hardness tester 8M Dr. Schleunger 
14 Cleaning machine Roots multiclean Ltd 
15 Standard weight box Mettler 
16 Thermometer Shoze 
17 Dissolution test apparatus USP Electrolab 
18 Tapped Density Apparatus Veego 
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7.0 PREFORMULATION STUDY
122-125
. 
 
Preformulation studies are the first step in the rational development of dosage form of 
a drug substance. The objective of preformulation studies is to develop a portfolio of 
information about the drug substance, so that this information is useful to develop 
formulation. Preformulation can be defined as investigation of physical and chemical 
properties of drug substance alone and when combined with excipients. 
Preformulation investigations are designed to identify those physicochemical 
properties and excipients that may influence the formulation design, method of manufacture, 
and pharmacokinetic-biopharmaceutical properties of the resulting product. 
 
7.1 Organoleptic Characteristics
122
 
  The color, odor, and taste of the Trimetazidine dihydrochloride were characterized 
and recorded using descriptive terminology; the results were shown in the table no.16  
7.2 Microscopic Examination
122
 
  In this study, pure drug was examined under compound microscope for crystal 
morphology. The results were shown in table no.16 
 
                      Table 16: Results of Organoleptic properties of Trimetazidine dihydrochloride 
Properties Results 
Description Crystalline 
Taste Slightly bitter 
Odor Odor less 
Colour Off white 
 
7.3 Melting point determination: 
 
The melting point of Trimetazidine dihydrochloride was determined by capillary method 
using programmable melting point apparatus (Veego Scientific, Model -VMPPM). 
Precautions were taken to maintain the uniform heating of silicon bath, in which the capillary 
containing the drug was placed. 
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The melting point of trimetazidine dihydrochloride was found to be 222°C, which was 
within the range given in the British Pharmacopoeia (220-225°C)
42
. Hence range observed is 
having good agreement with official value. 
7.4 Infra Red Spectrum: 
IR absorption spectrum of Trimetazidine dihydrochloride was recorded by 
potassium bromide dispersion technique in which dry sample of drug and potassium 
bromide was mixed uniformly and the mixed powder blend was placed in sample 
holder and an IR spectrum was recorded using FTIR spectrophotometer (FTIR-8400s). 
The infrared absorption spectrum of trimetazidine dihydrochloride obtained on a FTIR 
with diffused reflectance assembly is presented in Figure 10 (a). Spectral assignments for 
major absorption bands provided in Table 17 are consistent with the structure of trimetazidine 
dihydrochloride. 
Figure 10 (a) : Infrared absorption spectrum of Trimetazidine Dihydrochloride 
 
Table 17: IR spectrum interpretation of trimetazidine dihydrochloride 
Frequency (cm
-1
) Assignment 
1211 cm
-1
, 1232 cm
-1
, 1288 cm
-1
 3 Aromatic methoxy (-OCH3) 
2908 cm
-1
, 2945 cm
-1
, 2989 cm
-1
 3 Methyl stretching (-CH3) 
1600 cm
-1
-1430 cm
-1
 Aromatic C-N ring stretching 
2980 cm
-1
 Aromatic CH stretching 
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7.5 Sieve Analysis
123
 
Standard sieves of different meshes as per the specifications of USP were arranged in 
a nest with courses at the top. A sample of the 40 mesh passed powder was placed on top 
sieve. This sieve set was fixed to the mechanical shaker apparatus and shaken for a certain 
period of times. The powder retained on each sieve was weighed and percentage of powder 
retained on each sieve was calculated using the initial weight taken. The results were shown 
in the table no.19 
 
7.6 Bulk Density
122, 87
:  
  An accurately weighed quantity of powder, which was previously passed through 
sieve # 40 [USP] and carefully poured into graduated cylinder. Then after pouring the powder 
into the graduated cylinder the powder bed was made uniform without disturbing. Then the 
volume was measured directly from the graduation marks on the cylinder as ml. The volume 
measure was called as the bulk volume and the bulk density is calculated by following 
formula; 
 
Bulk density = Weight of powder / Bulk volume 
 
The results were shown in table no.19 
 
7.7 Tapped Density
122, 87
 
  After measuring the bulk volume the same measuring cylinder was set into tap density 
apparatus. The tap density apparatus was set to 300 taps drop per minute and operated for 500 
taps. Volume was noted as (Va) and again tapped for 750 times and volume was noted as 
(Vb).  If the difference between Va and Vb not greater than 2% then Vb is consider as final 
tapped volume. The tapped density is calculated by the following formula            
   
Tapped density = Weight of powder / Tapped volume 
 
Results were shown in table no.19 
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7.6 Carr’s Index [Compressibility Index] and Hausner’s Ratio 
  Carr’s index and Hausner’s ratio measure the propensity of powder to be compressed 
and the flowability of powder. Carr’s index and Hausner’s ratio can be calculated from the 
bulk and tapped density. 
Carr’s index = Tapped density - Bulk density X 100 
   Tapped Density 
 
Hausner’s ratio = Tapped density / Bulk density 
 
The relationship between % compressibility and flowability is shown in Table 18 
Table 18 : Relationship between % compressibility and flowability: 
% Compressibility Flowability 
5-15 Excellent 
12-16 Good 
18-21 Fair passable 
23-25 Poor 
33-38 Very Poor 
< 40 Very very poor 
 
The results of the above granulometry studies were as shown in table no.19 
Table 19: Granulometry properties of powder drug and excipients 
Parameter 
Results 
Trimetazidine 
dihydrochloride 
HPMC 
K4M 
Carbopol 
71G 
Povidone 
K30 
Lactose 
mono 
Loss on Drying 
(%w/w) 
1.55    0.497 0.376 0.43 0.35 
Bulk Density 
(gm/cm3) 
0.309
 
0.314 0.18 0.29 0.73 
Tapped Density 
(gm/cm3) 
0.4123 0.557 0.296 0.39 0.122 
Compressibility 
Index 
36.419 43.62 39.19 25.64 14.11 
Hauser’s Ratio 1.572 1.774 1.644 1.344 1.164 
Particle size 180-350 um 1-3um 2-4um 
75-130 
um 
65-175 
um  
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7.7 Drug Excipients Compatibility Study
123
 
Protocol for drug-excipients compatibility 
(a) Drug: Excipients Ratio 
1. API alone 
2. API:Diluent:- 1:8 
3. API:Binders and Lubricant :-1:1 
4. API:Polymer:-1:5 
(b) Pack details 
Plain glass vials with rubber stopper and aluminum seal 
(c) Storage condition 
1. 40ºC/75 %RH 
2. 60ºC 
3. Control sample at 2-8°C 
(d) Testing Frequency 
1. 2nd week for sample charged at 60ºC 
2. 4th week sample charged at 40ºC/75%RH 
Physical observation shall be done at every week, up to 4 week 
(e) Test to be performed 
1. Description 
2. DSC of initial sample 
3. Content determination by U.V 
  
Procedure 
API and excipients were thoroughly mixed in predetermined ratio given above and 
passed through the sieve no.40. The blend was filled in plain glass vials and closed with grey 
rubber stoppers and sealed with aluminum seal and charged in to stress condition at 2-8ºC, 
60ºC and 40º C/75%RH. Similarly API was also kept at all condition as per the sample. 
Samples were withdrawn for analysis within two day of sampling date as per the 
compatibility study plan. 
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Table 20 : Drug:Excipients combination and ratio for compatibility study 
Batch 
no. 
Drug-Excipients 
combination 
D:E 
ratio 
D:E 
(g) 
Batch 
size 
(g) 
Labeled 
claim 
(per gm) 
A API  alone - - 6 1 
B API + HPMC K4M 1:5 2:10 12 166.67 
C API + Carbopol 71G 1:5 2:10 12 166.67 
D API + Lactose 1:8 2:16 18 125 
E API + Povidone K30 1:1 3:3 6 500 
F API + Mg.Stearate 1:1 3:3 6 500 
G API + Talc 1:1 3:3 6 500 
 
Physical observation 
Physical observation of sample was done at every week for any color change or lumps 
formation and flow. The results of the physical observation were shown in table no.21 There 
was no color change and no lumps observed in sample charged at 40ºc/75%RH for 1 month 
and 60ºc for 15 days. 
 
Table 21: Results of the physical observation 
Batch 
no. 
Initial 
40ºc/75%RH 60º 
1
st
  
week 
2
nd
 
week 
3
rd
 
week 
4
th
 
week 
1
st
 
week 
2
nd
 
week 
A Off-White + + + + + + 
B Off-White + + + + + + 
C Off-White + + + + + + 
D White + + + + + + 
E Off-White + + + + + + 
F Off-White + + + + + + 
G Off-White + + + + + + 
 
+ indicates the there is no change in colure or lumps formation 
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7.8 Content determination  
The content of Trimetazidine dihydrochloride in each sample was determined by the 
assaying the sample in U.V at 270 nm. Weight of the powder equivalent to 60 mg of 
Trimetazidine dihhydrochloride was accurately weighed and dissolved in 500 ml distilled 
water in a volumetric flask with the aid of sonication for 20 min in bath sonicator. Five ml of 
sample was withdrawn from this solution and dilute up to 25 ml with distilled water in a 
volumetric flask. The sample was filtered through the 0.45 um mdi filter and absorbance of 
this solution was measured at 270 nm. in U.V. The content of each sample was determined in 
replicates of three. 
The results were shown in table no.22   
 
Table 22: Results of the content determination compatibility study 
Batch no. Controlled Sample at 2-8ºc 40ºc/75%RH for 1month 60ºc for 15 day 
A 101.05(±1.99) 99.08(±0.81) 98.58(±0.38) 
B 96.12(±3.71) 95.69(±3.01) 95.13(±2.92) 
C 98.21(±1.72) 97.23(±2.42) 98.09(±1.96) 
D 101.29(±1.21) 99.82(±0.55) 99.26(±0.49) 
E 100.68(±1.59) 98.03(±1.123) 96.67(±3.21) 
F 97.17(±4.20) 98.58(±1.11) 97.60(±0.74) 
G 102.83(±2.56) 100.37(±2.40) 97.60(±0.122) 
 
The results of the content determination shows that the amount of trimetazidine 
dihydrochloride was recovered in all the sample loaded at 40°c/75%RH for one month and 
60°c for 15 day, indicating that there is no incompatibility between drug and excipients. 
 
7.9 Differential scanning calorimetry 
A differential scanning calorimeter was used for thermal analysis of drug and mixture 
of drug and excipients. The drug and excipients were passed through the sieve no. 60 and 
mixed in ratio as shown in table no.15 the drug alone and mixture of drug and excipients was 
weighed directly in the pierced DSC aluminum pan (Aluminum Standard 40 ul) and scanned 
at the temperature range of 50-300 °c and at heating rate of 10 °c/min. and nitrogen purging 
rate 50 ml/min. the thermogram obtained were observed for any interaction. 
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The DSC thermogram of drug, drug-excipients, and excipients were shown in 
following figures. 
Figure 10: DSC thermogram of trimetazidine dihydrochloride 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: DSC thermogram of trimetazidine dihydrochloride + HPMC K4M 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Holder: Aluminum Standard 40ul 
Module: DSC822e/500/800/427210/8184/16/05/05,  
Method: trimetazidine dihydrochloride 
  50.0-300.0°C 10.00°C/min        N2 50.0 ml/min 
Method Name: trimetazidine dihydrochloride 
mW 
-16 
-14 
-12 
-10 
-8 
-6 
-4 
-2 
0 
min 
°C 60 80 100 120 140 160 180 200 220 240 260 280 
0 2 4 6 8 10 12 14 16 18 20 22 24 
^exo 
Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
Sample Holder: Aluminum Standard 40ul 
Module: DSC822e/500/800/427210/8184/16/05/05, 16.05.2005 15:29:00 
  50.0-300.0°C 10.00°C/min        N2 50.0 ml/min 
Integral -336.22 mJ 
  normalized -74.72 Jg^-1 
Onset 191.13 °C 
Endset 207.38 °C 
mW 
-6 
-4 
-2 
0 
2 
min 
°C 60 80 100 120 140 160 180 200 220 240 260 280 
0 2 4 6 8 10 12 14 16 18 20 22 24 
^exo 
Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
Trimetazidine dihycrochloride+HPMC K4M 
Trimetazidine dihycrochloride 
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Figure 12: DSC thermogram of trimetazidine dihydrochloride + Carbopol 71G 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: DSC thermogram of Trimetazidine dihydrochloride + Lactose Mono 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Holder: Aluminum Standard 40ul 
Module: DSC822e/500/800/427210/8184/16/05/05, 16.05.2005 15:29:00 
  50.0-300.0°C 10.00°C/min        N2 50.0 ml/min 
Integral -350.51 mJ 
Onset 192.59 °C 
Endset 209.77 °C 
mW 
-2 
-1 
0 
1 
2 
3 
min 
°C 60 80 100 120 140 160 180 200 220 240 260 280 
0 2 4 6 8 10 12 14 16 18 20 22 24 
^exo Trimetazidine dihycrochloride+Carbopol 71G  
Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
Sample Holder: Aluminum Standard 40ul 
Module: DSC822e/500/800/427210/8184/16/05/05, 16.05.2005 15:29:00 
Integral -305.26 mJ 
  normalized -76.31 Jg^-1 
Onset 194.71 °C 
Endset 211.59 °C 
Integral -333.61 mJ 
  normalized -83.40 Jg^-1 
Onset 164.14 °C 
Endset 177.03 °C 
mW 
-10 
-8 
-6 
-4 
-2 
0 
min 
°C 60 80 100 120 140 160 180 200 220 240 260 280 
0 2 4 6 8 10 12 14 16 18 20 22 24 
^exo Trimetazidine dihydrochloride + Lactose mono 
Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
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Figure 14: DSC thermogram of trimetazidine dihydrochloride + Povidone K30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: DSC thermogram of trimetazidine dihydrochloride + Mg. Stearate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trimetazidine dihydrochloride + Povidone K30 
  50.0-300.0°C 10.00°C/min        N2 50.0 ml/min 
Sample Holder: Aluminum Standard 40ul 
Module: DSC822e/500/800/427210/8184/16/05/05, 16.05.2005 15:29:00 
Integral -527.40 mJ 
  normalized -131.122 Jg^-1 
Onset 179.64 °C 
Endset 206.59 °C 
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^exo 
Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
Sample Holder: Aluminum Standard 40ul 
Module: DSC822e/500/800/427210/8184/16/05/05, 16.05.2005 15:29:00 
  50.0-300.0°C 10.00°C/min        N2 50.0 ml/min 
Integral -665.51 mJ 
  normalized -166.38 Jg^-1 
Onset 188.81 °C 
Endset 205.29 °C 
mW 
-10 
-8 
-6 
-4 
-2 
0 
min 
°C 60 80 100 120 140 160 180 200 220 240 260 280 
0 2 4 6 8 10 12 14 16 18 20 22 24 
^exo Trimetazidine dihydrochloride + Mg Stearate 
Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
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Figure16: DSC thermogram of trimetazidine dihydrochloride + Talc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: DSC thermogram of HPMC K4M 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Holder: Aluminum Standard 40ul 
Module: DSC822e/500/800/427210/8184/16/05/05, 16.05.2005 15:29:00 
  50.0-300.0°C 10.00°C/min        N2 50.0 ml/min 
Integral -915.87 mJ 
  normalized -218.06 Jg^-1 
Onset 191.48 °C 
Endset 208.25 °C 
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°C 60 80 100 120 140 160 180 200 220 240 260 280 
0 2 4 6 8 10 12 14 16 18 20 22 24 
^exo Trimetazidine dihydrochloride+ talc 
Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
Sample Holder: Aluminum Standard 40ul 
Module: DSC822e/500/800/427210/8184/16/05/05, 16.05.2005 15:29:00 
  50.0-300.0°C 10.00°C/min        N2 50.0 ml/min 
Integral -284.20 mJ 
  normalized -71.05 Jg^-1 
Onset 56.34 °C 
Endset 110.07 °C 
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°C 60 80 100 120 140 160 180 200 220 240 260 280 
0 2 4 6 8 10 12 14 16 18 20 22 24 
^exo 
Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
HPMC K4M 
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Figure 18: DSC thermogram of Carbopol 71G 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: DSC thermogram of Lactose monohydrate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Holder: Aluminum Standard 40ul 
Module: DSC822e/500/800/427210/8184/16/05/05, 16.05.2005 15:29:00 
  50.0-300.0°C 10.00°C/min        N2 50.0 ml/min 
Integral -429.67 mJ 
  normalized -110.17 Jg^-1 
Onset 193.56 °C 
Endset 257.50 °C 
mW 
0 
1 
2 
3 
4 
5 
6 
min 
°C 60 80 100 120 140 160 180 200 220 240 260 280 
0 2 4 6 8 10 12 14 16 18 20 22 24 
^exo Carbopol 71G 
Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
Sample Holder: Aluminum Standard 40ul 
Integral -565.11 mJ 
  normalized -141.28 Jg^-1 
Onset 218.94 °C 
Endset 230.71 °C 
Integral -478.96 mJ 
  normalized -119.74 Jg^-1 
Onset 181.19 °C 
Endset 191.91 °C 
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^exo Lactose monohydrate 
Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
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Figure 20: DSC thermogram of Povidone K/30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: DSC thermogram of Magnesium stearate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Holder: Aluminum Standard 40ul 
Module: DSC822e/500/800/427210/8184/16/05/05, 16.05.2005 15:29:00 
Method: trimetazidine dihydrochloride 
  50.0-300.0°C 10.00°C/min        N2 50.0 ml/min 
Integral -489.89 mJ 
  normalized -122.47 Jg^-1 
Onset 108.09 °C 
Endset 124.80 °C 
98.84 °C 
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Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
Sample Holder: Aluminum Standard 40ul 
Module: DSC822e/500/800/427210/8184/16/05/05, 16.05.2005 15:29:00 
  50.0-300.0°C 10.00°C/min        N2 50.0 ml/min 
Integral -606.02 mJ 
  normalized -151.51 Jg^-1 
Onset 54.39 °C 
Endset 95.122 °C 
P.V.P K29/30, 28.06.2006 16:24:50 
P.V.P K29/30, 4.0000 mg 
mW 
-10 
-8 
-6 
-4 
-2 
min 
°C 60 80 100 120 140 160 180 200 220 240 260 280 
0 2 4 6 8 10 12 14 16 18 20 22 24 
^exo Povidone K/30 
Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
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Figure 22: DSC thermogram of Talc 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 23: Interpretation of DSC Thermogram of Drug, Exipients and Mixture of Drug and excipients 
Combination 
Onset 
(°c) 
End set 
(°c) 
Peak 
(°c) 
Integral 
(mj) 
Trimetazidine dihydrochloride 190.61°c 210.03°c 203.47 1056.08 
Trimetazidine dihydrochloride 
+ HPMC K4M 
191.13 207.38 200.05 336.22 
Trimetazidine dihydrochloride 
+ Carbopol 71 G 
192.59 209.77 204 350.51 
Trimetazidine dihydrochloride 
+ Lactose mono 
194.71 211.59 198 305.26 
Trimetazidine dihydrochloride 
+ Povidone K30 
179.64 206.59 200 527.40 
Trimetazidine dihydrochloride 
+ Mg. Stearate 
188.81 205.29 202 665.51 
Trimetazidine dihydrochloride 
+ Talc 
191.48 208.25 202 915.87 
HPMC K4M 56.11 110.09 - 287.03 
Sample Holder: Aluminum Standard 40ul 
Module: DSC822e/500/800/427210/8184/16/05/05, 16.05.2005 15:29:00 
Method: trimetazidine dihydrochloride 
  50.0-300.0°C 10.00°C/min        N2 50.0 ml/min 
Method Name: trimetazidine dihydrochloride 
talc, 28.06.2006 10:57:31 
talc, 4.0000 mg 
mW 
1.5 
2.0 
2.5 
3.0 
3.5 
min 
°C 60 80 100 120 140 160 180 200 220 240 260 280 
0 2 4 6 8 10 12 14 16 18 20 22 24 
^exo Talc 
Lab: METTLER  SW 7.01 e R TA METTLER TOLEDO S 
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Carbopol 71G 193.56 257.50 - 429.67 
Lactose mono 218.94 230.71 - 565.11 
Povidone K30 54.39 95.122 - 606.02 
Mg.Stearate 82.82 98.84 - 489.89 
Talc - - - - 
 
 
The thermal behavior of the pure drug, respective excipients and the combination of 
drug and excipients is compared 
The DSC trace of trimetazidine dihydrochloride showed a sharp endothermic peak at 
203.47°c. In the DSC trace of the mixture of trimetazidine and excipients, the sharp 
endothermic peak observed neared to 203.47°c, in the majority of case. Melting endotherm of 
the drug was well preserved with a slight change in terms of broadening of peak or shifting 
towards the lower temperature. Thus these minor changes in the melting endotherm of drug 
could be due to the mixing of drug and excipients, which lowers the purity of each 
component in the mixture and may not necessarily indicating potential incompatibility.    
 
 
  
 
 
CHAPTER 8 
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8.0 Experimental trial for Monolayer osmotic Tablets of Trimetazidine dihydrochloride 
8.1 Feasibility trial of Core tablet:  
Batch size: 200 tablets    Table 24: Trial formulations  for Feasibility trial (Core) 
Sr 
no. 
Batch Code CT 1 CT2 CT 3 CT 4 CT 5 CT 6 CT 7 
Ingredients 
Qty. 
mg/Tab 
Qty. 
mg/200 
Tab 
Qty. 
mg/Tab 
Qty. 
mg/200 
Tab 
Qty. 
mg/Tab 
Qty. 
mg/200 
Tab 
Qty 
mg/Tab 
Qty. 
mg/200 
Tab 
Qty. 
mg/Tab 
Qty. 
mg/200 
Tab 
Qty. 
mg/Tab 
Qty. 
mg/200 
Tab 
Qty. 
mg/Tab 
Qty. 
mg/200 
Tab 
 Dry Mix 
1 Trimetazidine 60 12000 60 12000 60 12000 60 12000 60 12000 60 12000 60 12000 
2 HPMC K4M 100 20000 100 20000 100 20000 100 20000 100 20000 100 20000 100 20000 
3 Lactose Mono 155 31000 155 31000 155 31000 160 32000 155 31000 150 30000 145 29000 
 Binder Solution               
4 Povidone K30 20 4000 20 4000 20 4000 15 3000 20 4000 25 5000 30 6000 
5 IPA --  Qs 20000 qs 18000 qs 20000 qs 20000 qs 20000 qs 20000 
6 Water qs 15000 -- -- qs 2000 -- -- -- -- -- -- -- - 
 Extra Granular               
7 Carbopol 71 G 125 25000 125 25000 125 25000 125 25000 125 25000 125 25000 125 25000 
8 Na. Clorde 30 6000 30 6000 30 6000 30 6000 30 6000 30 6000 30 6000 
9 Mg Stearate 5 1000 5 1000 5 1000 5 1000 5 1000 5 1000 5 1000 
10 Talc 5 1000 5 1000 5 1000 5 1000 5 1000 5 1000 5 1000 
 Core tab Wt 500 100000 500 120000 500 100000 500 100000 500 100000 500 100000 500 100000 
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Granulation process: 
a. Dry mixing: 
TMZ, HPMC K4M and Lactose mono were dry mixed in the above proportion  in a 
polybag manually.   
b. Binder solution preparation: 
Povidone K30 was dissolved in various proportions of IPA and water as per the above 
table.  
c. Granulation: 
Dry mix blend was granulated with prepared binder solution. 
d. Drying: 
Wet mass was dried at 50 C in oven to get LOD below 2%w/w using Halogen moisture 
detector at 105 C temperature.   
e. Sizing: 
Dried granules were passed through 20# sieve. 
f. Extragranular mixing: 
Above sized granules were mixed with Carbopol 71G, sodium chloride and talc for 10 
minutes at 24 rpm in an octagonal blender.  
g. Lubrication: 
The above granules were lubricated with 60# passed Magnesium stearate for 5 minutes at 
24 rpm in an octagonal blender. 
h. Compression: 
Lubricated granules were compressed using 9.0 mm, round, standard concave punches, 
plain on both the sides in rotary compression machine.   
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8.1.1 Characterization of lubricated granules: 
The lubricated granules prepared as above were subjected to the following tests to select the best 
trial batch for further optimization 
8.1.1.1 Sieve Analysis
123
 
Standard sieves of different meshes as per the specifications of USP were arranged in a 
nest with courses at the top. A sample of the 40 mesh passed powder was placed on top sieve. 
This sieve set was fixed to the mechanical shaker apparatus and shaken for a certain period of 
times. The powder retained on each sieve was weighed and percentage of powder retained on 
each sieve was calculated using the initial weight taken. The results were shown in the table 
no.31 
8.1.1.2 Bulk Density
122,124
:  
  An accurately weighed quantity of powder, which was previously passed through sieve # 
40 [USP] and carefully poured into graduated cylinder. Then after pouring the powder into the 
graduated cylinder the powder bed was made uniform without disturbing. Then the volume was 
measured directly from the graduation marks on the cylinder as ml. The volume measure was 
called as the bulk volume and the bulk density is calculated by following formula; 
Bulk density = Weight of powder / Bulk volume 
The results were shown in table no. 31 
8.1.1.3 Tapped Density
122,124
 
  After measuring the bulk volume the same measuring cylinder was set into tap density 
apparatus. The tap density apparatus was set to 300 taps drop per minute and operated for 500 
taps. Volume was noted as (Va) and again tapped for 750 times and volume was noted as (Vb).  
If the difference between Va and Vb not greater than 2% then Vb is consider as final tapped 
volume. The tapped density is calculated by the following formula            
Tapped density = Weight of powder / Tapped volume 
Results were shown in table no. 31 
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8.1.1.4 Carr’s Index [Compressibility Index] and Hausner’s Ratio 
  Carr’s index and Hausner’s ratio measure the propensity of powder to be compressed and 
the flowability of powder. Carr’s index and Hausner’s ratio can be calculated from the bulk and 
tapped density. 
Carr’s index = Tapped density - Bulk density X 100 
   Tapped Density 
Hausner’s ratio = Tapped density / Bulk density 
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8.2 Feasibility trial of Coating:  
Batch size: 200 tablets      Table 25: Trial formulations for Feasibility trial Coating 
Sr 
no. 
Batch Code MT 1 MT 2 MT 3 MT 4 
Ingredients 
Qty 
mg/Tab 
Qty. 
mg/200 
Tab 
Qty. 
mg/Tab 
Qty. 
mg/200 
Tab 
Qty. 
mg/Tab 
Qty. 
mg/200 
Tab 
Qty. 
mg/Tab 
Qty. 
mg/200 
Tab 
 Dry Mix 
1 Trimetazidine 60 12000 60 12000 60 12000 60 12000 
2 HPMC K4M 100 20000 100 20000 100 20000 100 20000 
3 Lactose Mono 150 30000 150 30000 150 30000 150 30000 
 Binder Solution         
4 Povidone K30 25 5000 25 5000 25 5000 25 5000 
5 IPA qs 20000 qs 20000 qs 20000 qs 20000 
 Extra Granular         
6 Carbopol 71 G 125 25000 125 25000 125 25000 125 25000 
7 Na. Clorde 30 6000 30 6000 30 6000 30 6000 
8 Mg Stearate 5 1000 5 1000 5 1000 5 1000 
9 Talc 5 1000 5 1000 5 1000 5 1000 
 Core tab Wt 500 100000 500 100000 500 100000 500 100000 
 Coating 
 % wt. Gain 5% 7% 10% 12% 
10 
Celulose Acetate 
(75%) 
18.75 3750 26.25 5250 37.5 7500 45 9000 
11 
Dbutylcebacate 
(25%) 
6.25 1250 8.75 1750 12.5 2500 15 3000 
12 Ethanol (50%) QS 18333 QS 25666 QS 36666 QS 44000 
13 Acetone (50%) QS 18333 QS 25666 QS 36666 QS 44000 
 Coated tab wt. 525 141666 535 158332 550 183332 560 200000 
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Tablet manufacturing process:  
a. Dry mixing: 
TMZ, HPMC K4M and Lactose mono were dry mixed in the above proportion in a 
polybag manually.   
b. Binder solution preparation: 
Povidone K30 was dissolved in IPA with stirring.  
c. Granulation: 
Dry mix blend was granulated with prepared binder solution. 
d. Drying: 
Wet mass was dried at 50 C in oven to get LOD below 2%w/w using Halogen moisture 
detector at 105 C temperature.   
e. Sizing: 
Dried granules were passed through 20# sieve. 
f. Extragranular mixing: 
Above sized granules were mixed with Carbopol 71G, sodium chloride and talc for 10 
minutes at 24 rpm in an octagonal blender.  
g. Lubrication: 
The above granules were lubricated with 60# passed Magnesium stearate for 5 minutes at 
24 rpm in an octagonal blender 
h. Compression: 
Lubricated granules were compressed using 9.0 mm, round, standard concave punches, 
plain on both the sides in rotary compression machine.   
i. Preparation of coating solution: 
Coating solution was prepared by dissolving Cellulose acetate and dibutyl cebecate 
(75:25) in a mixture of ethanol and acetone (50:50) with constant stirring. 
j. Coating process: 
Core tablets were coated with prepared coating solution using conventional coating pan 
machine.  The coating parameter s were as follows: 
Inlet air temperature  : 45 C 
Bed temperature  : 38 C 
Pan rpm   : 6 to 8 rpm 
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Atomization Air pressure : 2.0 psi 
The average weight of tablet was checked periodically to achieve the desired target 
weight gain. 
( 5%, 7%, 10% and 12%)  
The coated tablets were dried at 50 C for 30 min in conventional coating pan at 1-2 rpm. 
k. Drilling of orifice: 
One orifice with a diameter of 0.5 mm was drilled on either side of coated tablet using a 
microdrill. 
 
The coated tablets were then subjected to in vitro analysis to select the best formulation 
for the optimization of HPMC K4M.
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8.3 Optimization of HPMC K4M for monolayer osmotic tablets:  
Batch size: 200 tablets   Table 26:   Trial formulations for Optimization Of HPMC K4M for monolayer osmotic tablets 
Sr.No 
Batch No MT5 MT6 MT 3 MT7 MT8 
Ingredients 
Qty. 
mg/Tab 
Qty    
mg/200 tab 
Qty. mg/Tab 
Qty    
mg/200tab 
Qty. mg/Tab 
Qty    
mg/200 tab 
Qty. 
mg/Tab 
Qty    
 mg/200 tab 
Qty. 
mg/Tab 
Qty    
mg/200 tab 
 Dry Mix 
1 Trimetazidne 60 12000 60 12000 60 12000 60 12000 60 12000 
2 HPMC K4M 50 10000 75 15000 100 20000 125 25000 150 30000 
3 Lactose Mono 200 40000 175 35000 150 30000 125 25000 100 20000 
 Binder Solution 
4 Povidone K30 25 5000 25 5000 25 5000 25 5000 25 5000 
6 Isopropyl  
alcohol 
Qs 20000 Qs 20000 qs 20000 qs 20000 qs 20000 
 Extra Granular 
6 Carbopol 71 G 125 25000 125 25000 125 25000 125 25000 125 25000 
7 NaCl 30 6000 30 6000 30 6000 30 6000 30 6000 
8 Mg Stearate 5 1000 5 1000 5 1000 5 1000 5 1000 
9 Talc 5 1000 5 1000 5 1000 5 1000 5 1000 
 Core tab Wt 500 120000 500 120000 500 120000 500 120000 500 120000 
 Coating 
 % wt. Gain 10% 10% 10% 10% 10% 
10 Cellulose 
Acetate (75%) 
37.5 7500 37.5 7500 37.5 7500 37.5 7500 37.5 7500 
11 Dibutylcebacate 
(25%) 
12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 
12 Ethanol (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
13 Acetone (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
 Coated tab wt. 550 203334 550 203334 550 203334 550 203334 550 203334 
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Tablet manufacturing process:  
 
a. Dry mixing: 
TMZ, HPMC K4M and Lactose mono were dry mixed in the above proportion in a 
polybag manually.  The change in quantity of HPMC K4M was compensated with a 
change in quantity of lactose mono 
b. Binder solution preparation: 
Povidone K30 was dissolved in IPA with stirring.  
c. Granulation: 
Dry mix blend was granulated with prepared binder solution. 
d. Drying: 
Wet mass was dried at 50 C in oven to get LOD below 2%w/w using Halogen moisture 
detector at 105 C temperature.   
e. Sizing: 
Dried granules were passed through 20# sieve. 
f. Extragranular mixing: 
Above sized granules were mixed with Carbopol 71G, sodium chloride and talc for 10 
minutes at 24 rpm in an octagonal blender.  
g. Lubrication: 
The above granules were lubricated with 60# passed Magnesium stearate for 5 minutes at 
24 rpm in an octagonal blender 
h. Compression: 
Lubricated granules were compressed using 9.0 mm, round, standard concave punches, 
plain on both the sides in rotary compression machine.   
i. Preparation of coating solution: 
Coating solution was prepared by dissolving Cellulose acetate and dibutyl cebecate 
(75:25) in a mixture of ethanol and acetone (50:50) with constant stirring. 
j. Coating process: 
Core tablets were coated with prepared coating solution using conventional coating pan 
machine.  The coating parameters were as follows: 
Inlet air temperature  : 45 C 
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Bed temperature  : 38 C 
Pan rpm   : 6 to 8 rpm 
Atomization Air pressure : 2.0 psi 
The average weight of tablet was checked periodically to achieve 10% weight gain of 
core tablet. 
The coated tablets were dried at 50 C for 30 min in conventional coating pan at 1-2 rpm. 
k. Drilling of orifice: 
One orifice with a diameter of 0.5 mm was drilled on either side of coated tablet using a 
microdrill. 
The prepared tablets were then subjected to in vitro analysis to select the best formulation 
for the optimization of Carbopol 71 G. 
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8.4 Optimization of Carbopol 71G for monolayer osmotic tablets:  
Batch size: 200 tablets       Table 27:   Trial formulations for Optimization Of Carbopol 71G for monolayer osmotic tablets 
Sr.No 
Batch No MT9 MT10 MT11 MT6 MT12 
Ingredients 
Qty. 
mg/Tab 
Qty    
mg/200 tab 
Qty. 
mg/Tab 
Qty    
mg/200 tab 
Qty. 
mg/Tab 
Qty    
mg/200 tab 
Qty. 
mg/Tab 
Qty    
mg/200 tab 
Qty. 
mg/Tab 
Qty    
mg/200 tab 
 Dry Mix 
1 Trimetazidne 60 12000 60 12000 60 12000 60 12000 60 12000 
2 HPMC K4M 75 15000 75 15000 75 15000 75 15000 75 15000 
3 Lactose Mono 250 50000 225 45000 200 40000 175 35000 150 30000 
 Binder Solution 
4 Povidone K30 25 5000 25 5000 25 5000 25 5000 25 5000 
5 IPA (90%) qs 20000 Qs 20000 qs 20000 qs 20000 Qs 20000 
 Extra Granular 
6 Carbopol 71 G 50 10000 75 15000 100 20000 125 25000 150 30000 
7 NaCl 30 6000 30 6000 30 6000 30 6000 30 6000 
8 Mg Stearate 5 1000 5 1000 5 1000 5 1000 5 1000 
9 Talc 5 1000 5 1000 5 1000 5 1000 5 1000 
 Core tab Wt 500 120000 500 120000 500 120000 500 120000 500 120000 
 Coating 
 % wt. Gain 10% 10% 10% 10% 10% 
10 Cellulose Acetate (75%) 37.5 7500 37.5 7500 37.5 7500 37.5 7500 37.5 7500 
11 Dibutylcebacate (25%) 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 
12 Ethanol (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
13 Acetone (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
 Coated tab wt. 550 203334 550 203334 550 203334 550 203334 550 203334 
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Tablet manufacturing process:  
 
a. Dry mixing: 
TMZ, HPMC K4M and Lactose mono were dry mixed in the above proportion in a 
polybag manually. The change in quantity of Carbopol 71G was compensated with a 
change in quantity of lactose mono. 
b. Binder solution preparation: 
Povidone K30 was dissolved in IPA with stirring.  
c. Granulation: 
Dry mix blend was granulated with prepared binder solution. 
d. Drying: 
Wet mass was dried at 50 C in oven to get LOD below 2%w/w using Halogen moisture 
detector at 105 C temperature.   
e. Sizing: 
Dried granules were passed through 20# sieve. 
f. Extragranular mixing: 
Above sized granules were mixed with Carbopol 71G (varying proportion), sodium 
chloride and talc for 10 minutes at 24 rpm in an octagonal blender.  
g. Lubrication: 
The above granules were lubricated with 60# passed Magnesium stearate for 5 minutes at 
24 rpm in an octagonal blender 
h. Compression: 
Lubricated granules were compressed using 9.0 mm, round, standard concave punches, 
plain on both the sides in rotary compression machine.   
i. Preparation of coating solution: 
Coating solution was prepared by dissolving Cellulose acetate and dibutyl cebecate 
(75:25) in a mixture of ethanol and acetone (50:50) with constant stirring. 
j. Coating process: 
Core tablets were coated with prepared coating solution using conventional coating pan 
machine.  The coating parameters were as follows: 
Inlet air temperature  : 45 C 
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Bed temperature  : 38 C 
Pan rpm   : 6 to 8 rpm 
Atomization Air pressure : 2.0 psi 
The average weight of tablet was checked periodically to achieve 10% weight gain of core 
tablet. 
The coated tablets were dried at 50 C for 30 min in conventional coating pan at 1-2 rpm. 
k. Drilling of orifice: 
One orifice with a diameter of 0.5 mm was drilled on either side of coated tablet using a 
microdrill. 
The prepared tablets were subjected to in vitro evaluation to select the best formulation for 
optimization of Osmogen (Sodium chloride and Mannitol)
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8.5 Optimization of Osmogens (Sodium chloride and mannitol) for monolayer osmotic tablets: 
Batch size: 200 tablets           Table 28: Optimization of osmogen (Sodium chloride and mannitol) for monolayer osmotic tablets: 
Sr. 
No 
Batch No MT11 MT13 MT14 MT15 MT16 MT17 MT18 
Ingredients 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
  Dry mix 
1 Trimetazidine 60 12000 60 12000 60 12000 60 12000 60 12000 60 12000 60 12000 
2 HPMC K4M 75 15000 75 15000 75 15000 75 15000 75 15000 75 15000 75 15000 
3 Lactose Mono 200 40000 210 42000 190 38000 200 40000 190 38000 180 36000 200 40000 
  Binder Solution 
4 Povidone K30 25 5000 25 5000 25 5000 25 5000 25 5000 25 5000 25 5000 
5 IPA (90%) Qs 20000 qs 20000 qs 20000 qs 20000 qs 20000 qs 20000 qs 20000 
  Extra Granular 
7 Carbopol 71 G 100 20000 100 20000 100 20000 100 20000 100 20000 100 20000 100 20000 
8 NaCl 30 6000 20 4000 40 8000 0 0 0 0 0 0 15 3000 
9 Mannitol 0 0 0 0 0 0 30 6000 40 8000 50 10000 15 3000 
10 Mg Stearate 5 1000 5 1000 5 1000 5 1000 5 1000 5 1000 5 1000 
11 Talc 5 1000 5 1000 5 1000 5 1000 5 1000 5 1000 5 1000 
 Core tab Wt 500 120000 500 120000 500 120000 500 120000 500 120000 500 120000 500 120000 
  Coating 
  % wt. Gain 10% 10% 10% 10% 10% 10% 10% 
12 CelluloseAcetate(75%) 37.5 7500 37.5 7500 37.5 7500 37.5 7500 37.5 7500 37.5 7500 37.5 7500 
13 Dibutylcebacate (25%) 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 
14 Ethanol (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
15 Acetone (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
  Coated tab wt. 550 203334 550 203334 550 203334 550 203334 550 203334 550 203334 550 203334 
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Tablet manufacturing process:  
 
a. Dry mixing: 
TMZ, HPMC K4M and Lactose mono were dry mixed in the above proportion in a 
polybag manually. The change in quantity of Mannitol/Sodium chloride was 
compensated with a change in quantity of lactose mono. 
b. Binder solution preparation: 
Povidone K30 was dissolved in IPA with stirring.  
c. Granulation: 
Dry mix blend was granulated with prepared binder solution. 
d. Drying: 
Wet mass was dried at 50 C in oven to get LOD below 2%w/w using Halogen moisture 
detector at 105 C temperature.   
e. Sizing: 
Dried granules were passed through 20# sieve. 
f. Extragranular mixing: 
Above sized granules were mixed with Carbopol 71G , mannitol/sodium chloride (in 
varying proportions as per above table) and talc for 10 minutes at 24 rpm in an octagonal 
blender.  
g. Lubrication: 
The above granules were lubricated with 60# passed Magnesium stearate for 5 minutes at 
24 rpm in an octagonal blender 
h. Compression: 
Lubricated granules were compressed using 9.0 mm, round, standard concave punches, 
plain on both the sides in rotary compression machine.   
i. Preparation of coating solution: 
Coating solution was prepared by dissolving Cellulose acetate and dibutyl cebecate 
(75:25) in a mixture of ethanol and acetone (50:50) with constant stirring. 
j. Coating process: 
Core tablets were coated with prepared coating solution using conventional coating pan 
machine.  The coating parameters were as follows: 
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Inlet air temperature  : 45 C 
Bed temperature  : 38 C 
Pan rpm   : 6 to 8 rpm 
Atomization Air pressure : 2.0 psi 
The average weight of tablet was checked periodically to achieve 10% weight gain of 
core tablet. 
The coated tablets were dried at 50 C for 30 min in conventional coating pan at 1-2 rpm. 
k. Drilling of orifice: 
One orifice with a diameter of 0.5 mm was drilled on either side of coated tablet using a 
microdrill. 
The prepared tablets were subjected to in vitro evaluation to select the best formulation 
for optimization of Coating composition. 
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8.6 Optimization of Coating composition for monolayer osmotic tablets: 
Table   29: Optimization of Coating composition for monolayer osmotic tablets 
                 Batch size: 200 tablets 
Sr.No 
Batch No MT11 MT19 MT20 
Ingredients 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
 Dry mix 
1 Trimetazidine 60 12000 60 12000 60 12000 
2 HPMC K4M 75 15000 75 15000 75 15000 
3 Lactose Mono 200 40000 200 40000 200 40000 
 Binder Solution 
4 Povidone K30 25 5000 25 5000 25 5000 
5 IPA (90%) qs 20000 qs 20000 qs 20000 
 Extra Granular 
6 Carbopol 71 G 100 20000 100 20000 100 20000 
7 NaCl 30 6000 30 6000 30 6000 
8 Mg Stearate 5 1000 5 1000 5 1000 
9 Talc 5 1000 5 1000 5 1000 
 Core tab Wt 500 120000 500 120000 500 120000 
 Coating 
 % wt. Gain 10% 10% 10% 
10 CelluloseAcetate 37.5(75%) 7500 35 (70%) 7000 40 (80%) 8000 
11 Dibutylcebacate 12.5(25%) 2500 15 (30%) 3000 10 (20%) 2000 
12 Ethanol (50%) QS 36667 QS 36667 QS 36667 
13 Acetone (50%) QS 36667 QS 36667 QS 36667 
 Coated tab wt. 550 203334 550 203334 550 203334 
 
Tablet manufacturing process:  
a. Dry mixing: 
TMZ, HPMC K4M and Lactose mono were dry mixed in the above proportion in a 
polybag manually. 
b. Binder solution preparation: 
Povidone K30 was dissolved in IPA with stirring.  
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c. Granulation: 
Dry mix blend was granulated with prepared binder solution. 
d. Drying: 
Wet mass was dried at 50 C in oven to get LOD below 2%w/w using Halogen moisture 
detector at 105 C temperature.   
e. Sizing: 
Dried granules were passed through 20# sieve. 
f. Extragranular mixing: 
Above sized granules were mixed with Carbopol 71G,sodium chloride and talc for 10 
minutes at 24 rpm in an octagonal blender.  
g. Lubrication: 
The above granules were lubricated with 60# passed Magnesium stearate for 5 minutes at 
24 rpm in an octagonal blender 
h. Compression: 
Lubricated granules were compressed using 9.0 mm, round, standard concave punches, 
plain on both the sides in rotary compression machine.   
i. Preparation of coating solution: 
Coating solution was prepared by dissolving Cellulose acetate and dibutyl cebecate 
(75:25, 70:30 and 80:20) in a mixture of ethanol and acetone (50:50) with constant 
stirring. 
j. Coating process: 
Core tablets were coated with prepared coating solution using conventional coating pan 
machine.  The coating parameters were as follows: 
Inlet air temperature  : 45 C 
Bed temperature  : 38 C 
Pan rpm   : 6 to 8 rpm 
Atomization Air pressure : 2.0 psi 
The average weight of tablet was checked periodically to achieve 10% weight gain of 
core tablet. 
The coated tablets were dried at 50 C for 30 min in conventional coating pan at 1-2 rpm. 
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k. Drilling of orifice: 
One orifice with a diameter of 0.5 mm was drilled on either side of coated tablet using a 
microdrill.  
The prepared tablets were subjected to in vitro evaluation to select the best formulation 
for optimization of Coating composition 
The optimized formulation was then subjected to stability study as per ICH guidelines for 
stability study.  
8.7 Compression and coating parameters: 
8.7.1 Weight variation: 
To find out weight variation, 20 tablets of each type of formulation were weighed 
individually using an electronic balance, average weight was calculated and individual 
tablet weight was then compared with average value to find the deviation in weight from 
average weight. 
The specifications for tablets to pass the weight variation test as per Pharmacopoeia of 
India are mentioned in Table 30. Not more than 2 of the individual masses deviate from the 
average mass by more than the percentage deviation shown in Table 30 and none deviates 
by more than twice the percentage. 
Table 30:  Specifications for weight variation in tablets as per Pharmacopoeia of India. 
Sr no. Average Weight of tablet 
% allowable 
deviation 
1 80 mg or less 10 
2 
More than 80 mg but less than 250 
mg 
7.5 
3 250 mg or more 5 
8.7.2  Hardness: 
For each type of formulation the hardness values for 10 tablets were determined 
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using Monsanto hardness tester. The tablet was held along its oblong axis in between the 
two jaws of the tester. At this point, reading should be 0 kg/cm
2
. Then constant force 
was applied by rotating the knob until the tablet fractured. The value at this point was 
noted in kg/cm
2 
8.7.3 Thickness: 
The thickness of the tablets was determined using a Digital Vernier Calliper (Mitutoyo CD-
6"CS). Five tablets from each type of formulation were used and average values were 
calculated. 
8.7.4 Friability: 
For each type of formulation the friability was determined as follows- 
Twenty tablets were weighed accurately and placed in Roche friabilator. The 
speed of rotation of Roche friabilator was kept 25 rpm. The drum was rotated 100 times. 
The tablets were removed and then weighed.  The percent friability was determined 
using following formula: 
% friability = initial weight - final weight     x 100 
                   Initial weight  
 According to Indian Pharmacopoeia, friability of the prepared tablets should not exceed 
1%w/w 
 
8.7.5 Orifice diameter size: 
The orifice diameter of 10 intact tablets was measured using a Digital Vernier Calliper 
(Mitutoyo CD-6"CS) and the average value was reported.   
8.8 In vitro dissolution study: 
All the feasibility trial batches were subjected to In vitro dissolution study for drug release and to 
study the effect of variables. The operating conditions for drug release were adjusted as follows.  
Dissolution test apparatus  : USP type II (paddle) 
Speed     : 50 RPM 
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Temperature    : 37° C ± 0.5 ° C 
Dissolution medium  : 900 ml distilled water 
Sampling time   : every 1 hr  
Sample withdrawn   : 10 ml 
Method of analysis   : UV spectrophotometer 
UV maxima    : 270 nm 
Samples were suitably diluted and absorbance was measured. Cumulative percentage drug 
released was calculated for each batch. The study was performed in triplicate and the average 
was reported. 
8.9 Statistical treatment: 
The data of % cumulative release from each trial batch were subjected to kinetic release studies 
to assess the fit into the zero-order release kinetics. The r
2
 value was found out to determine the 
best fit zero order release kinetics.  The trial batch having the nearest value to 1 was selected as 
the best trial formulation.  Also the difference factor (f1) and similarity factor (f2) for each batch 
was found out by comparing it with the theoretical target release profile using the following 
equations: 
 
where Rt and Tt are the cumulative percentage dissolved at each of the selected n time points of 
the reference and test product respectively. The factor f1 is proportional to the average difference 
between the two profiles, where as factor f2 is inversely proportional to the average squared 
difference between the two profiles, with emphasis on the larger difference among all the time-
points. The factor f2 measures the closeness between the two profiles. 
  Values of f1 (<15) and f2 (>50) indicate, that the curves can be considered similar. 
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8.10 Effect of variables on release profiles of optimized formulations for monolayer osmotic      
        tablets:  
 The optimized formulation was then subjected to various comparative tests under 
different conditions to study the following effects of variables:  
a. Effect of Osmotically active Dissolution Medium on drug release 
b. Effect of Agitation rate on drug release 
c. Effect of orifice size on the drug release from optimized formulations 
 
8.11 Stability study: 
 The optimized formulation was subject to accelerated stability study at various 
temperature and humidity conditions as per the criterion mentioned in the ICH guidelines for 
stability study, to see whether the final product is sufficiently rugged for marketing worldwide 
under various climated conditions including tropical, subtropical and temperate.   
. 
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8.12 Results and discussion for Monolayer osmotic Tablets of Trimetazidine         
        dihydrochloride 
8.12.1 Characterization of lubricated granules: 
The result obtained from the granulometry study is shown in the table below: 
Table 31: Granulometry study result of the feasibility core trial: 
Batch No CT1 CT2 CT3 CT4 CT5 CT6 CT7 
Bulk Density (gm/ml) 0.452 0.442 0.472 0.449 0.452 0.482 0.462 
Tapped Density 
(gm/ml) 0.621 0.593 0.593 0.592 0.572 0.591 0.582 
Carr’s Index 27.214 25.464 20.405 24.155 20.979 18.443 20.619 
Hausner Ration 1.374 1.342 1.256 1.318 1.265 1.226 1.260 
Angle of Repose 48 47 38 44 42 38 43 
LOD % w/w (at 105ºC) 1.92 1.82 1.69 1.57 1.68 1.29 1.63 
Sieve analysis        
% Retained on 20# 12 8 6.5 4 8 5.2 6 
% Retained on 40# 30 18 19 22 26 25 23 
% Retained on 60# 22 27 25 26 27 30 29 
% Retained on 80# 10 29 17 18 15 22 21 
% Retained on 100# 5 12 19 15 12 10 18 
% Passed through 100# 21 6 13.5 15 12 7.8 3 
 100 100 100 100 100 100 100 
 
From the above trial it is evident that trial CT6 having an angle of repose of 38
0
, 
Hausner’s ratio of 1.226 and Carr’s index of 18.443, shows the best flow and compressibility 
properties among all the trial granule batches.  Hence the trial batch CT6 was selected as the 
optimized batch for preparation of compressed tablets.
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8.12.2 Compression and coating parameters (for core and coated tablets) 
Table 32: Compression and coating parameters (for core and coated tablets) for monolayer osmotic tablets trial formulations: 
Batch 
No 
Core Tablets Parameter Coated Tablets Parameter 
Avg wt  
(mg) 
Hardness 
kg/cm2 
Thickness 
(mm) 
Friability 
(%) 
Weight 
Variation 
Avg wt  
(mg) 
Thickness 
(mm) 
Weight 
Variation 
Initial Wt. 
(mg) 
Final wt. 
(mg) 
% wt. 
gain 
Orifice diameter 
(mm) 
CT1 502 6.5 5.8 0.18 Complies -- -- -- -- -- -- -- 
CT2 503 6.8 5.82 0.201 Complies -- -- -- -- -- -- -- 
CT3 501 7.8 5.91 0.208 Complies -- -- -- -- -- -- -- 
CT4 503 4.8 5.82 0.128 Complies -- -- -- -- -- -- -- 
CT5 504 6.2 5.91 0.125 Complies -- -- -- -- -- -- -- 
CT6 502 8.1 5.95 0.201 Complies -- -- -- -- -- -- -- 
CT7 501 8.9 5.92 0.305 Complies -- -- -- -- -- -- -- 
MT1 504 6.9 5.96 0.218 Complies 524 6.01 Complies 504 524 3.97 0.52 
MT2 500 7.1 5.89 0.258 Complies 536 6.02 Complies 500 536 7.20 0.51 
MT3 500 8.1 5.86 0.256 Complies 551 6.09 Complies 500 551 10.20 0.53 
MT4 502 7.8 5.92 0.247 Complies 559 6.09 Complies 502 559 11.35 0.51 
MT5 503 7.6 5.91 0.289 Complies 551 6.1 Complies 503 551 9.54 0.54 
MT6 502 7.5 5.96 0.242 Complies 550 6.08 Complies 502 550 9.56 0.56 
MT7 502 7.6 5.99 0.282 Complies 549 6.05 Complies 502 549 9.36 0.52 
MT8 502 7.6 5.98 0.212 Complies 548 6.1 Complies 502 548 9.16 0.54 
MT9 503 7.9 5.94 0.231 Complies 550 6.11 Complies 503 550 9.34 0.52 
MT10 504 7.8 5.92 0.172 Complies 549 6.06 Complies 504 549 8.93 0.5 
MT11 504 8.1 5.89 0.156 Complies 550 6.04 Complies 504 550 9.13 0.52 
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MT12 501 8.2 5.88 0.124 Complies 548 6.03 Complies 501 548 9.38 0.51 
MT13 504 8.1 5.89 0.138 Complies 549 6.02 Complies 504 549 8.93 0.53 
MT14 502 8.2 5.99 0.218 Complies 550 6.08 Complies 502 550 9.56 0.54 
MT15 501 7.9 5.86 0.218 Complies 549 6.05 Complies 501 549 9.58 0.52 
MT16 500 7.7 5.92 0.211 Complies 550 6.11 Complies 500 550 10.00 0.52 
MT17 501 7.6 5.92 0.186 Complies 550 6.1 Complies 501 550 9.78 0.51 
MT18 501 7.7 5.99 0.154 Complies 551 6.06 Complies 501 551 9.98 0.53 
MT19 502 7.4 5.86 0.254 Complies 551 6.09 Complies 502 551 9.76 0.51 
MT20 503 7.6 5.92 0.231 Complies 549 6.08 Complies 503 549 9.15 0.52 
 
It is evident from the above table that all the trial formulations comply with the standard specification mentioned in the Indian Pharmacopoeia 
for average weight and weight variation and friability.  Also the thickness and hardness parameters of the prepared tablets complied with the 
in house specifications.  The orifice diameter was found to be in the range of 0.5 to 0.56 mm. 
Chapter 8                                                                                 Monolayer osmotic drug delivery system 
Osmotic Drug Delivery System                                                                                                                      Page 119 
 
8.12.3 In vitro dissolution study: 
The dissolution profile results for the various formulation trials are as follows: 
8.12.3.1 Coating feasibility trial: 
Table 33: % cumulative release data for coating feasibility trial for monolayer osmotic tablets 
                     
              (Average reported for 3 readings) 
 % cumulative release 
Time 
(hr) MT 1 MT 2 MT 3 MT 4 
0 0 0 0 0 
1 9.3 5.1 2.1 0 
2 15.2 10.2 5.2 3.2 
4 35.1 24.3 17.4 12.2 
6 63.5 48.2 28.2 24.1 
8 80.3 72.5 34.4 30.6 
12 94.5 88.6 47.3 80.5 
18 98.2 97.2 74.1 75.2 
24 99.2 99.3 95.2 89.7 
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Figure 23:  % cumulative release v/s Time (hr) plot for coating feasibility trial for monolayer 
osmotic tablets 
 
Table 34: Statistical parameters for dissolution data of coating feasibility trial for monolayer 
osmotic tablets 
Parameters MT 1 MT 2 MT 3 MT 4 
f1 (Difference Factor) 81.50 63.17 14.37 22.10 
f2 (Similarity factor) 24.00 28.79 61.82 49.71 
Zero order kinetic  
(r
2
 value) 
0.783 0.848 0.992 0.9587 
  
From the above results of % cumulative release and zero order kinetic (r
2
 value), it was seen that 
batch MT3 and MT4 showed good zero order release kinetics.  Batch MT3 showed a cumulative 
release of 95%, which was comparatively higher than the % cumulative release of MT4 after 24 
hours. Also analyzing the f1(<15) and f2(>50) values, it was seen that batch MT3 showed a 
release profile which could be considered similar to the theoretical target profile.    Hence batch 
T3 was further optimized for HPMC K4M concentration.  
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8.12.3.2 Optimization of HPMC K4M: 
Table 35: % cumulative release data for optimization of HPMC K4M for monolayer osmotic 
tablets 
                 (Average reported for 3 readings) 
 
% cumulative release 
Time 
(hr) MT5 MT6 MT 3 MT7 MT8 
0 0 0 0 0 0 
1 13.2 2. 4.2 0 0 
2 23.1 5.5 9.4 1.3 0.2 
4 40.4 13.3 21.3 11.2 5.1 
6 55.2 23.5 38.7 21.4 15.2 
8 68.2 35.5 55.8 33.4 26.3 
12 85.6 54.4 80.2 52.6 47.1 
18 95.5 79.3 91.3 76.5 65.4 
24 99.1 98.4 95.1 90.1 87.4 
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Figure 24:  % cumulative release v/s Time (hr) plot for optimization of HPMC K4M for 
monolayer osmotic tablets 
 
Table 36: Statistical parameters for dissolution data of optimization of HPMC K4M for 
monolayer osmotic tablets 
Parameter MT5 MT6 MT 3 MT7 MT8 
f1 (Difference Factor) 76.00 62.61 47.74 11.44 11.29 
f2 (Similarity factor) 26.87 14.74 35.81 63.33 58.86 
Zero order kinetic   
(r
2
 value) 
0.8568 0.994 0.9057 0.9857 0.9872 
 
 From the above results of % cumulative release and zero order kinetic (r
2
 value), it is 
seen that batch MT6, MT7 and MT8 showed good zero order release.  But it can be seen from 
the % cumulative release profile that the tablets of batch MT7 and MT8 did not achieve 100% 
release after 24 hours.  Batch MT6 showed a cumulative release of 99% after 24 hours.  Also 
analyzing the f1 and f2 value of batch MT6, it was concluded that the formulation MT6 showed 
similar release profile to the theoretical target release profile.  Hence batch MT6 was further 
optimized for Carbopol 71G concentrations. 
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8.12.3.3 Optimization of Carbopol 71G: 
Table  37: % cumulative release data for optimization of Carbopol 71G for monolayer osmotic 
tablets 
                                                      (Average reported for 3 readings) 
 % Cumulative release 
Time 
(hr) MT9 MT10 MT11 MT6 MT12 
0 0 0 0 0 0 
1 17.2 10.4 1.5 5.2 0 
2 29.3 18.3 4.5 12.1 0 
4 46.4 40.5 14.5 25.3 2.1 
6 60.4 52.1 19.2 39.3 14.1 
8 75.6 65.2 34.1 52.2 24.4 
12 93.1 85.6 53.5 71.3 43.2 
18 98.2 99.4 85.3 89.4 65.4 
24 99.3 98.2 99.1 99.1 81.1 
 
 
 
 
Figure 25:  % cumulative release v/s Time (hr) plot for optimization of Carbopol 71G for 
monolayer osmotic tablets 
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Table 38: Statistical parameters for dissolution data of optimization of Carbopol 71G for 
monolayer osmotic tablets 
Parameter MT9 MT10 MT11 MT6 MT12 
f1 (Difference Factor) 90.25 72.65 14.88 44.43 16.06 
f2 (Similarity factor) 23.23 27.76 59.64 38.12 51.73 
Zero order kinetic  
 (r
2
 value) 
0.803 0.8633 0.9882 0.9488 0.9822 
 
From the above results of % cumulative release and zero order kinetic (r
2
 value), it is seen that 
batch MT11 and MT12 showed good zero order release.  But it can be seen from the % 
cumulative release profile that the tablets of batch T12 did not achieve 100% release after 24 
hours.  Batch T11 showed a cumulative release of 99% after 24 hours.  Also analyzing the  f1 and 
f2   value  of trial formulation MT11, a similarity could be established between it and the 
theoretical target profile.  Hence batch T11 was further optimized for osmogen concentration. 
8.12.3.4 Optimization of osmogen: 
Table  39 : % cumulative release data for optimization of Osmogen for monolayer osmotic 
tablets 
 (Average reported for 3 readings) 
 % Cumulative release 
Time 
(hr) MT11 MT13 MT14 MT15 MT16 MT17 MT18 
0 0 0 0 0 0 0 0 
1 1.5 0 6.1 0 7.1 11.2 3.3 
2 4.5 2.1 13.4 0 14.3 17.4 7.4 
4 14.5 15.3 25.2 12.2 27.2 32.3 19.2 
6 19.2 29.4 37.3 24.2 38.1 43.2 33.4 
8 34.1 40.3 48.4 38.3 46.8 52.4 45.5 
12 53.5 60.5 67.1 60.2 65.6 71.5 64.3 
18 85.3 80.4 87.3 84.4 84.2 89. 85.2 
24 99.1 90.1 99.3 95.4 96.1 99.8 99.7 
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Figure 26:  % cumulative release v/s Time (hr) plot for optimization of osmogen for monolayer 
osmotic tablets 
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Table 39 (a) : Statistical parameters for dissolution data of optimization of osmogen 
Parameter MT11 MT13 MT14 MT15 MT16 MT17 MT18 
f1 (Difference Factor) 14.88 23.17 40.76 18.40 41.13 52.13 30.87 
f2 (Similarity factor) 59.64 50.20 40.52 51.44 40.96 33.90 45.68 
Zero order kinetic   
(r
2
 value) 
0.9882 0.9644 0.9659 0.973 0.9643 0.9492 0.9574 
 
From the above results of % cumulative release and zero order kinetic (r
2
 value), it is seen that 
batch MT11 and MT16 showed good zero order release as compared to the other trial batches.  
But it can be seen from the % cumulative release profile that the tablets of batch T16 achieved a 
96% release after 24 hours.  Batch T11 showed a cumulative release of 99% after 24 hours.  Also 
analyzing the  f1 and f2   value  of trial formulation MT11, a similarity could be established 
between it and the theoretical target profile Hence batch T11 was further optimized for coating 
concentration. 
Chapter 8                                                                                 Monolayer osmotic drug delivery system 
Osmotic Drug Delivery System                                                                                                                      Page 126 
 
8.12.3.5  Optimization of coating: 
Table 40: % cumulative release data for optimization of Coating for monolayer osmotic 
tablets 
                                                                              (Average reported for 3 readings) 
 % cumulative release 
Time 
(hr) MT11 MT19 MT20 
0 0 2.2 0 
1 1.5 9.3 2.2 
2 4.5 16.4 6.6 
4 14.5 30.1 14.5 
6 19.2 44.3 23.4 
8 34.1 57.5 34.3 
12 53.5 76.3 55.2 
18 85.3 95.4 80.4 
24 99.1 99.4 100 
 
Figure  27 :  % cumulative release v/s Time (hr) plot for optimization of osmogen for 
monolayer osmotic tablets 
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Table 41: Statistical parameters for dissolution data of optimization of osmogen for 
monolayer osmotic tablets 
Parameter MT11 MT19 MT20 
f1 (Difference Factor) 14.88 56.52 14.59 
f2 (Similarity factor) 59.64 31.76 60.57 
Zero order kinetic   
(r
2
 value) 
0.9882 0.931 0.995 
 
From the above results of % cumulative release and zero order kinetic (r
2
 value), it is seen that 
all the batches showed good zero order release kinetics.  But the batch MT20 showed an almost a 
perfect zero order release (r
2 
= 0.995).   Also batch T20 showed a % cumulative release of 100% 
after 24 hours.  Also analyzing the  f1 and f2   value  of trial formulation MT20, a similarity could 
be established between it and the theoretical target profile. Hence batch MT20 was considered as 
the final optimized formulation for monolayer osmotic drug delivery system and was further 
forwarded for stability study analysis.     
 
8.12.4 Effect of variables on the optimized formulation:  
The optimized formulation was then subjected to various comparative tests under different 
conditions to study the following effects of variables:  
a. Effect of Osmotically active Dissolution Medium on drug release 
b. Effect of Agitation rate on drug release 
c. Effect of orifice size on the drug release from optimized formulations.   
The results of the study are as follows:  
 
 
8.12.4.1 Effect of Osmotically active Dissolution Medium on drug release: 
Active drug is released from the system mainly by osmosis and less by diffusion through 
osmotic tablets. Performance of the system depends on its design so that it can release active 
substance by osmosis only. In order to investigate the actual mechanism of the drug released 
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from the tablet, dissolution study was conducted in water (0-8 h), 2.4 % w/w magnesium 
sulphate solution in water (8-16 hr) and in water (17-24 hr) alternatively. Table shows 
dissolution profile for the optimized formulation (MT20)  in water (upto 8th hour), then 
magnesium sulphate (upto 16th hour) and lastly followed by water (upto 24th hour). 
 
Table 42: cumulative % drug release of the selected optimized formulation (MT20)  in 
different dissolution medium 
Time  
(hr) 
Dissolution 
media 
cumulative % drug 
release for optimized 
batch (MT20) 
0 
water 
0 
1 2.2 
2 6.6 
4 14.5 
6 23.4 
8 34.3 
8 
2.4% magnesium 
sulphate solution 
34.3 
12 40.1 
16 44.8 
16 
water 
44.8 
20 59.8 
24 72.4 
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Figure 28:  % cumulative release v/s Time (hr) plot for optimized formulation (MT20) to study 
the effect of Osmotically active Dissolution Medium on drug release: 
 
In magnesium sulphate solution drug release takes place by diffusion only as its osmotic pressure 
is high enough to cease the drug release by osmosis. In water, drug release takes place by 
osmosis and diffusion.  
The drug release rate (mg/hr) for the selected optimized formulation (MT20) after duration of 8 
hrs in alternative media is as shown in the table below:  
Table 43 : Drug release rate for selected optimized formulation (MT20)  after duration of 8 hrs 
in alternative media: 
 
Sr 
no. 
Time 
duration 
Dissolution 
medium 
 Drug release 
rate for MT20 
1 0-8 hrs water 2.6 + 0.09 mg/hr 
2 9-16 hrs 
2.4% 
magnesium 
sulphate 
solution 
0.78 + 0.02 mg/hr 
3 17-24 hrs water 2.07 + 0.08 mg/hr 
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Drug release rate of 2.6 + 0.09 mg/hr was observed with water for first 8 hr for the 
optimized formulation MT20 while in the next 8 hours i.e upto 16
th
 hour, in 2.4 % magnesium 
sulphate solution it was found to be 0.78 + 0.02 mg/hr.  Again in water for next 8 hrs i.e upto 24
th
 
hour it was found to increase upto 2.07 + 0.08 mg/hr. The results revealed that in water, effective 
osmotic pressure across the membrane was obtained which led to high drug release rate.  
Pressure drop across the membrane was very less in case of magnesium sulphate solution, which 
shows slow drug release rate.  
From above results it can be concluded that in case of osmotic drug delivery system, the 
drug release rate is mainly contributed by osmotic pressure only.  
 
 
8.12.4.2 Effect of Agitation rate on drug release 
The optimized formulation MT20 was subjected to dissolution study at different agitation 
rates. In the present investigation dissolution study was performed at three different agitation 
rates.  Agitation rates of 50, 100 and 150 rpm were selected for the study. 
 
The following table shows percent drug release from the optimized formulation at three 
different agitation rates with time. 
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Table 44: Effect of agitation rate on in-vitro drug release of the optimized formulation MT20 osmotic 
tablet: 
 
Time 
(hr) 
 cumulative % drug released 
of MT20 
50 rpm 100 rpm 150 rpm 
0 0 0 0 
1 2.3 2.6 2.7 
2 6.4 6.1 7.2 
4 15.1 15.5 16.1 
6 22.7 27.5 28.1 
8 35.5 36.5 37.5 
12 57.2 56.4 57.9 
18 81.5 82.3 84.3 
24 99.8 99.6 99.1 
 
Figure 29:  % cumulative release v/s Time (hr) plot for formulation MT20 to study the effect of 
agitation rate on drug release 
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When drug is released by diffusion mechanism only, agitation rates have significant effect on 
drug release due to the formation of saturated drug layer on the surface of the tablets, which 
reduces further drug release. However, this phenomenon was not observed with osmotic pressure 
driven drug release system as could be seen with the above data.  No significant changes were 
observed during drug release study with agitation rate, which strongly indicates that release of 
the drug from the system takes place mainly through osmotic pressure generated within the 
system. Therefore, it might be predicted that the mobility of the gastrointestinal tract hardly 
affected the drug release of the prepared osmotic tablet. Since drug release was independent of 
agitation rate, the prepared osmotic tablets might exhibit a comparable in vitro/in vivo release 
profile. 
 
8.12.4.3 Effect of orifice size on the drug release from optimized formulations: 
 
To study the effect of orifice size on the drug release from the optimized formulations, 
the in vitro analysis of the selected tablets formulations was carried out.  Coated tablets were 
selected from each of the optimized batch and orifices with varying sizes (0.5 mm, 1.0 mm, 
1.5mm and 2.0mm) were drilled using a mechanical microdrill.  The shape and diameter of the 
created orifice was visually inspected and measured using a 50 X microscope.  The data for the 
cumulative % drug release with varying orifice size for the selected formulation MT20 is as 
shown in the table below: 
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Table 45: Cumulative % drug release from optimized formulation MT20 with various orifice 
sizes 
Time 
(hr) 
 cumulative % drug released 
Orifice size (MT20) 
0.2 
mm 
0.5 
mm 
1.0 
mm 
1.5 
mm 
2.0 
mm 
0 0 0.1 0.2 0.4 1.4 
1 1.4 2.3 2.6 2.7 3.8 
2 2.5 6.4 6.1 7.2 11.8 
4 8.1 15.1 15.5 16.1 24.6 
6 14.6 22.7 27.5 28.1 37.8 
8 21.6 35.5 36.5 37.5 46.5 
12 31.4 57.2 56.4 57.9 78.4 
18 46.8 81.5 82.3 84.3 98.6 
24 64.9 99.8 99.6 99.1 99.6 
 
 
Figure 30:  % cumulative release v/s Time (hr) plot for formulation MT20 to study the 
effect of orifice size on drug release  
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As can be seen from the results of the above study of varying orifice sizes, it was observed that 
there was no significant change in the drug release pattern with orifice size in the range of 0.5 
mm to 1.5mm.  However, as can be seen from the above observations, it was found that a 
comparative higher release pattern and rapid release of drug was seen in tablets drilled with an 
orifice of 2.0 mm.  It was found that almost 100% drug was released around the 20
th
 hour and 
hence a sustained release comparable to the theoretical target release profile was not achieved.  
This may be due to the result of higher diffusion of fluids from the bigger orifice.  On the other 
hand, a low release rate and anomalous release were exhibited at an orifice diameter of 0.2 mm. 
The drug or excipients granules in insoluble form may occlude such a small orifice, therefore, 
leading to a low drug release rate. 
Hence it was concluded that the release rates were independent of the orifice size in the range of 
0.5mm to 1.5mm.  However, a higher orifice size (2.0mm) or a lower orifice size (0.2mm) had a 
significant influence on the release rate of drug from the osmotic drug delivery system.   
 
8.12.5 Accelerated Stability studies of the optimized formulation for monolayer osmotic 
drug delivey system:  
The stability of a product can be ensured during its various phases of development and to 
arrive at the proper storage conditions and the expiry date.  This is the requirement in most of the 
countries and is stipulated by the regulatory agencies of those countries.  These studies would 
very quickly identify the need, if any; to stabilize the active substance or the formulation and 
save invaluable time and effort from being spend on an unmarketable formulation.  With the 
recent trend towards globalization of manufacturing operation, it is imperative that the final 
product be sufficiently rugged for marketing worldwide under various climatic conditions 
including tropical, sub tropical and temperate.   
The accelerated stability testing was performed on the selected formulation (MT20) 
which gave the most optimum results amongst all the previous trial batch formulation. The test 
was carried out by placing the tablets of each selected formula in closed glass container in an 
ALU ALU Blister pack and stored in thermostatically controlled ovens adjusted at different 
temperatures and humidity percentage, namely, 40⁰C/75%, 30⁰C/65% and 25⁰C/60% 
(maintained using a saturated solution of NaCl) for a period of 3 months. The stored tablets were 
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examined visually for any changes in color and/or appearance every month. Also the average 
weight, hardness and loss on drying of the selected batch formulations were determined at a 
period of 1 month for total 3 months.  Three tablets were taken from the ovens after a period of 1 
month for 3 months and analyzed for the determination of cumulative % drug release.  Limits 
were set for each of the above parameter (i.e. average weight, hardness, loss on drying and 
cumulative % drug release) using the ICH guidelines for accelerated stability studies.   
The results of the optimized formulations MT20 after conducting accelerated stability studies for 
3 months are as follows:  
Table 46: Stability study data for the optimized monolayer osmotic tablet batch (MT20): 
 
 
Monolayer osmotic Tablets (Alu-Alu Blister Pack) Batch MT20 
Sr. 
No 
Test Limit Initial 
Storage condition 
40⁰C/75% 30⁰C/65% 25⁰C/60% 
1 
Month 
2  
Month 
3  
Month 
1 
Month 
2  
Month 
3  
Month 
3  
Month 
1 Description * * * * * * * * * 
2 Avg. Wt 500mg ± 3% 500.2 500.4 501 500.9 500 501 501.2 500.9 
3 Hardness 
NLT 5.0 
kg/cm2 
7.5 7.4 7.3 7.6 7.5 7.8 7.4 7.9 
4 
Loss on 
Drying 
NMT 5% 2.26% 2.50% 2.75% 2.80% 2.30% 2.38% 2.45% 2.50% 
5 Dissolution                   
  Time (hr) % Drug Dissolved (as an average of 3 readings) 
  2 NMT 5% 6.2 5.1 5.3 6.8 5.4 6.1 6.6 5.2 
  6 10-30% 23.3 23.9 22.3 23.5 24.3 24.2 23.4 22.4 
  8 20-40% 34.2 35.2 35.4 33.9 35.4 35.1 34.4 35.6 
  12 45-65 % 55.1 56.3 54.1 54.6 54.2 56.7 55.2 54.2 
  18 65 -85% 80.8 81.9 79.9 78.3 81.6 79.3 80.4 81.3 
  24 NLT 85 % 100.0 99.2 98.8 98.4 100.0 99.3 100.0 99.1 
6 
f1   
(Difference 
Factor) 
<15 
  
1.9 2.1 1.9 1.6 1.9 0.4 1.9 
7 
f2  
(Similarity 
factor) 
>50 
  
92.6 92.0 89.6 93.0 91.7 99.2 92.8 
 
* White to off white, round, biconvex film coated tablets  
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It can be seen from the above table, that there was no significant variation in the physical 
appearance, average weight, hardness and loss of drying after placing the tablets at various 
temperature and humidity conditions for a period of 3 months.   
Also the cumulative % drug release data showed that the optimized formulation (MT20) 
released a drug amount, within the limits laid down as per the ICH guidelines for stability 
studies.  A very low f1 value and a value of f2 higher than 50 in each of the above formulation 
batches at various time intervals, suggested that the release profile remained similar to the initial 
release profile even after subjecting the tablets to the above temperature and humidity parameters 
for a period of 3 months.  Hence it was concluded that the optimized formulation batches did not 
show any significant change in their release profiles after 3 months duration under the above 
temperature and humidity conditions.   
              Thus the optimized formulations could be considered stable for a period of 2 years.   
 
 
 
  
 
 
CHAPTER 9 
BILAYER OSMOTIC DRUG 
DELIVERY SYSTEM 
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9.0 Experimental trials for Bilayer Osmotic Tablets of Trimetazidine Dihydrochloride:  
9.1 Optimization of HPMC K4M: 
Table 47:   Trial formulations for Optimization Of HPMC K4M for bilayer osmotic tablets 
Batch size:  200 tablets  
Sr.N
o 
Batch No BT1 BT2 BT3 BT4 BT5 
Ingredients 
Qty. 
mg/Ta
b 
Qty    
mg/20
0 tab 
Qty. 
mg/Ta
b 
Qty    
mg/20
0 tab 
Qty. 
mg/Ta
b 
Qty    
mg/20
0 tab 
Qty. 
mg/Ta
b 
Qty    
mg/20
0 tab 
Qty. 
mg/Ta
b 
Qty    
mg/20
0 tab 
  
Drug layer 
    
 (Layer 1) 
1 Trimetazidine 60 12000 60 12000 60 12000 60 12000 60 12000 
2 HPMC K4M 50 10000 75 15000 100 20000 125 25000 139.5 27900 
3 Lactose Mono 89.5 17900 64.5 12900 39.5 7900 14.5 2900 0 0 
4 Ferric oxide Red 2 400 2 400 2 400 2 400 2 400 
5 Nacl 30 6000 30 6000 30 6000 30 6000 30 6000 
6 Povidone K30 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 
7 isopropyl alcohol qs 14000 qs 14000 qs 14000 qs 14000 qs 14000 
8 Mg Stearate 3 600 3 600 3 600 3 600 3 600 
9 Talc 3 600 3 600 3 600 3 600 3 600 
  Wt. 250 50000 250 50000 250 50000 250 50000 250 50000 
  
Push layer  
                    
(Layer 2) 
10 Carbopol 71 G 60 12000 60 12000 60 12000 60 12000 60 12000 
11 Lactose DCl 21 141.5 28300 141.5 28300 141.5 28300 141.5 28300 141.5 28300 
12 Povidone K30 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 
13 NaCl 30 6000 30 6000 30 6000 30 6000 30 6000 
14 Mg Stearate 3 600 3 600 3 600 3 600 3 600 
15 Talc 3 600 3 600 3 600 3 600 3 600 
  Core tab Wt 500 100000 500 100000 500 100000 500 100000 500 100000 
  Coating                     
  % wt. gain 10%   10%   10%   10% 20 10%   
16 
Celulose Acetate 
(75%) 
40 8000 40 8000 40 8000 40 8000 40 8000 
17 
Dibutylcebacate 
(25%) 
10 2000 10 2000 10 2000 10 2000 10 2000 
18 Ethanol (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
19 Acetone (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
  Coated tab wt. 550 110000 550 110000 550 110000 550 110000 550 110000 
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Procedure: 
 Layer 1 (Drug Layer) 
a. Dry mixing: 
TMZ, HPMC K4M, Lactose mono, NaCl and  FeO(colourant)  were dry mixed in the 
above proportion in a polybag manually. The increase in the quantity of HPMC K4M in 
each batch was compensated with a corresponding decrease in the quantity of Lactose 
mono.  
b. Binder solution preparation: 
Povidone K30 was dissolved in IPA with stirring.  
c. Granulation: 
Dry mix blend was granulated with prepared binder solution. 
d. Drying: 
Wet mass was dried at 50 C in oven to get LOD below 2%w/w using Halogen moisture 
detector at 105 C temperature.   
e. Sizing: 
Dried granules were passed through 20# sieve. 
f. Lubrication: 
The above blend was mixed with talc for 5 min at 24 rpm in an octagonal blender.  This 
blend was then lubricated with Mg stearate for 5 min at 24 rpm in an octagonal blender 
 
Layer 2 (Push layer):  
 
g. Mixing: 
Carbopol 71G, sodium chloride, Lactose DCL, Povidone K 30 and talc were mixed for 20 
minutes at 24 rpm in an octagonal blender.  
h. Lubrication: 
The above granules were lubricated with 60# passed Magnesium stearate for 5 minutes at 
24 rpm in an octagonal blender 
i. Compression: 
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The bilayer tablet was compressed using the above prepared blend 1 and blend 2 using a 
bilayer rotary compression machine.   
Lubricated granules were compressed using 9.0 mm, round, standard concave punches, 
plain on both the sides in rotary compression machine.   
j. Preparation of coating solution: 
Coating solution was prepared by dissolving Cellulose acetate and dibutyl cebecate 
(75:25) in a mixture of ethanol and acetone (50:50) with constant stirring. 
k. Coating process: 
Core tablets were coated with prepared coating solution using conventional coating pan 
machine.  The coating parameters were as follows: 
Inlet air temperature  : 45 C 
Bed temperature  : 38 C 
Pan rpm   : 6 to 8 rpm 
Atomization Air pressure : 2.0 psi 
The average weight of tablet was checked periodically to achieve 10% weight gain of core 
tablet. 
The coated tablets were dried at 50 C for 30 min in conventional coating pan at 1-2 rpm. 
l. Drilling of orifice: 
One orifice with a diameter of 0.5 mm was drilled on the coloured side of coated tablet 
using a microdrill. 
m. In vitro dissolution study: 
The prepared tablets were then subjected to in vitro analysis to select the best formulation 
for the optimization of Carbopol 71 G 
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9.2 Optimization of Carbopol 71G: 
Table 48:   Trial formulations for Optimization Of Carbopol 71 G for bilayer osmotic tablets 
Batch size: 200 tablets 
Sr. 
No 
Batch No BT6 BT4 BT7 BT8 BT9 
Ingredients 
Qty. 
mg/Ta
b 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
  Drug layer     
1 Trimetazidine 60 12000 60 12000 60 12000 60 12000 60 12000 
2 HPMC K4M 125 25000 125 25000 125 25000 125 25000 125 25000 
3 Lactose Mono 14.5 2900 14.5 2900 14.5 2900 14.5 2900 14.5 2900 
4 Ferric oxide Red 2 400 2 400 2 400 2 400 2 400 
5 Nacl 30 6000 30 6000 30 6000 30 6000 30 6000 
6 Povidone K30 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 
7 isopropyl alcohol qs 14000 qs 14000 qs 14000 qs 14000 qs 14000 
8 Mg Stearate 3 600 3 600 3 600 3 600 3 600 
9 Talc 3 600 3 600 3 600 3 600 3 600 
  Wt. 250 50000 250 50000 250 50000 250 50000 250 50000 
  Push layer (Layer 2)                     
10 Carbopol 71 G 45 9000 60 12000 80 16000 100 20000 120 24000 
11 Lactose DCl 21 156.5 31300 141.5 28300 121.5 24300 101.5 20300 81.5 16300 
12 Povidone K30 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 
13 NaCl 30 6000 30 6000 30 6000 30 6000 30 6000 
14 Mg Stearate 3 600 3 600 3 600 3 600 3 600 
15 Talc 3 600 3 600 3 600 3 600 3 600 
  Core tab Wt 500 100000 500 100000 500 100000 500 100000 500 100000 
  Coating                     
  % wt. gain 10%   10%   10%   10%   10%   
16 
Celulose Acetate 
(75%) 40 8000 40 8000 40 8000 40 8000 40 8000 
17 
Dibutylcebacate 
(25%) 10 2000 10 2000 10 2000 10 2000 10 2000 
18 Ethanol (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
19 Acetone (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
  Coated tab wt. 550 110000 550 110000 550 110000 550 110000 550 110000 
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Procedure: 
 Layer 1 (Drug Layer) 
a. Dry mixing: 
TMZ, HPMC K4M, Lactose mono, NaCl and  FeO(colourant)  were dry mixed in the 
above proportion in a polybag manually.  
b. Binder solution preparation: 
Povidone K30 was dissolved in IPA with stirring.  
c. Granulation: 
Dry mix blend was granulated with prepared binder solution. 
d. Drying: 
Wet mass was dried at 50 C in oven to get LOD below 2%w/w using Halogen moisture 
detector at 105 C temperature.   
e. Sizing: 
Dried granules were passed through 20# sieve. 
f. Lubrication: 
The above blend was mixed with talc for 5 min at 24 rpm in an octagonal blender.  This 
blend was then lubricated with Mg stearate for 5 min at 24 rpm in an octagonal blender 
Layer 2 (Push layer):  
g. Mixing: 
Carbopol 71G, sodium chloride, Lactose DCL, Povidone K 30 and talc were mixed for 20 
minutes at 24 rpm in an octagonal blender. The increase in the weight of Carbopol 71G 
for each batch was compensated with a corresponding decrease in the weight of Lactose 
DCL 
h. Lubrication: 
The above granules were lubricated with 60# passed Magnesium stearate for 5 minutes at 
24 rpm in an octagonal blender 
i. Compression: 
The bilayer tablet was compressed using the above prepared blend 1 and blend 2 using a 
bilayer rotary compression machine.   
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Lubricated granules were compressed using 9.0 mm, round, standard concave punches, 
plain on both the sides in rotary compression machine.   
j. Preparation of coating solution: 
Coating solution was prepared by dissolving Cellulose acetate and dibutyl cebecate 
(75:25) in a mixture of ethanol and acetone (50:50) with constant stirring. 
      h. Coating process: 
Core tablets were coated with prepared coating solution using conventional coating pan 
machine.  The coating parameters were as follows: 
Inlet air temperature  : 45 C 
Bed temperature  : 38 C 
Pan rpm   : 6 to 8 rpm 
Atomization Air pressure : 2.0 psi 
The average weight of tablet was checked periodically to achieve 10% weight gain of core 
tablet. 
The coated tablets were dried at 50 C for 30 min in conventional coating pan at 1-2 rpm. 
i. Drilling of orifice: 
One orifice with a diameter of 0.5 mm was drilled on the coloured side of coated tablet 
using a microdrill.  
The prepared tablets were subjected to in vitro evaluation to select the best formulation for 
optimization of Coating composition 
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9.3 Optimization of Osmogen: 
Table 49:   Trial formulations for Optimization Of Osmogen for bilayer osmotic tablets 
Batch size: 200 tablets 
Sr.No 
Batch No BT10 BT8 BT11 BT12 BT13 BT14 
Ingredients  
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
  
Drug layer 
(Layer 1) 
                        
1 Trimetazidine 60 12000 60 12000 60 12000 60 12000 60 12000 60 12000 
2 HPMC K4M 125 25000 125 25000 125 25000 125 25000 125 25000 125 25000 
3 Lactose Mono 24.5 4900 14.5 2900 4.5 900 14.5 2900 14.5 2900 24.5 4900 
4 Ferric oxide Red 2 400 2 400 2 400 2 400 2 400 2 400 
5 NaCl  20 4000 30 6000 40 8000 30 6000 30 6000 20 4000 
6 Mannitol 0 0 0 0 0 0 0 0 0 0 0 0 
7 Povidone K30 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 
8 
isopropyl 
alcohol 
qs 14000 qs 14000 qs 14000 qs 14000 qs 14000 qs 14000 
9 Mg Stearate 3 600 3 600 3 600 3 600 3 600 3 600 
10 Talc 3 600 3 600 3 600 3 600 3 600 3 600 
  Wt. 250 50000 250 50000 250 50000 250 50000 250 50000 250 50000 
  
Push layer 
(Layer 2) 
                        
11 Carbopol 71 G 100 20000 100 20000 100 20000 100 20000 100 20000 100 20000 
12 Lactose DCl 21 101.5 20300 101.5 20300 101.5 20300 111.5 22300 91.5 18300 91.5 18300 
13 Povidone K30 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 
14 NaCl  30 6000 30 6000 30 6000 20 4000 40 8000 40 8000 
15 Mannitol 0 0 0 0 0 0 0 0 0 0 0 0 
16 Mg Stearate 3 600 3 600 3 600 3 600 3 600 3 600 
17 Talc 3 600 3 600 3 600 3 600 3 600 3 600 
  Core tab Wt 500 100000 500 100000 500 100000 500 100000 500 100000 500 100000 
  Coating                         
  % wt. gain 10%   10%   10%   10%   10%   10%   
18 
Celulose 
Acetate (75%) 
40 8000 40 8000 40 8000 40 8000 40 8000 40 8000 
19 
Dibutylcebacate 
(25%) 
10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 
20 Ethanol (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
21 Acetone (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
  Coated tab wt. 550 110000 550 110000 550 110000 550 110000 550 110000 550 110000 
 
Continued---- 
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9.3 (contd) Optimization of Osmogen (Part II) 
Table 49 (contd):   Trial formulations for Optimization Of osmogen for bilayer osmotic tablets 
 
 
 
 
 
 
 
 
 
 
 
 
Sr.No 
Batch No BT15 BT16 BT17 BT18 BT19 BT20 
Ingredients  
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
Qty. 
mg/Tab 
Qty    
mg/200 
tab 
  Drug layer (Layer 1)                         
1 Trimetazidine 60 12000 60 12000 60 12000 60 12000 60 12000 60 12000 
2 HPMC K4M 125 25000 125 25000 125 25000 125 25000 125 25000 125 25000 
3 Lactose Mono 4.5 900 14.5 2900 14.5 2900 14.5 2900 24.5 4900 14.5 2900 
4 Ferric oxide Red 2 400 2 400 2 400 2 400 2 400 2 400 
5 NaCl  40 8000 0 0 0 0 30 6000 15 3000 0 0 
6 Mannitol 0 0 30 6000 30 6000 0 0 15 3000 40 8000 
7 Povidone K30 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 
8 isopropyl alcohol qs 14000 qs 14000 qs 14000 qs 14000 qs 14000 qs 14000 
9 Mg Stearate 3 600 3 600 3 600 3 600 3 600 3 600 
10 Talc 3 600 3 600 3 600 3 600 3 600 3 600 
  Wt. 250 50000 250 50000 250 50000 250 50000 260 52000 260 52000 
  Push layer (Layer 2)                         
11 Carbopol 71 G 100 20000 100 20000 100 20000 100 20000 100 20000 100 20000 
12 Lactose DCl 21 111.5 22300 91.5 18300 91.5 18300 91.5 18300 91.5 18300 91.5 18300 
13 Povidone K30 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 12.5 2500 
14 NaCl  20 4000 0 0 40 8000 0 0 20 4000 30 6000 
15 Mannitol 0 0 40 8000 0 0 40 8000 20 4000 0 0 
16 Mg Stearate 3 600 3 600 3 600 3 600 3 600 3 600 
17 Talc 3 600 3 600 3 600 3 600 3 600 3 600 
  Core tab Wt 500 100000 500 100000 500 100000 500 100000 510 102000 500 100000 
  Coating                         
  % wt. gain 10%   10%   10%   10%   10%   10%   
18 
Celulose Acetate 
(75%) 
40 8000 40 8000 40 8000 40 8000 40 8000 40 8000 
19 
Dibutylcebacate 
(25%) 
10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 
20 Ethanol (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
21 Acetone (50%) QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 QS 36667 
  Coated tab wt. 550 110000 550 110000 550 110000 550 110000 560 112000 550 110000 
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Procedure: 
 Layer 1 (Drug Layer) 
a. Dry mixing: 
TMZ, HPMC K4M, Lactose mono, NaCl and Mannitol (Osmogens) and  FeO(colourant)  
were dry mixed in the above proportion in a polybag manually. The proportion of NaCl 
and Mannitol was varied in each trial batch as per the above table 
b. Binder solution preparation: 
Povidone K30 was dissolved in IPA with stirring.  
c. Granulation: 
Dry mix blend was granulated with prepared binder solution. 
d. Drying: 
Wet mass was dried at 50 C in oven to get LOD below 2%w/w using Halogen moisture 
detector at 105 C temperature.   
e. Sizing: 
Dried granules were passed through 20# sieve. 
f. Lubrication: 
The above blend was mixed with talc for 5 min at 24 rpm in an octagonal blender.  This 
blend was then lubricated with Mg stearate for 5 min at 24 rpm in an octagonal blender 
Layer 2 (Push layer):  
g. Mixing: 
Carbopol 71G, sodium chloride, Mannitol, Lactose DCL, Povidone K 30 and talc were 
mixed for 20 minutes at 24 rpm in an octagonal blender. The proportion of NaCl and 
Mannitol was varied in the push layer as per the above table. 
 
h. Lubrication: 
The above granules were lubricated with 60# passed Magnesium stearate for 5 minutes at 
24 rpm in an octagonal blender. 
i. Compression:  
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The bilayer tablet was compressed using the above prepared blend 1 and blend 2 using a 
bilayer rotary compression machine.  Lubricated granules were compressed using 9.0 mm, 
round, standard concave punches, plain on both the sides in rotary compression machine.   
j. Preparation of coating solution: 
Coating solution was prepared by dissolving Cellulose acetate and dibutyl cebecate 
(75:25) in a mixture of ethanol and acetone (50:50) with constant stirring. 
      h. Coating process: 
Core tablets were coated with prepared coating solution using conventional coating pan 
machine.  The coating parameters were as follows: 
Inlet air temperature  : 45 C 
Bed temperature  : 38 C 
Pan rpm   : 6 to 8 rpm 
Atomization Air pressure : 2.0 psi 
The average weight of tablet was checked periodically to achieve 10% weight gain of core 
tablet. 
The coated tablets were dried at 50 C for 30 min in conventional coating pan at 1-2 rpm. 
ii. Drilling of orifice: 
One orifice with a diameter of 0.5 mm was drilled on the coloured side of coated tablet 
using a microdrill. 
The prepared tablets were subjected to in vitro evaluation to select the best formulation for 
optimization of osmogen 
The optimized formulation was then subjected to stability study as per ICH 
guidelines for stability study. 
 
9.4 Compression and coating parameters for bilayer osmotic tablets: 
The above prepared tablets were analysed for the various compression and coating parameters as 
discussed for monolayer osmotic tablets viz. Weight variation, hardness, friability, % weight gain 
for coated tablets and orifice diameter.  
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9.5 In vitro dissolution study for bilayer osmotic tablets: 
All the feasibility trial batches were subjected to In vitro dissolution study for drug release and to 
study the effect of variables. The operating conditions for drug release were adjusted as follows.  
Dissolution test apparatus  : USP type II (paddle) 
Speed     : 50 RPM 
Temperature    : 37° C ±  0.5  
Dissolution medium  : 900 ml distilled water 
Sampling time   : every 1 hr  
Sample withdrawn   : 10 ml 
Method of analysis   : UV spectrophotometer 
UV maxima    : 270 nm 
Samples were suitably diluted and absorbance was measured. Cumulative percentage drug 
released was calculated for each batch. The study was performed in triplicate and the average 
was reported. 
9.6 Statistical treatment for bilayer osmotic tablets: 
The data of % cumulative release from each trial batch were subjected to kinetic release studies to 
assess the fit into the zero-order release kinetics. The r
2
 value was found out to determine the best 
fit zero order release kinetics.  The trial batch having the nearest value to 1 was selected as the 
best trial formulation.  Also the difference factor (f1) and similarity factor (F2) for each batch was 
found out by comparing it with the theoretical target release profile   
9.7 Effect of variables on release profiles of optimized formulations for bilayer osmotic      
        tablets:  
The optimized formulation was then subjected to various comparative tests under different 
conditions to study the following effects of variables:  
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a. Effect of Osmotically active Dissolution Medium on drug release 
b. Effect of Agitation rate on drug release 
c. Effect of orifice size on the drug release from optimized formulations 
 
9.8 Stability study of optimized formulation of bilayer osmotic tablets : 
The optimized formulation was subject to accelerated stability study at various 
temperature and humidity conditions as per the criterion mentioned in the ICH guidelines for 
stability study, to see whether the final product is sufficiently rugged for marketing worldwide 
under various climated conditions including tropical, subtropical and temperate.   
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9.9 Result and discussion: Bilayer osmotic drug delivery system:  
9.9.1 Compression and coating parameters (for core and coated tablets) of bilayer osmotic drug delivery system: 
Table 50: Compression and coating parameters (for core and coated tablets) of bilayer osmotic drug delivery system: 
Batch 
No 
Core Tablets Parameter Coated Tablets Parameter 
Avg.wt. 
(layer 
1) 
(mg) 
Avg.wt. 
(layer 
2) 
(mg) 
Avg wt 
 (Bilayer 
Tablet) 
 (mg) 
Hardness 
(kg/cm
2
) 
Thickness  
(mm) 
Friability 
 (%) 
Weight  
Variation 
Avg 
wt  
(mg) 
Thickness 
(mm) 
Weight  
Variation 
Initial 
Wt. 
(mg) 
Final 
wt. 
(mg) 
% 
wt.gain 
Orifice 
Diameter 
(mm) 
BT1 251 250 501 7.2 6.01 0.218 Complies 556 6.21 Complies 501 556 10.98 0.51 
BT2 249 250 499 7.9 6.1 0.258 Complies 549 6.19 Complies 499 549 10.02 0.52 
BT3 248 251 499 7.2 6.11 0.256 Complies 548 6.18 Complies 499 548 9.82 0.54 
BT4 251 249 500 8.1 6.12 0.247 Complies 551 6.21 Complies 500 551 10.20 0.5 
BT5 250 248 498 8.5 6.11 0.289 Complies 552 6.22 Complies 498 552 10.84 0.51 
BT6 248 252 500 8.1 6.12 0.242 Complies 550 6.21 Complies 500 550 10.00 0.53 
BT7 249 251 500 7.9 6.13 0.282 Complies 551 6.2 Complies 500 551 10.20 0.54 
BT8 252 248 500 7.8 6.01 0.212 Complies 551 6.21 Complies 500 551 10.20 0.52 
BT9 251 249 500 7.5 6.12 0.231 Complies 550 6.19 Complies 500 550 10.00 0.53 
BT10 252 250 502 7.8 6.11 0.172 Complies 552 6.18 Complies 502 552 9.96 0.51 
BT11 248 251 499 8.2 6.08 0.156 Complies 551 6.19 Complies 499 551 10.42 0.52 
BT12 249 252 501 8.1 6.09 0.124 Complies 549 6.17 Complies 501 549 9.58 0.55 
BT13 251 249 500 8 6.07 0.138 Complies 549 6.2 Complies 500 549 9.80 0.52 
BT14 251 252 503 7.9 6.09 0.218 Complies 548 6.21 Complies 503 548 8.95 0.51 
BT15 250 252 502 8.1 6.1 0.218 Complies 552 6.23 Complies 502 552 9.96 0.53 
BT16 248 249 497 8.2 6.11 0.211 Complies 551 6.22 Complies 497 551 10.87 0.55 
BT17 249 248 497 7.9 6.12 0.186 Complies 553 6.21 Complies 497 553 11.27 0.52 
BT18 249 251 500 8 6.11 0.154 Complies 552 6.21 Complies 500 552 10.40 0.53 
BT19 249 250 499 8.1 6.09 0.254 Complies 553 6.22 Complies 499 553 10.82 0.51 
BT20 250 251 501 8.1 6.08 0.231 Complies 551 6.21 Complies 501 551 9.98 0.52 
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It is evident from the above table that all the trial formulations comply with the standard 
specification mentioned in the Indian Pharmacopoeia for average weight, weight variation and 
friability.  Also the thickness and hardness parameters of the prepared tablets complied with the 
in house specifications.  The orifice diameter was found to be in the range of 0.5 to 0.55 mm. 
 
9.9.2 In vitro dissolution study for bilayer osmotic drug delivery system: 
The dissolution profile results for the various formulation trials for bilayer osmotic drug 
delivery system are as follows: 
9.9.2.1 Optimization of HPMC K4M for bilayer osmotic drug delivery system: 
Table 51 : % cumulative release data for optimization of HPMC K4M for bilayer osmotic drug 
delivery system 
                                        (Average reported for 3 readings) 
 % cumulative release 
Time 
(hr) 
BT 1 BT 2 BT 3 BT 4 BT5 
0 0 0 0 0 0 
1 8.2 5.1 2.1 0 0 
2 12.3 8.4 6.2 1.3 0 
4 30.4 22.5 18.3 10.4 4.1 
6 61.1 49.4 33.4 22.6 13.2 
8 72.2 62.4 50.2 33.8 22.3 
12 79.3 75.6 66.4 52.4 44.4 
18 85.4 80.5 78.2 65.3 61.3 
24 88.3 84.4 80.3 77.4 75.2 
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Figure 31:  % cumulative release v/s Time (hr) plot for optimization of HPMC K4M for bilayer 
osmotic drug delivery system 
 
Table 52: Statistical parameters for dissolution data of optimization of HPMC K4M for bilayer 
osmotic drug delivery system 
Parameter BT 1 BT 2 BT 3 BT 4 BT5 
f1 (Difference Factor) 68.26 52.86 36.73 17.82 19.72 
f2 (Similarity factor) 28.31 33.68 41.75 50.21 46.20 
Zero order kinetic  
(r
2
 value) 
0.7698 0.8226 0.8963 0.9656 0.979 
 
From the above results of % cumulative release and zero order kinetic (r
2
 value), it was seen that 
batch BT4 and BT5 showed good zero order release kinetics.  But BT4 showed a slightly higher 
% cumulative release than BT5.  Also analyzing the f1 and  f2  values of the formulation BT4, it 
was found to show a similar release profile to the theoretical release target profile. The batch 
BT5 also showed a slightly higher lag release (4 hrs) as compared to BT4.  Hence BT4 was 
further selected for Carbopol 71G optimization. 
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9.9.2.2 Optimization of Carbopol 71G for bilayer osmotic drug delivery system: 
Table 53: % cumulative release data for optimization of Carbopol 71G for bilayer osmotic drug 
delivery system:   
                                        (Average reported for 3 readings) 
 % cumulative release 
Time 
(hr) 
BT 6 BT 4 BT 7 BT 8 BT9 
0 0 0 0 0 0 
1 0 0 0 0 0 
2 1.2 1.4 1.7 2.1 3.1 
4 10.4 10.3 11.2 10.2 13.2 
6 19.2 22.5 21.3 23.3 26.3 
8 28.3 33.4 35.4 38.4 45.2 
12 48.8 52.3 55.2 58.6 62.8 
18 60.6 65.2 70.6 77.5 83.6 
24 69.2 77.4 82.2 88.4 92.2 
 
Figure 32:  % cumulative release v/s Time (hr) plot for optimization of Carbopol 71G for 
bilayer osmotic drug delivery system: 
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Table 54: Statistical parameters for dissolution data of optimization of Carbopol 71G for 
bilayer osmotic drug delivery system: 
Parameter BT 6 BT 4 BT 7 BT 8 BT9 
f1 (Difference Factor) 18.18 17.82 15.98 14.30 24.63 
f2 (Similarity factor) 44.72 50.21 53.65 54.37 47.92 
Zero order kinetic  
(r
2
 value) 
0.9638 0.9656 0.9671 0.9673 0.9573 
 
From the above results of % cumulative release and zero order kinetic (r
2
 value), it was seen that 
batch all the batches showed good zero order release kinetics.  But BT8 and BT9 showed a 
slightly higher % cumulative release nearer to the target profile.  Between BT8 and BT9, batch 
BT8 showed a better zero order release kinetic parameter. Also analyzing f1 and  f2  values of the 
formulation BT8, it was found to show a similar release profile to the theoretical release target 
profile. Hence BT8 was selected for further optimization of osmogen.  
9.9.2.3 Optimization of Osmogen for bilayer osmotic drug delivery system: 
Table 55: % cumulative release data for optimization of osmogen for bilayer osmotic drug delivery system:   
                                                                                                                               (Average reported for 3 readings) 
 
  % cumulative release 
Time 
(hr) BT10 BT8 BT11 BT12 BT13 BT14 BT15 BT16 BT17 BT18 BT19 BT20 
0 0 0 0 0 0 0 0 0 0 0 0 0 
1 0 0 0 0 0 0 0 0 0 0 0 0 
2 0 2.1 6.2 1.2 0 0 7 2.5 0 1.2 3.1 2.3 
4 6.2 10.1 16.3 11.4 9.2 5.1 18.4 12.3 9.1 11.2 12.2 13.6 
6 18.3 23.3 30.4 22.3 21.1 19.4 32.2 25.1 21.3 26.3 24.3 26.3 
8 33.5 38.2 45.3 35.6 36.3 34.1 38.3 38.6 37.5 37.3 38.3 39.3 
12 53.6 58.3 62.8 51.5 60.8 58.3 53.5 62.5 58.8 61.6 64.3 62.2 
18 76.5 77.2 80.3 72.4 82.6 80.4 74.8 85.3 84.3 84.5 85.8 84.4 
24 87.3 88.4 91.3 80.3 98.1 97.2 82.3 100 100.1 99.2 100.1 98.6 
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Figure 33:  % cumulative release v/s Time (hr) plot for optimization of osmogen for bilayer 
osmotic drug delivery system: 
 
Table 56: Statistical parameters for dissolution data of optimization of osmogen for bilayer 
osmotic drug delivery system: 
Parameter BT10 BT8 BT11 BT12 BT13 BT14 BT15 BT16 BT17 BT18 BT19 BT20 
f1  (Difference 
Factor) 
12.02 17.3 27.57 14.88 13.71 12.61 24.63 19.13 13.34 17.67 19.5 20.23 
f2  (Similarity 
factor) 
58.11 54.37 46.69 53.31 54.67 58.01 48.25 51.59 52.67 52.91 48.88 51.18 
Zero order kinetic     
(r2 value) 
0.973 0.967 0.959 0.969 0.979 0.977 0.962 0.98 0.982 0.977 0.977 0.977 
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From the above results of % cumulative release and zero order kinetic (r
2
 value), it was seen that 
all the batches showed good zero order release kinetics.  But BT16, BT17 and BT19 showed a 
slightly higher % cumulative release nearer to the target profile.  Between BT16, BT17 and 
BT19, batch BT17 showed a slightly better zero order release kinetic parameter.  Also analyzing 
f1 and  f2  values of the formulation BT17, it was found to show a similar release profile to the 
theoretical release target profile. Hence BT17 was selected as the final optimized batch for 
bilayer osmotic drug delivery system and was further forwarded for stability study analysis.     
 
9.9.3 Effect of variables on the optimized formulation:  
The optimized formulation (BT 17) was then subjected to various comparative tests under 
different conditions to study the following effects of variables:  
a. Effect of Osmotically active Dissolution Medium on drug release 
b. Effect of Agitation rate on drug release 
c. Effect of orifice size on the drug release from optimized formulations.   
The results of the study are as follows:  
 
9.9.3.1 Effect of Osmotically active Dissolution Medium on drug release: 
The effect of osmotically active dissolution medium on drug release from bilayer osmotic 
tablets was carried out in a procedure similar to that in the case of monolayer osmotic drug 
delivery system.  In order to investigate the actual mechanism of the drug released from the 
tablet, dissolution study was conducted in water (0-8 h), 2.4 % w/w magnesium sulphate solution 
in water (8-16 hr) and in water (17-24 hr) alternatively. Table shows dissolution profile for the 
optimized formulation (BT17)  in water (upto 8th hour), then magnesium sulphate (upto 16th 
hour) and lastly followed by water (upto 24th hour). 
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Table 57: cumulative % drug release of the selected optimized formulations (BT17) in 
different medium 
Time  
(hr) 
Dissolution 
media 
cumulative % drug 
release for optimized 
batch (BT17) 
0 
water 
0 
1 0 
2 0 
4 9.1 
6 21.3 
8 37.5 
8 
2.4% magnesium 
sulphate solution 
37.5 
12 41.5 
16 48.6 
16 
water 
48.6 
20 61.4 
24 73.4 
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Figure  34 :  % cumulative release v/s Time (hr) plot for optimized formulation (BT17) to study the 
effect of Osmotically active Dissolution Medium on drug release: 
 
The drug release rate (mg/hr) for the selected optimized formulation (BT17) after duration of 8 
hrs in alternative media is as shown in the table below:  
Table 58 : Drug release rate for selected optimized formulation (BT17)  after duration of 8 hrs 
in alternative media: 
 
Sr 
no. 
Time 
duration 
Dissolution 
medium 
 Drug release 
rate for BT17 
1 0-8 hrs water 
2.81 + 0.06   
mg/hr 
2 9-16 hrs 
2.4% 
magnesium 
sulphate 
solution 
0.8325 + 0.01  
 mg/hr 
3 17-24 hrs water 
1.186 + 0.04   
mg/hr 
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Drug release rate of 2.81 + 0.06 mg/hr was observed with water for first 8 hr for the 
optimized formulation BT17 while in the next 8 hours i.e upto 16
th
 hour, in 2.4 % magnesium 
sulphate solution it was found to be 0.8325 + 0.01  mg/hr.  Again in water for next 8 hrs i.e upto 
24
th
 hour it was found to increase upto 1.186 + 0.04 mg/hr. The results revealed that in water, 
effective osmotic pressure across the membrane was obtained which led to high drug release 
rate.  Pressure drop across the membrane was very less in case of magnesium sulphate solution, 
which shows slow drug release rate.  
From above results it can be concluded that as in the case of monolayer osmotic tablets, 
for bilayer osmotic tablets also, the drug release rate is mainly contributed by osmotic pressure 
only.  
 
9.9.3.2 Effect of Agitation rate on drug release 
The optimized formulation BT17 was subjected to dissolution study at different agitation 
rates. In the present investigation dissolution study was performed at three different agitation 
rates.  Agitation rates of 50, 100 and 150 rpm were selected for the study. 
 
The following table shows percent drug release from the optimized formulation BT17 at 
three different agitation rates with time. 
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Table 59  : Effect of agitation rate on in-vitro drug release of the optimized formulation BT17 osmotic 
tablet: 
 
Time 
(hr) 
 cumulative % drug released 
of BT17 
50 rpm 100 rpm 150 rpm 
0 
0 0 0.2 
1 
0.1 0.3 0.8 
2 
0.6 0.4 1.2 
4 
7.9 8.2 9.1 
6 
22.1 22.8 23.4 
8 
38.5 39.8 40.1 
12 
57.9 59.6 61.5 
18 
83.1 82.9 86.4 
24 
99.8 99.6 99.8 
 
Figure 35:  % cumulative release v/s Time (hr) plot for formulation BT17 to study the effect of 
agitation rate on drug release 
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As can be seen with above data, no significant changes were observed during drug release study 
with agitation rate, which strongly indicates that release of the drug from the system takes place 
mainly through osmotic pressure generated within the system. Therefore, it might be predicted 
that the mobility of the gastrointestinal tract hardly affected the drug release of the prepared 
osmotic tablet. Since drug release was independent of agitation rate, the prepared osmotic tablets 
might exhibit a comparable in vitro/in vivo release profile. 
 
 
9.9.3.3 Effect of orifice size on the drug release from optimized formulations: 
 
To study the effect of orifice size on the drug release from the optimized formulations, 
the in vitro analysis of the selected tablets formulations was carried out.  Coated tablets were 
selected from the optimized batch BT17 and orifices with varying sizes (0.5 mm, 1.0 mm, 
1.5mm and 2.0mm) were drilled using a mechanical micro drill. The shape and diameter of the 
created orifice was visually inspected and measured using a 50 X microscope.  The data for the 
cumulative % drug release with varying orifice size for the selected formulation BT17 is as 
shown in the table below: 
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Table 60: Cumulative % drug release from optimized formulation BT17 with various orifice sizes 
Time 
(hr) 
 cumulative % drug released 
Orifice size (BT17) 
0.2 
mm 
0.5 
mm 
1.0 
mm 
1.5 
mm 
2.0 
mm 
0 0.1 0 0.2 0 0.8 
1 0.2 0.1 0.8 0.3 2.4 
2 0.2 0.6 1.2 0.4 4.2 
4 2.3 7.9 9.1 8.2 13.4 
6 7.4 22.1 23.4 22.8 29.8 
8 14.8 38.5 40.1 39.8 48.4 
12 23.4 57.9 61.5 59.6 73.4 
18 39.4 83.1 86.4 82.9 96.2 
24 61.5 99.8 99.8 99.6 99.8 
 
Figure 36:  % cumulative release v/s Time (hr) plot for formulation BT17 to study the 
effect of orifice size on drug release  
 
Chapter 9                                                                                                        Bilayer osmotic drug delivery system 
Osmotic Drug Delivery System                                                                                                                      Page 163 
 
 
As can be seen from the results of the above study of varying orifice sizes, it was 
observed that there was no significant change in the drug release pattern with orifice size in the 
range of 0.5 mm to 1.5mm.  However, as can be seen from the above observations, it was found 
that a comparative higher release pattern and rapid release of drug was seen in tablets drilled 
with an orifice of 2.0 mm.  It was found that almost 100% drug was released around the 18
th
 hour 
and hence a sustained release comparable to the theoretical target release profile was not 
achieved.  This may be due to the result of higher diffusion of fluids from the bigger orifice.  On 
the other hand, a low release rate and anomalous release were exhibited at an orifice diameter of 
0.2 mm. The drug or excipients granules in insoluble form may occlude such a small orifice, 
therefore, leading to a low drug release rate. 
Hence it was concluded that the release rates were independent of the orifice size in the 
range of 0.5mm to 1.5mm.  However, a higher orifice size (2.0mm) or a lower orifice size 
(0.2mm) had a significant influence on the release rate of drug from the osmotic drug delivery 
system. 
 
9.9.4 Accelerated Stability studies of the optimized formulation for osmotic bilayer drug 
delivery system: 
The accelerated stability testing was performed on the selected formulation (BT17) which gave 
the most optimum results amongst all the previous trial batch formulation. The test was carried 
out by placing the tablets of each selected formula in closed glass container in an ALU ALU 
Blister pack and stored in thermostatically controlled ovens adjusted at different temperatures 
and humidity percentage, namely, 40⁰C/75%, 30⁰C/65% and 25⁰C/60% (maintained using a 
saturated solution of NaCl) for a period of 3 months. The stored tablets were examined visually 
for any changes in color and/or appearance every month. Also the average weight, hardness and 
loss on drying of the selected batch formulations were determined at a period of 1 month for total 
3 months.  Three tablets were taken from the ovens after a period of 1 month for 3 months and 
analyzed for the determination of cumulative % drug release.  Limits were set for each of the 
above parameter (i.e. average weight, hardness, loss on drying and cumulative % drug release) 
using the ICH guidelines for accelerated stability studies.   
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The results of the optimized formulations BT17 after conducting accelerated stability studies for 
3 months are as follows: 
 
Table 61: Stability study data for the optimized bilayer osmotic tablet batch (BT17): 
 
 
Bilayer osmotic Tablets (Alu-Alu Blister Pack) Batch BT17 
Sr. 
No 
Test Limit Initial 
Storage condition 
40⁰C/75% 30⁰C/65% 25⁰C/60% 
1 
Month 
2  
Month 
3  
Month 
1 
Month 
2  
Month 
3  
Month 
3  
Month 
1 Description * * * * * * * * * 
2 Avg. Wt 500mg ± 3% 500.4 500.4 500.3 500.9 500 501 501.2 500.9 
3 Hardness NLT 5.0 kg/cm2 7.6 7.4 7.4 7.6 7.5 7.7 7.5 7.9 
4 Loss on Drying NMT 5% 2.30% 2.38% 2.75% 2.80% 2.26% 2.50% 2.45% 2.50% 
5 Dissolution                   
  Time (hr) % Drug Dissolved (as an average of 3 readings) 
  2 NMT 5% 0.0 0.4 0.2 0.1 0.3 0.1 0.1 0.0 
  6 10-30% 21.3 21.7 22.1 21.8 21.5 21.3 21.4 22.1 
  8 20-40% 37.5 35.2 35.4 36.4 36.2 36.4 36.8 36.4 
  12 45-65 % 58.8 57.4 57.4 57.3 58.1 58.2 58.6 58.5 
  18 65 -85% 84.3 84.2 84.3 84.3 84.1 84.1 84.3 83.9 
  24 NLT 85 % 100.1 99.2 99.4 99.6 100.0 99.3 100.0 99.1 
6 
f1   (Difference 
Factor) 
<15 
  
1.8 1.7 1.2 0.9 0.9 0.4 1.2 
7 f2  (Similarity 
factor) 
>50 
  
90.5 90.0 93.7 96.4 96.0 98.9 94.8 
 
* bicoloured (white and red) , round, biconvex film coated tablets  
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It can be seen from the above table, that there was no significant variation in the physical 
appearance, average weight, hardness and loss of drying after placing the tablets at various 
temperature and humidity conditions for a period of 3 months.   
Also the cumulative % drug release data showed that the optimized formulation (BT17) 
released a drug amount, within the limits laid down as per the ICH guidelines for stability 
studies.  A very low f1 value and a value of f2 higher than 50 in each of the above formulation 
batches at various time intervals, suggested that the release profile remained similar to the initial 
release profile even after subjecting the tablets to the above temperature and humidity parameters 
for a period of 3 months.  Hence it was concluded that the optimized formulation batches did not 
show any significant change in their release profiles after 3 months duration under the above 
temperature and humidity conditions.   
              Thus the optimized formulations could be considered stable for a period of 2 years.   
 
 
  
 
 
CHAPTER 10 
TRILAYER OSMOTIC 
DRUG DELIVERY SYSTEM 
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10.0 Experimental trials for Trilayer Osmotic Tablet of Trimetazidine Dihydrochloride 
10.1 Optimization of HPMC K4M: 
Batch size: 200 tablets Table 62:  Trial formulations for Optimization Of HPMC K4M for trilayer osmotic tablets 
Sr.No 
Batch no. TT1 TT2 TT3 TT4 TT5 TT6 TT7 
Ingredients 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
 
Drug layer I 
              
1 Trimetazidine 30 6000 30 6000 30 6000 30 6000 30 6000 30 6000 30 6000 
2 HPMC K4M 30 6000 40 8000 50 10000 60 12000 70 14000 80 16000 90 18000 
3 Lactose Mono 105 21000 95 19000 85 17000 75 15000 65 13000 55 11000 45 9000 
4 NaCl 20 4000 20 4000 20 4000 20 4000 20 4000 20 4000 20 4000 
6 Povidone K30 10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 
7 IPA (90%) qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 
8 Mg Stearate 2 400 2 400 2 400 2 400 2 400 2 400 2 400 
9 Talc 1 200 1 200 1 200 1 200 1 200 1 200 1 200 
 
Wt. 200 40000 200 40000 200 40000 200 40000 200 40000 200 40000 200 40000 
 
Push Layer 
              
10 Carbopol 71 G 80 16000 80 16000 80 16000 80 16000 80 16000 80 16000 80 16000 
11 Lactose DCl 21 87 17400 87 17400 87 17400 87 17400 87 17400 87 17400 87 17400 
12 Povidone K30 10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 
13 NaCl 20 4000 20 4000 20 4000 20 4000 20 4000 20 4000 20 4000 
14 Mg Stearate 2 400 2 400 2 400 2 400 2 400 2 400 2 400 
15 Talc 1 200 1 200 1 200 1 200 1 200 1 200 1 200 
 
Wt 200 40000 200 40000 200 40000 200 40000 200 40000 200 40000 200 40000 
 
Drug layer II 
              
17 Trimetazidine 30 6000 30 6000 30 6000 30 6000 30 6000 30 6000 30 6000 
18 HPMC K4M 30 6000 40 8000 50 10000 60 12000 70 14000 80 16000 80 16000 
19 Lactose Mono 105 21000 95 19000 85 17000 75 15000 65 13000 55 11000 55 11000 
20 NaCl 20 4000 20 4000 20 4000 20 4000 20 4000 20 4000 20 4000 
22 Povidone K30 10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 
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23 IPA (90%) Qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 
24 Mg Stearate 2 400 2 400 2 400 2 400 2 400 2 400 2 400 
25 Talc 1 200 1 200 1 200 1 200 1 200 1 200 1 200 
 
Wt. 200 40000 200 40000 200 40000 200 40000 200 40000 200 40000 200 40000 
 
Total weight 600 120000 600 120000 600 120000 600 120000 600 120000 600 120000 600 120000 
 
Coating 
              
 
% wt. Gain 
10% 
 
10% 
 
10% 
 
10% 
 
10% 
 
10% 
 
10% 
 
27 
Celulose Acetate 
(75%) 
45 9000 45 9000 45 9000 45 9000 45 9000 45 9000 45 9000 
28 
Dibutylcebacate 
(25%) 
15 3000 15 3000 15 3000 15 3000 15 3000 15 3000 15 3000 
29 Ethanol (50%) QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 
30 Acetone (50%) QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 
 
Coated tab wt. 660 132000 660 132000 660 132000 660 132000 660 132000 660 132000 660 132000 
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Procedure: 
For formulating the trilayer osmotic tablet, a push layer was sandwitched between two drug 
layers.  The composition of each drug layer was identical.   
Formulation of drug layer I and drug layer II 
a. Dry mixing: 
TMZ, HPMC K4M, Lactose mono,  and NaCl were dry mixed in the proportion required 
as per the above table in a polybag manually. The increase in the quantity of HPMC K4M 
in each batch was compensated with a corresponding decrease in the quantity of Lactose 
mono.  
b. Binder solution preparation: 
Povidone K30 was dissolved in IPA with stirring.  
c. Granulation: 
Dry mix blend was granulated with prepared binder solution: 
Wet mass was dried at 50 C in oven to get LOD below 2%w/w using Halogen moisture 
detector at 105 C temperature.   
d. Sizing: 
Dried granules were passed through 20# sieve. 
e. Lubrication: 
The above blends were individually mixed with talc for 5 min at 24 rpm in an octagonal 
blender.  This blend was then lubricated with Mg stearate for 5 min at 24 rpm in an 
octagonal blender. 
The prepared drug layer blend was weighed and divided in two equal parts to compose 
the two drug layers.   
 
Formulation of Push layer:  
 
f. Mixing: 
Carbopol 71G, sodium chloride, Lactose DCL, Povidone K 30 and talc were mixed for 
20 minutes at 24 rpm in an octagonal blender.  
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g. Lubrication: 
The above granules were lubricated with 60# passed Magnesium stearate for 5 minutes at 
24 rpm in an octagonal blender. 
 
h. Compression: 
The trilayer tablet was compressed manually using the above prepared blends using a 
rotary compression machine.   
Initially the granule blends of drug layer I (weighing 200mg) was filled in the die punch 
cavity. Then the granule blend of the push layer was (weighing 200mg) filled on top of it.  
Finally the blend of drug layer II (weighing 200 mg) was filled in the die cavity.   
The filled lubricated granules were compressed manually one at a time using 9.0 mm, 
round, standard concave punches, plain on both the sides in rotary compression machine. 
 
i. Preparation of coating solution: 
Coating solution was prepared by dissolving Cellulose acetate and dibutyl cebecate 
(75:25) in a mixture of ethanol and acetone (50:50) with constant stirring. 
 
j. Coating process: 
Core tablets were coated with prepared coating solution using conventional coating pan 
machine.  The coating parameters were as follows: 
Inlet air temperature : 45 C 
Bed temperature  : 38 C 
Pan rpm   : 6 to 8 rpm 
Atomization Air pressure : 2.0 psi 
The average weight of tablet was checked periodically to achieve 10% weight gain of 
core tablet. 
The coated tablets were dried at 50 C for 30 min in conventional coating pan at 1-2 rpm. 
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k. Drilling of orifice: 
One orifice with a diameter of 0.5 mm was drilled on the coloured side of coated tablet 
using a microdrill. 
l. In vitro dissolution study: 
The prepared tablets were then subjected to in vitro analysis to select the best formulation 
for the optimization of Carbopol 71 G 
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10.2 Optimization of Carbopol 71G: 
Table 63:  Trial formulations for Optimization Of Carbopol 71G for trilayer osmotic tablets 
Batch size: 200 tablets: 
Sr.No 
Batch no.  TT8 TT9 TT10 TT5 TT11 TT12 TT13 
Ingredients 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
Qty 
mg/Tab 
Qty    
mg/200 
tab 
  Drug layer I                             
1 Trimetazidine 30 6000 30 6000 30 6000 30 6000 30 6000 30 6000 30 6000 
2 HPMC K4M 70 14000 70 14000 70 14000 70 14000 70 14000 70 14000 70 14000 
3 Lactose Mono 65 13000 65 13000 65 13000 65 13000 65 13000 65 13000 65 13000 
4 NaCl 20 4000 20 4000 20 4000 20 4000 20 4000 20 4000 20 4000 
6 Povidone K30 10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 
7 IPA (90%) qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 
8 Mg Stearate 2 400 2 400 2 400 2 400 2 400 2 400 2 400 
9 Talc 1 200 1 200 1 200 1 200 1 200 1 200 1 200 
  Wt. 200 40000 200 40000 200 40000 200 40000 200 40000 200 40000 200 40000 
  Push Layer                             
10 Carbopol 71 G 50 10000 60 12000 70 14000 80 16000 90 18000 100 20000 110 22000 
11 Lactose DCl 21 117 23400 107 21400 97 19400 87 17400 77 15400 67 13400 57 11400 
12 Povidone K30 10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 
13 NaCl 20 4000 20 4000 20 4000 20 4000 20 4000 20 4000 20 4000 
14 Mg Stearate 2 400 2 400 2 400 2 400 2 400 2 400 2 400 
15 Talc 1 200 1 200 1 200 1 200 1 200 1 200 1 200 
   Wt 200 40000 200 40000 200 40000 200 40000 200 40000 200 40000 200 40000 
  Drug layer II                             
17 Trimetazidine 30 6000 30 6000 30 6000 30 6000 30 6000 30 6000 30 6000 
18 HPMC K4M 70 14000 70 14000 70 14000 70 14000 70 14000 70 14000 70 14000 
19 Lactose Mono 65 13000 65 13000 65 13000 65 13000 65 13000 65 13000 65 13000 
20 NaCl 20 4000 20 4000 20 4000 20 4000 20 4000 20 4000 20 4000 
22 Povidone K30 10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 10 2000 
23 IPA (90%) qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 
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24 Mg Stearate 2 400 2 400 2 400 2 400 2 400 2 400 2 400 
25 Talc 1 200 1 200 1 200 1 200 1 200 1 200 1 200 
  Wt. 200 40000 200 40000 200 40000 200 40000 200 40000 200 40000 200 40000 
  Total weight 600 120000 600 120000 600 120000 600 120000 600 120000 600 120000 600 120000 
  Coating                             
  % wt. Gain 10% 10% 10% 10% 10% 10% 10% 
27 
Celulose Acetate 
(75%) 45 9000 45 9000 45 9000 45 9000 45 9000 45 9000 45 9000 
28 
Dibutylcebacate 
(25%) 15 3000 15 3000 15 3000 15 3000 15 3000 15 3000 15 3000 
29 Ethanol (50%) QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 
30 Acetone (50%) QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 
  Coated tab wt. 660 132000 660 132000 660 132000 660 132000 660 132000 660 132000 660 132000 
 
Method: 
The trilayer tablets for optimization of Carbopol 71 G were prepared using the same method as mentioned above; the increase in the 
weight of Carbopol in the push layer was compensated with the corresponding decrease in the weight of Lactose DCI.  The prepared 
tablets were subjected to in vitro evaluation to select the best formulation for optimization of osmogen 
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10.3 Optimization of Osmogen  ( in drug layer): 
Table 64:  Trial formulations for Optimization Of osmogen (in drug layer) for trilayer osmotic 
tablets 
Batch size: 200 tablets 
Sr.N
o 
Batch no.  TT14 TT15 TT12 TT16 TT17 
Ingredients 
Qty 
mg/Ta
b 
Qty    
mg/20
0 tab 
Qty 
mg/Ta
b 
Qty    
mg/20
0 tab 
Qty 
mg/Ta
b 
Qty    
mg/20
0 tab 
Qty 
mg/Ta
b 
Qty    
mg/20
0 tab 
Qty 
mg/Ta
b 
Qty    
mg/20
0 tab 
  Drug layer I                     
1 Trimetazidine 30 6000 30 6000 30 6000 30 6000 30 6000 
2 HPMC K4M 70 14000 70 14000 70 14000 70 14000 70 14000 
3 Lactose Mono 75 15000 70 14000 65 13000 60 12000 55 11000 
4 NaCl 10 2000 15 3000 20 4000 25 5000 30 6000 
6 Povidone K30 10 2000 10 2000 10 2000 10 2000 10 2000 
7 IPA (90%) qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 
8 Mg Stearate 2 400 2 400 2 400 2 400 2 400 
9 Talc 1 200 1 200 1 200 1 200 1 200 
  Wt. 200 40000 200 40000 200 40000 200 40000 200 40000 
  Push Layer                     
10 Carbopol 71 G 100 20000 100 20000 100 20000 100 20000 100 20000 
11 Lactose DCl 21 67 13400 67 13400 67 13400 67 13400 67 13400 
12 Povidone K30 10 2000 10 2000 10 2000 10 2000 10 2000 
13 NaCl 20 4000 20 4000 20 4000 20 4000 20 4000 
14 Mg Stearate 2 400 2 400 2 400 2 400 2 400 
15 Talc 1 200 1 200 1 200 1 200 1 200 
   Wt 200 40000 200 40000 200 40000 200 40000 200 40000 
  Drug layer II                     
17 Trimetazidine 30 6000 30 6000 30 6000 30 6000 30 6000 
18 HPMC K4M 70 14000 70 14000 70 14000 70 14000 70 14000 
19 Lactose Mono 75 15000 70 14000 65 13000 60 12000 55 11000 
20 NaCl 10 2000 15 3000 20 4000 25 5000 30 6000 
22 Povidone K30 10 2000 10 2000 10 2000 10 2000 10 2000 
23 IPA (90%) qs 11200 qs 11200 qs 11200 qs 11200 qs 11200 
24 Mg Stearate 2 400 2 400 2 400 2 400 2 400 
25 Talc 1 200 1 200 1 200 1 200 1 200 
  Wt. 200 40000 200 40000 200 40000 200 40000 200 40000 
  Total weight 600 
12000
0 
600 
12000
0 
600 
12000
0 
600 
12000
0 
600 
12000
0 
  Coating                     
  % wt. Gain 10% 10% 10% 10% 10% 
27 
Celulose Acetate 
(75%) 
45 9000 45 9000 45 9000 45 9000 45 9000 
28 
Dibutylcebacate 
(25%) 
15 3000 15 3000 15 3000 15 3000 15 3000 
29 Ethanol (50%) QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 
30 Acetone (50%) QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 
  Coated tab wt. 660 
13200
0 
660 
13200
0 
660 
13200
0 
660 
13200
0 
660 
13200
0 
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Method: 
The trilayer tablets for optimization of osmogen in the drug layer were prepared using the same 
method as mentioned above; the increase in the weight of NaCl (osmogen) in each drug layer 
layer was compensated with the corresponding decrease in the weight of Lactose mono. The 
prepared tablets were subjected to in vitro evaluation to select the best formulation for 
optimization of osmogen (in push layer) 
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10.4 Optimization of osmogen (in Push layer):  
Table 65:  Trial formulations for Optimization Of osmogen (in push layer) for trilayer osmotic 
tablets 
Batch size: 200 tablets: 
Sr.N
o 
Batch no.  TT18 TT19 TT16 TT20 TT21 
Ingredients 
Qty 
mg/Ta
b 
Qty    
mg/20
0 tab 
Qty 
mg/Ta
b 
Qty    
mg/20
0 tab 
Qty 
mg/Ta
b 
Qty    
mg/20
0 tab 
Qty 
mg/Ta
b 
Qty    
mg/20
0 tab 
Qty 
mg/Ta
b 
Qty    
mg/20
0 tab 
  Drug layer I                     
1 Trimetazidine 30 6000 30 6000 30 6000 30 6000 30 6000 
2 HPMC K4M 70 14000 70 14000 70 14000 70 14000 70 14000 
3 Lactose Mono 60 12000 60 12000 60 12000 60 12000 60 12000 
4 NaCl 25 5000 25 5000 25 5000 25 5000 25 5000 
6 Povidone K30 10 2000 10 2000 10 2000 10 2000 10 2000 
7 IPA (90%) qs 11200 qs 11200 qs 11200 qs 11200 Qs 11200 
8 Mg Stearate 2 400 2 400 2 400 2 400 2 400 
9 Talc 1 200 1 200 1 200 1 200 1 200 
  Wt. 200 40000 200 40000 200 40000 200 40000 200 40000 
  Push Layer                     
10 Carbopol 71 G 100 20000 100 20000 100 20000 100 20000 100 20000 
11 Lactose DCl 21 77 15400 72 14400 67 13400 62 12400 57 11400 
12 Povidone K30 10 2000 10 2000 10 2000 10 2000 10 2000 
13 NaCl 10 2000 15 3000 20 4000 25 5000 30 6000 
14 Mg Stearate 2 400 2 400 2 400 2 400 2 400 
15 Talc 1 200 1 200 1 200 1 200 1 200 
  Core tab Wt 200 40000 200 40000 200 40000 200 40000 200 40000 
  Drug layer II                     
17 Trimetazidine 30 6000 30 6000 30 6000 30 6000 30 6000 
18 HPMC K4M 70 14000 70 14000 70 14000 70 14000 70 14000 
19 Lactose Mono 60 12000 60 12000 60 12000 60 12000 60 12000 
20 NaCl 25 5000 25 5000 25 5000 25 5000 25 5000 
22 Povidone K30 10 2000 10 2000 10 2000 10 2000 10 2000 
23 IPA (90%) qs 11200 qs 11200 qs 11200 qs 11200 Qs 11200 
24 Mg Stearate 2 400 2 400 2 400 2 400 2 400 
25 Talc 1 200 1 200 1 200 1 200 1 200 
  Wt. 200 40000 200 40000 200 40000 200 40000 200 40000 
  Total weight 600 120000 600 120000 600 120000 600 120000 600 120000 
  Coating                     
  % wt. Gain 10%   10%   10%   10%   10%   
27 
Celulose Acetate 
(75%) 
45 9000 45 9000 45 9000 45 9000 45 9000 
28 
Dibutylcebacate 
(25%) 
15 3000 15 3000 15 3000 15 3000 15 3000 
29 Ethanol (50%) QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 
30 Acetone (50%) QS 44000 QS 44000 QS 44000 QS 44000 QS 44000 
  Coated tab wt. 660 132000 660 132000 660 132000 660 132000 660 132000 
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Method: 
The trilayer tablets for optimization of osmogen in the push layer were prepared using the same 
method as mentioned above for optimization of HPMC K4M; the increase in the weight of NaCl 
(osmogen) in push layer was compensated with the corresponding decrease in the weight of 
Lactose mono in the push layer.   
The optimized formulation was then subjected to stability study as per ICH guidelines for 
stability study. 
 
10.5 Compression and coating parameters: 
The above prepared tablets were analysed for the various compression and coating parameters as 
discussed for monolayer osmotic tablets viz. Weight variation, hardness, friability, % weight 
gain for coated tablets and orifice diameter. The results of the study are mentioned in table 66  
 
10.6 In vitro dissolution study 
All the feasibility trial batches were subjected to In vitro dissolution study for drug release and to 
study the effect of variables. The operating conditions for drug release were adjusted as follows.  
Dissolution test apparatus  : USP type II (paddle) 
Speed     : 50 RPM 
Temperature    : 37° C ±  0.5  
Dissolution medium  : 900 ml distilled water 
Sampling time   : every 1 hr  
Sample withdrawn   : 10 ml 
Method of analysis   : UV spectrophotometer 
UV maxima    : 270 nm 
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Samples were suitably diluted and absorbance was measured. Cumulative percentage drug 
released was calculated for each batch. The study was performed in triplicate and the average 
was reported. 
10.7 Statistical treatment: 
The data of % cumulative release from each trial batch were subjected to kinetic release studies 
to assess the fit into the zero-order release kinetics. The r
2
 value was found out to determine the 
best fit zero order release kinetics.  The trial batch having the nearest value to 1 was selected as 
the best trial formulation.  Also the difference factor (f1) and similarity factor (F2) for each batch 
was found out by comparing it with the theoretical target release profile 
10.8 Effect of variables on release profiles of optimized formulations for trilayer osmotic      
        tablets:  
The optimized formulation was then subjected to various comparative tests under different 
conditions to study the following effects of variables:  
a. Effect of Osmotically active Dissolution Medium on drug release 
b. Effect of Agitation rate on drug release 
c. Effect of orifice size on the drug release from optimized formulations 
 
10.9 Stability study: 
The optimized formulation was subject to accelerated stability study at various 
temperature and humidity conditions as per the criterion mentioned in the ICH guidelines for 
stability study, to see whether the final product is sufficiently rugged for marketing worldwide 
under various climate conditions including tropical, subtropical and temperate.   
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10.10 Result and Discussion: Trial layer osmotic drug delivery system 
10.10.1 Compression and coating parameters (for core and coated tablets) of trilayer osmotic drug delivery system: 
Table 66: Compression and coating parameters (for core and coated tablets) for trilayer osmotic tablets: 
Batch 
No 
Core Tablets Parameter Coated Tablets Parameter 
Avg wt 
 (Trilayer 
Tablet) 
 (mg) 
Hardness 
(kg/cm
2
) 
Thickness  
(mm) 
Friability 
 (%) 
Weight  
Variation 
Avg 
wt  
(mg) 
Thickness 
(mm) 
Weight  
Variation 
Initial 
Wt. 
(mg) 
Final 
wt. 
(mg) 
% 
wt.gain 
Orifice 
Diameter 
(mm) 
TT1 603 7.2 7.01 0.218 Complies 665.1 7.21 Complies 603 665.1 10.30 0.52 
TT2 605 7.9 7.1 0.258 Complies 665.4 7.14 Complies 605 665.4 9.98 0.55 
TT3 601 7.2 7.11 0.256 Complies 662.5 7.16 Complies 601 662.5 10.23 0.52 
TT4 611 8.1 7.12 0.247 Complies 673.1 7.21 Complies 611 673.1 10.16 0.51 
TT5 605 8.5 7.11 0.289 Complies 666.5 7.17 Complies 605 666.5 10.17 0.53 
TT6 599 8.1 7.12 0.242 Complies 659.1 7.19 Complies 599 659.1 10.03 0.55 
TT7 602 7.9 7.12 0.282 Complies 664.5 7.2 Complies 602 664.5 10.38 0.52 
TT8 603 7.8 7.05 0.212 Complies 667.5 7.21 Complies 603 667.5 10.70 0.53 
TT9 605 7.5 7.11 0.231 Complies 668.5 7.19 Complies 605 668.5 10.50 0.51 
TT10 604 7.8 7.1 0.172 Complies 665.4 7.21 Complies 604 665.4 10.17 0.52 
TT11 607 8.2 7.2 0.156 Complies 669.2 7.25 Complies 607 669.2 10.25 0.51 
TT12 601 8.1 6.9 0.124 Complies 661.2 7.14 Complies 601 661.2 10.02 0.52 
TT13 605 8 7.2 0.138 Complies 665.5 7.21 Complies 605 665.5 10.00 0.54 
TT14 602 7.9 7.1 0.218 Complies 664.1 7.21 Complies 602 664.1 10.32 0.5 
TT15 600 8.1 7.1 0.218 Complies 665.2 7.23 Complies 600 665.2 10.87 0.51 
TT16 604 8.2 7.1 0.211 Complies 665.2 7.25 Complies 604 665.2 10.13 0.53 
TT17 605 7.9 7.21 0.186 Complies 666.4 7.31 Complies 605 666.4 10.15 0.54 
TT18 606 8 7.15 0.154 Complies 667.4 7.25 Complies 606 667.4 10.13 0.52 
TT19 605 8.1 7.2 0.254 Complies 666.4 7.29 Complies 605 666.4 10.15 0.53 
TT20 603 8.1 7.1 0.231 Complies 664.2 7.21 Complies 603 664.2 10.15 0.51 
TT21 603 8.1 7.1 0.231 Complies 664.2 7.21 Complies 603 664.2 10.15 0.51 
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It is evident from the above table that all the trial formulations comply with the standard 
specification mentioned in the Indian Pharmacopoeia for average weight, weight variation and 
friability.  Also the thickness and hardness parameters of the prepared tablets complied with the 
in house specifications.  The orifice diameter was found to be in the range of 0.5 to 0.55 mm. 
 
10.10.2 In vitro dissolution study for trilayer osmotic drug delivery system: 
The dissolution profile results for the various formulation trials are as follows: 
10.10.2.1 Optimization of HPMC K4M for trilayer osmotic tablets: 
Table 67: % cumulative release data for optimization of HPMC K4M for trilayer osmotic 
tablets 
                                                                         (Average reported for 3 readings) 
 % cumulative release 
Time 
(hr) 
TT 1 TT 2 TT 3 TT 4 TT5 TT6 TT7 
0 0 0 0 0 0 0 0 
1 11.2 6.1 1.1 0 0 0 0 
2 23.3 13.6 4.2 1.3 0 0 0 
4 42.4 25.3 12.3 8.3 3.1 1.2 0 
6 55.1 39.4 24.4 18.2 12.5 10.1 8.2 
8 71.2 55.5 35.2 28.4 22.3 18.4 12.3 
12 92.8 75.6 55.3 49.6 40.4 38.5 30.9 
18 99.3 92. 82.8 72.5 60.5 55.6 50.3 
24 100 100 92.6 85.1 80.2 78.2 70.2 
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Figure 37:  % cumulative release v/s Time (hr) plot for optimization of HPMC K4M for trilayer 
osmotic tablets 
 
Table 68: Statistical parameters for dissolution data of optimization of HPMC K4M for trilayer 
osmotic tablets 
Parameter TT 1 TT 2 TT 3 TT 4 TT5 TT6 TT7 
f1 (Difference Factor) 80.72 48.46 17.67 8.14 20.45 26.69 37.68 
f2 (Similarity factor) 23.75 34.54 58.46 61.29 48.31 43.63 36.49 
Zero order kinetic  
(r
2
 value) 
0.835 0.938 0.981 0.984 0.986 0.979 0.971 
 
From the above results of % cumulative release and zero order kinetic (r
2
 value), it was seen that 
batch TT4 and TT5 showed good zero order release kinetics.  Batch TT4 showed a slightly better 
% cumulative release after 24 hours (85.1%) as compared to batch TT5 (80.2%).  Also analyzing 
the f1 and  f2  values of the formulation TT4, it was found to show a similar release profile to the 
theoretical release target profile hence was selected for further optimization of Carbopol 71G. 
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10.10.2.2 Optimization of Carbopol 71G for trilayer osmotic drug delivery system: 
Table 69: % cumulative release data for optimization of Carbopol 71G for trilayer osmotic 
tablets 
 
                                                                         (Average reported for 3 readings) 
 % cumulative release 
Time 
(hr) 
TT8 TT9 TT10 TT4 TT11 TT12 TT13 
0 0 0 0 0 0 0 0 
1 
0 0 0 0 0 0 0 
2 0 0 0 1.3 0 1.2 2.3 
4 2.1 2.1 3.1 8.3 4.4 6.6 9.3 
6 
8.3 10.3 12.2 18.2 14.3 17.1 21.3 
8 14.5 19.4 20.6 28.4 25.1 29.2 35.4 
12 
35.4 37.3 39.8 49.6 45.5 49.6 57.3 
18 53.3 56.2 59.1 72.5 64.3 70.1 74.2 
24 75.6 79.4 80.3 85.1 84.4 89.3 90.4 
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Figure 38:  % cumulative release v/s Time (hr) plot for optimization of Carbopol 71G for 
trilayer osmotic tablets 
 
Table 70: Statistical parameters for dissolution data of optimization of Carbopol 71G for 
trilayer osmotic tablets 
Parameter TT8 TT9 TT10 TT4 TT11 TT12 TT13 
f1 (Difference Factor) 31.45 25.59 21.92 8.14 13.49 8.87 12.98 
f2 (Similarity factor) 40.34 44.62 47.36 61.29 54.76 65.86 58.77 
Zero order kinetic 
(r
2
 value) 
0.975 0.983 0.986 0.984 0.986 0.987 0.976 
 
From the above results of % cumulative release and zero order kinetic (r
2
 value), it was seen that 
batch TT10, TT4, TT11 and TT12 showed good zero order release kinetics.  But batch TT12 
showed a slightly higher % cumulative release nearer to the target profile. Also analyzing the f1 
and  f2  values of the formulation TT12, it was found to show a similar release profile to the 
theoretical release  Hence TT12 was selected for further optimization of osmogen.  
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10.10.2.3 Optimization of Osmogen (Drug layer): 
Table 71: % cumulative release data for optimization of osmogen (Drug layer) for trilayer osmotic 
tablets: 
                                                                         (Average reported for 3 readings) 
 % cumulative release 
Time 
(hr) 
TT14 TT15 TT12 TT16 TT17 
0 0 0 0 0 0 
1 0 0 0 0 0 
2 0 0 1.1 1.8 3.2 
4 0 1.2 6.2 7.3 10.1 
6 10.2 12.3 17.1 19.8 23.9 
8 19.3 22.8 29.8 31.2 37.2 
12 45.4 47.1 49.4 52.4 58.3 
18 65.2 68.6 70.1 76.3 79.4 
24 85.1 89.6 89.2 91.5 95.8 
 
 
Figure 39:  % cumulative release v/s Time (hr) plot for optimization of osmogen (Drug layer) for trilayer osmotic tablets: 
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Table 72: Statistical parameters for dissolution data of optimization of osmogen (Drug layer): 
Parameter TT14 TT15 TT12 TT16 TT17 
f1 (Difference Factor) 17.89 13.49 8.87 9.68 15.47 
f2 (Similarity factor) 51.78 58.14 65.86 65.96 57.38 
Zero order kinetic  
(r
2
 value) 
0.972 0.977 0.987 0.991 0.981 
 
From the above results of % cumulative release and zero order kinetic (r
2
 value), it was seen that 
batch TT16 showed the best zero order release kinetics.  Also it showed an acceptable % 
cumulative release (91.5%).  Also analyzing the f1 and  f2  values of the formulation TT16, it was 
found to show a similar release profile to the theoretical release.  Hence batch TT16 was selected 
for further optimization of osmogen in push layer.  
10.10.2.4: Optimization of Osmogen (Push layer): 
Table 73: % cumulative release data for optimization of osmogen  (Push layer) for trilayer osmotic 
tablets:   
 
                                                                        (Average reported for 3 readings) 
 % cumulative release 
Time 
(hr) 
TT18 TT16 TT19 TT20 TT21 
0 0 0 0 0 0 
1 0 0 0 0 0 
2 0 1.4 1.6 0.7 5.5 
4 5.2 6.2 8.4 9.5 11.4 
6 15.4 17.7 21.6 23.4 27.9 
8 28.5 29.3 33.8 35.6 39.6 
12 48.1 49.7 53.3 56.2 58.5 
18 69.2 70.4 76.5 79.9 81.3 
24 86.6 89.7 94.3 99.5 99.7 
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Figure 40:  % cumulative release v/s Time (hr) plot for optimization of osmogen (Push layer) 
for trilayer osmotic tablets: 
 
Table 74: Statistical parameters for dissolution data of optimization of osmogen (Push layer) 
for trilayer osmotic tablets: 
Parameter TT18 TT16 TT19 TT20 TT21 
f1 (Difference Factor) 10.34 8.87 10.04 11.88 18.04 
f2 (Similarity factor) 59.53 65.86 66.53 61.43 54.19 
Zero order kinetic  
(r
2
 value) 
0.983 0.9878 0.9874 0.9987 0.9856 
 
From the above results of % cumulative release and zero order kinetic (r
2
 value), it was seen all 
batches showed good zero order release kinetics.  But, batch TT20 showed the best zero order 
release kinetics, nearer to the target profile.  Also it showed 99% cumulative release after 24 hrs.  
The values of f1 and  f2 confirmed the similarity between the release profile of batch TT20 and 
the theoretical target release profile.  Hence batch TT20 was selected as the optimized batch for 
trilayer osmotic tablets and was further forwarded for stability study analysis.     
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10.10.3 Effect of variables on the optimized formulation:  
The optimized formulation was then subjected to various comparative tests under different 
conditions to study the following effects of variables:  
a. Effect of Osmotically active Dissolution Medium on drug release 
b. Effect of Agitation rate on drug release 
c. Effect of orifice size on the drug release from optimized formulations.   
 
The results of the study are as follows: 
 
10.10.3.1 Effect of Osmotically active Dissolution Medium on drug release: 
 
The effect of osmotically active dissolution medium on drug release from trilayer osmotic 
tablets was carried out in a procedure similar to that in the case of monolayer osmotic drug 
delivery system.  In order to investigate the actual mechanism of the drug released from the 
tablet, dissolution study was conducted in water (0-8 h), 2.4 % w/w magnesium sulphate solution 
in water (8-16 hr) and in water (17-24 hr) alternatively. Table shows dissolution profile for the 
optimized formulation (TT20) in water (upto 8th hour), then magnesium sulphate (upto 16th 
hour) and lastly followed by water (upto 24th hour). 
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Table 75: cumulative % drug release of the selected optimized formulations (TT20) in 
different medium 
Time  
(hr) 
Dissolution 
media 
cumulative % drug 
release for optimized 
batch (TT20) 
0 
water 
0 
1 0 
2 2.3 
4 9.5 
6 23.4 
8 35.6 
8 
2.4% magnesium 
sulphate solution 
35.6 
12 43.5 
16 47.4 
16 
water 
47.4 
20 68.4 
24 79.2 
 
 
 
 
Chapter 10                                                                                                    Trilayer osmotic drug delivery system 
Osmotic Drug Delivery System                                                                                                                      Page 188 
 
Figure 41:  % cumulative release v/s Time (hr) plot for optimized formulation (TT20) to study the effect 
of Osmotically active Dissolution Medium on drug release: 
 
The drug release rate (mg/hr) for the selected optimized formulation (TT20) after duration of 8 
hrs in alternative media is as shown in the table below:  
Table 76: Drug release rate for selected optimized formulation (TT20)  after duration of 8 hrs 
in alternative media: 
 
Sr 
no. 
Time 
duration 
Dissolution 
medium 
 Drug release 
rate for TT20 
1 0-8 hrs water 2.67 + 0.05 mg/hr 
2 9-16 hrs 
2.4% 
magnesium 
sulphate 
solution 
0.885 + 0.02 mg/hr 
3 17-24 hrs water 2.385 + 0.06 mg/hr 
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Drug release rate of 2.67 + 0.05 mg/hr was observed with water for first 8 hr for the 
optimized formulation MT20 while in the next 8 hours i.e upto 16
th
 hour, in 2.4 % magnesium 
sulphate solution it was found to be 0.885 + 0.02  mg/hr.  Again in water for next 8 hrs i.e upto 
24
th
 hour it was found to increase upto 2.385 + 0.06 mg/hr. The results revealed that in water, 
effective osmotic pressure across the membrane was obtained which led to high drug release 
rate.  Pressure drop across the membrane was very less in case of magnesium sulphate solution, 
which shows slow drug release rate.  
From above results it can be concluded that as in the case of monolayer osmotic tablets, 
for trilayer osmotic tablets also, the drug release rate is mainly contributed by osmotic pressure 
only.  
 
10.3.3.2 Effect of Agitation rate on drug release 
The optimized formulation TT20 was subjected to dissolution study at different agitation 
rates. In the present investigation dissolution study was performed at three different agitation 
rates.  Agitation rates of 50, 100 and 150 rpm were selected for the study. 
 
The following table shows percent drug release from the optimized formulation TT20 at 
three different agitation rates with time. 
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Table 77 : Effect of agitation rate on in-vitro drug release of the optimized formulation TT20 osmotic 
tablet: 
 
Time 
(hr) 
 cumulative % drug released 
of TT20 
50 rpm 100 rpm 150 rpm 
0 
0 0.2 0.8 
1 
0.4 0.9 101 
2 
2.6 3.4 3.3 
4 
10.4 11.2 11.8 
6 
22.5 23.1 24.1 
8 
37.6 38.1 39.4 
12 
55.9 56.1 55.7 
18 
80.1 81.2 82.8 
24 
99.6 99.5 99.6 
 
Figure 42:  % cumulative release v/s Time (hr) plot for formulation TT20 to study the effect of 
agitation rate on drug release 
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  As seen in the above data, no significant changes were observed during drug release 
study with agitation rate, which strongly indicates that release of the drug from the system takes 
place mainly through osmotic pressure generated within the system. Therefore, it might be 
predicted that the mobility of the gastrointestinal tract hardly affected the drug release of the 
prepared osmotic tablet. Since drug release was independent of agitation rate, the prepared 
trilayer osmotic tablets might exhibit a comparable in vitro/in vivo release profile. 
 
10.10.3.3 Effect of orifice size on the drug release from optimized formulations: 
 
To study the effect of orifice size on the drug release from the optimized formulations, 
the in vitro analysis of the selected tablets formulations was carried out.  Coated tablets were 
selected from the optimized batch TT20 and orifices with varying sizes ( 0.5 mm, 1.0 mm, 
1.5mm and 2.0mm) were drilled using a mechanical microdrill (Servo Product, Co., Pasadena, 
CA), equipped with cobalt microdrill (Guhring, Germany) on both sides of the tablets.  The 
shape and diameter of the created orifice was visually inspected and measured using a 50 X 
microscope.  The data for the cumulative % drug release with varying orifice size for the selected 
formulation TT20 is as shown in the table below: 
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Table 78: Cumulative % drug release from optimized formulation TT20 with various orifice 
sizes 
Time 
(hr) 
 cumulative % drug released 
Orifice size (TT20) 
0.2 
mm 
0.5 
mm 
1.0 
mm 
1.5 
mm 
2.0 
mm 
0 0.1 0 0.2 0.8 2.4 
1 0.2 0.4 0.8 1.1 4.1 
2 0.3 2.7 3.4 4.1 6.8 
4 2.3 11.4 11.5 13.4 17.9 
6 5.9 23.2 23.1 25.9 31.5 
8 14.8 38.4 38.1 40.2 46.8 
12 22.4 56.1 56.1 56.1 71.5 
18 40.2 81.2 81.2 83.4 94.8 
24 59.5 99.7 99.5 99.6 99.8 
 
 
 
Figure 43:  % cumulative release v/s Time (hr) plot for formulation TT20 to study the 
effect of orifice size on drug release  
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As can be seen from the results of the above study of varying orifice sizes, it was observed that 
there was no significant change in the drug release pattern with orifice size in the range of 0.5 
mm to 1.5mm.  However, as can be seen from the above observations, it was found that a 
comparative higher release pattern and rapid release of drug was seen in tablets drilled with an 
orifice of 2.0 mm.  It was found that almost 100% drug was released around the 18
th
 hour and 
hence a sustained release comparable to the theoretical target release profile was not achieved.  
This may be due to the result of higher diffusion of fluids from the bigger orifice.  On the other 
hand, a low release rate and anomalous release were exhibited at an orifice diameter of 0.2 mm. 
The drug or excipients granules in insoluble form may occlude such a small orifice, therefore, 
leading to a low drug release rate. 
Hence it was concluded that the release rates were independent of the orifice size in the range of 
0.5mm to 1.5mm.  However, a higher orifice size (2.0mm) or a lower orifice size (0.2mm) had a 
significant influence on the release rate of drug from the osmotic drug delivery system.   
 
10.10.4 Accelerated Stability studies of the optimized formulation for osmotic trilayer drug 
delivery system: 
The accelerated stability testing was performed on the selected formulation (TT20) which gave 
the most optimum results amongst all the previous trial batch formulation. The test was carried 
out by placing the tablets of each selected formula in closed glass container in an ALU ALU 
Blister pack and stored in thermostatically controlled ovens adjusted at different temperatures 
and humidity percentage, namely, 40⁰C/75%, 30⁰C/65% and 25⁰C/60% (maintained using a 
saturated solution of NaCl) for a period of 3 months. The stored tablets were examined visually 
for any changes in color and/or appearance every month. Also the average weight, hardness and 
loss on drying of the selected batch formulations were determined at a period of 1 month for total 
3 months.  Three tablets were taken from the ovens after a period of 1 month for 3 months and 
analyzed for the determination of cumulative % drug release.  Limits were set for each of the 
above parameter (i.e. average weight, hardness, loss on drying and cumulative % drug release) 
using the ICH guidelines for accelerated stability studies.   
The results of the optimized formulations TT20 after conducting accelerated stability studies for 
3 months are as follows: 
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Table 79: Stability study data for the optimized trilayer osmotic tablet batch (TT20): 
 
Trilayer osmotic Tablets (Alu-Alu Blister Pack) Batch TT20 
Sr. 
No 
Test Limit Initial 
Storage condition 
40⁰C/75% 30⁰C/65% 25⁰C/60% 
1 Month 
2  
Month 
3  
Month 
1 
Month 
2  
Month 
3  
Month 
3  
Month 
1 Description * * * * * * * * * 
2 Avg. Wt 600mg ± 3% 602.4 602.1 603.4 603.2 602.4 602.9 603.1 603.1 
3 Hardness 
NLT 5.0 
kg/cm2 
7.9 7.4 7.2 7.6 7.9 8.1 7.2 7.7 
4 Loss on Drying NMT 5% 2.80% 2.45% 2.86% 2.87% 2.48% 2.76% 2.82% 2.94% 
5 Dissolution                   
  Time (hr) % Drug Dissolved (as an average of 3 readings) 
  2 NMT 5% 2.3 2.4 2.6 2.4 2.8 2.7 2.6 2.4 
  6 10-30% 23.4 23.8 24.1 23.4 24.1 24.1 23.4 24.1 
  8 20-40% 35.6 34.7 35.1 35.7 36.2 36.8 34.2 36.5 
  12 45-65 % 56.2 55.8 56.4 56.2 56.4 57.2 56.9 57.1 
  18 65 -85% 79.9 78.4 79.2 80.1 79.3 80.1 80.3 79.4 
  24 NLT 85 % 99.5 99.6 99.8 99.5 99.1 99.2 99.6 99.2 
6 
f1   (Difference 
Factor) 
<15 
  
1.2 0.9 0.1 1.0 1.3 1.0 1.2 
7 f2  (Similarity 
factor) 
>50 
  
95.1 97.7 99.8 97.3 95.3 95.3 96.3 
 
               * white to off white , round, slightly oblong,  biconvex film coated tablets  
 
It can be seen from the above tables, that in above optimized formulation, there was 
no significant variation in the physical appearance, average weight, hardness and loss 
of drying after placing the tablets at various temperature and humidity conditions for 
a period of 3 months.   
Also the cumulative % drug release data showed that each of the formulation released 
a drug amount, within the limits laid down as per the ICH guidelines for stability 
studies.  A very low f1 value and a value of f2 higher than 50 in each of the above 
formulation batches at various time intervals, suggested that the release profile 
remained similar to the initial release profile even after subjecting the tablets to the 
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above temperature and humidity parameters for a period of 3 months.  Hence it was 
concluded that the optimized formulation batches did not show any significant 
change in their release profiles after 3 months duration under the above temperature 
and humidity conditions.   
              Thus the optimized formulations could be considered stable for a period of 2 years.   
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11.0 Summmary and conclusions:  
The present work was aimed at formulating a solid dosage form system (tablets) for 
Trimetazidine dihydrochloride using the principles of osmosis which will bring down its 
dosing frequency to once a day and at the same time produce a zero-order release system. It 
was planned to formulate the 3 types of osmotic drug delivery system viz. Monolayer 
osmotic Tablets (Elementary osmotic pump), Bilayer osmotic tablets (Push-pull osmotic 
pump) and trilayer osmotic tablets (Sandwitched osmotic tablet system). 
 
11.1 Formulation of monolayer osmotic drug delivery system (Elementary osmotic 
pump): 
A monolayer osmotic tablet was formulated by coating the core tablet (containing 60 
mg of drug and osmogen) with a semi permeable membrane to permit the penetration of 
water and drilling an orifice which would permit the release of drug after development of 
suitable osmotic pressure.   
For formulating a monolayer osmotic tablet, initially core and coating feasibility trials 
were carried out to select the best formulation for optimization study.  Optimization study of 
HPMC K4M, Carbopol 71G, Osmogen (Mannitol and sodium chloride) and coating 
composition was done by varying the proportion of each in various formulations (MT1 to 
MT20) and analysing the release profile kinetics.  Comparison of the release profiles of each 
formulations was made with the theoretically calculated target release profile using the f1 
(Difference Factor) and f2 (Similarity factor).  Formulation MT20 was selected as the final 
optimized formulation for monolayer osmotic drug delivery system.  It showed an almost 
perfect zero order release (r
2
 = 0.995) and almost 100 % release after 24 hours.  However 
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there was a release of more than 7% of drug in the initial two hours and hence did not show a 
lag phase which is desired in case of osmotic drug delivery systems.  To achieve this lag 
phase and to further fine tune the release characteristics and achieve desirable control over 
the release kinetics, it was decided to formulate a bilayer osmotic drug delivery system.   
 
11.2 Formulation of bilayer osmotic drug delivery system (Push-pull osmotic system): 
 A bilayer osmotic tablet was formulated by compressing two seperate layers viz a 
drug layer and a push layer (osmogen).  The compressed tablet was then coated with a 
semipermeable membrane and an orifice of suitable size was drilled to permit the release of 
drug.    
Optimization study of HPMC K4M, Carbopol 71G, and Osmogen was done by 
varying the proportion of each in various formulations (BT1 to BT20) and analysing the 
release profile kinetics.  Comparison of the release profiles of each formulations was made 
with the theoretically calculated target release profile using the f1 (Difference Factor) and f2 
(Similarity factor).  Bilayer osmotic tablets showed better release kinetics as compared to the 
monolayer osmotic tablets.  However, formulation BT17 was selected as the final optimized 
formulation for bilayer osmotic drug delivery system.  It showed a good zero order release (r
2
 
= 0.982) and almost 100 % release after 24 hours.  Also it showed no release in the inital two 
hours and hence we could achieve a desired inital lag phase of 2 hrs required for osmotic 
drug delivery system.   However the major drawback was the side identification of the drug 
layer for drilling of orifice.  A colorant (ferric oxide red) was added to the drug layer to help 
in side identification for drilling of orifice, which gave a slightly bizarre look to the tablet.   
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To further fine tune the release kinetics and eliminate the disadvantage of side identification, 
it was decided to formulate a trilayer osmotic drug delivery system.   
11.3 Formulation of trlayer osmotic drug delivery system (sandwitched osmotic tablet 
system): 
 A trilayer osmotic tablet system was formulated by compressing two layers of drug 
(30 mg each) on either side of a central push layer (osmogen).  However compression of the 
trilayer tablet was found to be a tedious and time consuming process as each layer weighing 
200mg had to be individually filled in the die cavity.  The tablet system was then coated with 
a semipermeable membrane and orifices of specific sizes were drilled on both the sides of the 
tablet; thus eliminating the problem of side identification.   
Optimization study of HPMC K4M, Carbopol 71G, and Osmogen (in drug layer and 
push layer) was done by varying the proportion of each in various formulations (TT1 to 
TT21) and analysing the release profile kinetics.  Comparison of the release profiles of each 
formulations was made with the theoretically calculated target release profile using the f1 
(Difference Factor) and f2 (Similarity factor).  Trilayer osmotic tablets showed better release 
kinetics as compared to the bilayer osmotic tablets.  Formulation TT20 was selected as the 
final optimized formulation for trilayer osmotic drug delivery system.  It showed an almost 
perfect zero order release (r
2
 = 0.9987) and almost 100 % release after 24 hours.  Also it 
showed no release in the inital two hours and hence we could achieve a desired inital lag 
phase of 2 hrs required for osmotic drug delivery system.  The major advantage achieved was 
the elimination of side identification problem and hence no colorant was required to be added 
in the formulation; which gave an aesthetic look to the tablet, instead of a multi colored 
tablet.   
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 Thus we could conclude that if the compression process could be automated for a 
trilayer osmotic tablet preparation, it could be the system of choice amongst all the three 
forms of osmotic tablets, as it offered desirable release kinetics and showed no constraints of 
side identification; which was seen with bilayer tablet formulations.   
 
11.4 Effect of variables on release profiles of optimized formulations: 
 The optimized formulations (MT20, BT17 and TT20) were subjected to various 
comparative tests to study the effect of variables on release profiles of the optimized 
formulations.  The effect of osmotically active dissolution medium, effect of agitation rate 
and the effect of orifice diameter were studied. 
 
11.4.1 Effect of Osmotically active Dissolution Medium on drug release: 
 To study the effect of osmotically active dissolution medium, the optimized 
formulations were subjected to dissolution studies in alternative media at an interval of 8 hrs. 
The dissolution study was conducted in water (0-8 h), 2.4 % w/w magnesium sulphate 
solution in water (8-16 hr) and in water (17-24 hr) alternatively.   A sharp retardation in the 
drug release was observed when the tablets were kept in the 2.4 % w/w magnesium sulphate 
solution in water; which showed that in water, effective osmotic pressure across the 
membrane was obtained which led to high drug release rate.  Pressure drop across the 
membrane was very less in case of magnesium sulphate solution, which shows slow drug 
release rate.  
From above results it can be concluded that in case of the optimized formulations of osmotic 
drug delivery system, the drug release rate is mainly contributed by osmotic pressure only.  
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11.4.2 Effect of Agitation rate on drug release:  
 Optimized formulations (MT20, BT17 and TT20) were subjected to dissolution study 
at different agitation rates. In the present investigation dissolution study was performed at 
three different agitation rates.  Agitation rates of 50, 100 and 150 rpm were selected for the 
study. 
No significant changes were observed during drug release study with agitation rate, which 
strongly indicates that release of the drug from the system takes place mainly through 
osmotic pressure generated within the system. Therefore, it might be predicted that the 
mobility of the gastrointestinal tract hardly affected the drug release of the prepared osmotic 
tablet. Since drug release was independent of agitation rate, the prepared osmotic tablets 
might exhibit a comparable in vitro/in vivo release profile. 
 
11.4.3 Effect of orifice size on the drug release from optimized formulations: 
To study the effect of orifice size on the drug release from the optimized 
formulations, the in vitro analysis of the selected tablets formulations was carried out.  
Coated tablets were selected from each of the optimized batch and orifices with varying sizes 
(0.5 mm, 1.0 mm, 1.5mm and 2.0mm) were drilled.  It was observed that there was no 
significant change in the drug release pattern with orifice size in the range of 0.5 mm to 
1.5mm.  However, it was found that a comparative higher release pattern and rapid release of 
drug was seen in tablets drilled with an orifice of 2.0 mm.  It was found that almost 100% 
drug was released around the 18
th
 hour and hence a sustained release comparable to the 
theoretical target release profile was not achieved.  This may be due to the result of higher 
diffusion of fluids from the bigger orifice.  On the other hand, a low release rate and 
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anomalous release were exhibited at an orifice diameter of 0.2 mm. The drug or excipients 
granules in insoluble form may occlude such a small orifice, therefore, leading to a low drug 
release rate. 
Hence it was concluded that the release rates were independent of the orifice size in the range 
of 0.5mm to 1.5mm.  However, a higher orifice size (2.0mm) or a lower orifice size (0.2mm) 
had a significant influence on the release rate of drug from the osmotic drug delivery system. 
 
11.5 Accelerated stability study of optimized formulations: 
The accelerated stability testing was performed on the selected formulas which gave the most 
optimum results amongst all the previous trial batch formulation. The test was carried out by 
placing the tablets of each selected formula in closed glass container in an ALU ALU Blister 
pack and stored in thermostatically controlled ovens adjusted at different temperatures and 
humidity percentage, namely, 40⁰C/75%, 30⁰C/65% and 25⁰C/60% 
It was observed that there was no significant variation in the physical appearance, average 
weight, hardness and loss of drying after placing the tablets at various temperature and 
humidity conditions for a period of 3 months.   
Also the cumulative % drug release data showed that each of the formulation released a drug 
amount, within the limits laid down as per the ICH guidelines for stability studies.  A very 
low f1 value and a value of f2 higher than 50 in each of the formulation batches at various 
time intervals, suggested that the release profile remained similar to the initial release profile 
even after subjecting the tablets to the above temperature and humidity parameters for a 
period of 3 months.  Hence it was concluded that the optimized formulation batches did not 
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show any significant change in their release profiles after 3 months duration under the above 
temperature and humidity conditions.   
            Thus the optimized formulations could be considered stable for a period of 2 years. 
 It can thus be concluded that osmotic tablets systems could be used as a potential tool 
for delivering zero-order release for highly water soluble drugs like Trimetazidine 
dihydrochloride; which have a comparatively lower half-life.  It was found to reduce the dose 
dumping; as is the case with most sustained release matrix tablet systems and can 
simultaneously reduce the dose frequency of the drug to once a day; thus providing a better 
patient compliance.   
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